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ABSTRACT 
 
Antiretroviral drug detection in urine using high performance 
liquid chromatography 
Background: Human immunodeficiency virus (HIV) and acquired immunodeficiency 
syndrome (AIDS) was first recognised in 1981.  The explosive worldwide pandemic has 
become the leading cause of death in South Africa.  An estimated 10.2% of the South 
African population is currently infected with HIV/AIDS and more than 2500 new 
infections occur on a daily basis, revealing South Africa as the country with the highest 
infection rate worldwide.  A devastating fifteen percent of new infections worldwide occur 
in South Africa alone despite extensive roll out programs implemented by the 
department of health. 
Extensive research and drug development was conducted since its discovery.  Many 
antiretroviral drugs (ARVs) have been developed and various treatment protocols have 
been implemented to combat the epidemic, but no cure has been discovered yet.  When 
a patient is first diagnosed, an aggressive treatment regimen of 3 or more antiretrovirals 
is prescribed to reduce the viral load and increase the life expectancy of a positive 
patient.   
The ARVs are well absorbed with good bioavailability after oral administration.  The 
drugs are metabolised by the liver and mainly excreted in the urine.  Unfortunately all 
ARVs pose the threat of toxicity.  The roll out program implemented by the department of 
health now reaches more infected patients than ever before.  The increased availability 
of these drugs increases the likelihood of misuse or accidental toxicity.  Treatment of 
such a patient can be problematic and very costly if a correct diagnosis cannot be made. 
Increased requests for therapeutic drug monitoring of the ARVs to establish patient 
compliance and to monitor pharmacokinetic interactions with other drugs was also a key 
motivator for the development of a method for ARV determination in our area.  The 
current high performance liquid chromatography (HPLC) method developed by the 
Department of Pharmacology/Toxicology can identify the presence of lamivudine, 
abacavir, zidovudine, nevirapine and efavirenz in urine.  Continued research in the field 
of drug development launches new drugs on the market on a regular basis.  Treatment 
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regimens change as the new drugs become available, and older line ARVs become 
outdated.  This dynamic and TDM requests warrant the necessity to extend the 
application of the method to accommodate new ARVs.  It is also important as part of 
method validation to analyse samples from patients using antiretroviral drugs to see if 
the method that was developed complies with the analytical criteria required.   
Methods: Lamivudine, abacavir, zidovudine, nevirapine, efavirenz, stavudine, lopinavir 
and tenofovir were extracted from urine using a liquid-liquid extraction and analysed with 
a Hewlett-Packard (HP) 1090 Liquid Chromatograph.  The eluent was monitored and full 
spectra of each peak were recorded at 210 nanometre (nm) with an ultraviolet-visible 
spectrophotometry (UV/VIS) Diode Array detector. 
Results: Spectra recorded for each peak showed excellent reproducibility and 
agreement to database recorded spectra.  The calibration curves of the ARVs were 
linear and reproducible.  Recovery exceeded 74%.  Validation data for control samples 
show inter – assay precision with a coefficient of variation (CV) of < 16.9%.  Short-term 
stability testing indicated that concentrations remained stable at room temperature and 
refrigeration, but freezing of samples is not advised. 
Conclusion: A qualitative HPLC method for the identification of ARVs in urine was 
developed and validated.  This analysis can be used as a component of an emergency 
toxicological screening in suspected overdoses.  It requires minimal sample pre–
treatment, small sample volume, minimal expertise, and provides results within 30 
minutes.  
© Central University of Technology, Free State
  xi 
Acknowledgments 
 
I would like to express my sincere gratitude and appreciation to my supervisor, Dr. J.B. 
du Plessis and my co-supervisor, Dr. D. Olivier for their input and guidance during the 
course of the working period. 
 
I would like to express my appreciation to the Department of Pharmacology/Toxicology 
of the University of the Free State for supplying me with the necessary laboratory 
environment, equipment and consumables required for the completion of the project.  
 
I would like to express my sincere gratitude and appreciation to Sr. Malefane (Pelonomi 
HIV centre of excellence), Dr. Steyn and Dr. Van Vuuren (Pelonomi Internal medicine) 
for their time and effort in the identification of candidates and sample collection. 
 
I would like to thank Mrs. H.A. de Villiers for valuable assistance with chemical 
preparation and Mrs. M. Viljoen for her input regarding statistical data logistics. 
 
I would like to thank my colleagues, parents, friends and fellow students for their 
continual support, understanding and encouragement during my study period. 
 
Finally, I would like to thank my Creator for providing me with the ability, strength and the 
privilege to learn. 
 
  
© Central University of Technology, Free State
  xii 
LIST OF ABBREVIATIONS 
3TC    Lamivudine 
α     Column selectivity  
k’    Capacity  
ABC    Abacavir 
AIDS    Acquired immunodeficiency syndrome 
AIVR Acquired immunodeficiency virus-associated retrovirus 
ARV    Antiretroviral 
ARVs    Antiretroviral drugs 
ATV    Atazanavir 
ATV/r    Atazanavir/Ritonavir 
AUC    Area under the curve 
AZT    Zidovudine 
BMI    Body mass index 
CC-CKR- 5   Chemokine receptor gene 5 
CCR5    Chemokine receptor 5  
CD4    Cluster of differentiation 4 
CDC    Centre for disease control 
CH2Cl2    Dichloromethane  
CH3CH(OH)CH3  Isopropanol 
Cmax  Maximum concentration of the drug reached in the plasma 
CNS  Central nervous system 
CSF  Cerebrospinal fluid 
CUT    Central University of Technology 
CV    Coefficient of variation 
CXCR4   Chemokine (C-X-C Motif) Receptor 4 
d4T    Stavudine 
ddl    Didanosine 
DLV    Delavirdine 
DMSO    Dimethyl sulfoxide 
DNA    Deoxyribonucleic acid 
DRV    Darunavir 
EFV    Efavirenz 
© Central University of Technology, Free State
  xiii 
ENF    Enfuvirtide 
ESI-MS/MS   Electrospray tandem mass spectrometry 
ETR    Etravirine 
EVG    Elvitegravir 
FDC    Fixed-dose combination 
FPV    Fosamprenavir 
FTC    Emtricitabine 
GC/MS   Gas chromatography/Mass spectrometry 
GC/MS-SIM   Gas chromatography-mass spectroscopy in selected ion 
    monitoring mode 
GCS    Glascow coma scale 
g/dl    Gram per decilitre 
GI    Gastrointestinal 
GLP    Good laboratory practice 
gp41    Glycoprotein 41 
H3PO4    Phosphoric Acid 
Hb    Haemoglobin 
HETP    Highest equivalent of theoretical plates 
HIV    Human Immunodeficiency virus 
HP    Hewlett-Packard 
HPLC    High performance liquid chromatography 
HPLC-MS   High performance liquid chromatography-mass  
    spectrometry 
HR1    Heptad repeat 1 
HR2    Heptad repeat 2 
HTLV –III   Human T cell lymphotropic virus type III 
ICH    International conference on harmonisation  
ID    Identification 
IDV    Indinavir 
IV    Intravenous 
LAV    Lymphadenopathy associated virus 
LC    Liquid chromatography 
LC/MS    Liquid chromatography-mass spectrometry 
L/kg    Litres per kilogram 
© Central University of Technology, Free State
  xiv 
LPV    Lopinavir 
LPV/r    Lopinavir/ritonavir 
K2CO3    Potassium bicarbonate 
KS    Kaposi’s sarcoma 
MIC    Minimum inhibitory concentration 
ml/min    Millilitres per minute 
mm³    Cubic millimetre 
MMWR   Morbidity and mortality weekly report  
MS    Mass spectrometry 
MVC    Maraviroc 
N    Quantity of theoretical plates 
NaHCO3   Sodium hydroxy carbonate 
nm    Nanometre 
NNRTI    Non-nucleoside reverse transcriptase inhibitors  
nRTI  Nucleoside and nucleotide reverse transcriptase inhibitors  
NSAIDs   Non-steroidal anti-inflammatory drugs 
NVF    Nelfinavir 
NVP    Nevirapine 
P    Statistical significance 
PIs     Protease Inhibitors  
R    Resolution 
r    Correlation coefficient 
r²    Coefficient of determination 
RAL    Raltegravir 
RAM    Restricted access material 
rpm    Revolutions per minute 
RPV    Rilpivirine 
Rx    Treatment 
SQV    Saquinavir 
TB    Tuberculosis 
TDF    Tenofovir 
TDM    Therapeutic drug monitoring 
TEAP    Tetraethylammonium phosphate 
TOF    Time of flight mass spectrometry 
© Central University of Technology, Free State
  xv 
TPV    Tipranavir 
tR1     Retention time of peak 1 
tR2     Retention time of peak 2 
tm     Retention time of solvent front 
µg/ml    Micrograms per millilitre 
µl    micro litre 
u    Flow rate 
UGT1A1   Uridine diphosphate glucuronyl transferse 1A1  
UGT1A3   UDP glucuronosyltransferase 1 family, polypeptide A3  
UPLC    Ultra performance liquid chromatography 
UV    Ultraviolet 
UV/VIS   Ultraviolet-visible spectrophotometry 
V3 loop   third variable loop 
WB1 Peak width at base of peak 1 
WB2 Peak width at base of peak 2 
 
  
© Central University of Technology, Free State
  xvi 
LIST OF FIGURES 
FIGURE NAME PAGE 
1 Site of action of ARVs in the HIV life cycle 9 
2 Resolution of physical separation between two components 35 
3 The HPLC system 45 
4.1 Chromatogram of Blank urine sample 57 
4.2 Chromatogram of Internal standard Clomipramine 58 
4.3 Chromatogram of Abacavir and Clomipramine 59 
4.4 Chromatogram of Efavirenz and Clomipramine 60 
4.5 Chromatogram of Lamivudine and Clomipramine 61 
4.6 Chromatogram of Lopinavir and Clomipramine 62 
4.7 Chromatogram of Nevirapine and Clomipramine 63 
4.8 Chromatogram of Stavudine and Clomipramine 64 
4.9 Chromatogram of Tenofovir and Clomipramine 65 
4.10 Chromatogram of Zidovudine and Clomipramine 66 
4.11 Chromatogram of Abacavir, Efavirenz, Lamivudine, Lopinavir, 
Nevirapine, Stavudine, Tenofovir, Zidovudine and Clomipramine 
67 
4.12 Average calibration curve of Abacavir for the 3 daily 
calibrations 
69 
4.13 Average calibration curve of Efavirenz for the 3 daily  
calibrations 
71 
4.14 Average calibration curve of Lamivudine for the 3 daily  
calibrations 
73 
4.15 Average calibration curve of Lopinavir for the 3 daily  
calibrations 
75 
4.16 Average calibration curve of Nevirapine for the 3 daily  
calibrations 
77 
4.17 Average calibration curve of Stavudine for the 3 daily  
calibrations 
79 
4.18 Average calibration curve of Tenofovir for the 3 daily  
Calibrations 
 
 
81 
© Central University of Technology, Free State
  xvii 
4.19 Average calibration curve of Zidovudine for the 3 daily  
calibrations 
83 
4.20 Short-term stability of 19.20 µg/ml Abacavir 91 
4.21 Short-term stability of 38.40 µg/ml Abacavir 91 
4.22 Short-term stability of 85.20 µg/ml Efavirenz 92 
4.23 Short-term stability of 170.4 µg/ml Efavirenz 92 
4.24 Short-term stability of 15.17 µg/ml Lamivudine 93 
4.25 Short-term stability of 30.33 µg/ml Lamivudine 93 
4.26 Short-term stability of 19.80 µg/ml Lopinavir 94 
4.27 Short-term stability of 44.55 µg/ml Lopinavir 94 
4.28 Short-term stability of 31.60 µg/ml Nevirapine 95 
4.29 Short-term stability of 63.20 µg/ml Nevirapine 95 
4.30 Short-term stability of 11.24 µg/ml Stavudine 96 
4.31 Short-term stability of 16.86 µg/ml Stavudine 96 
4.32 Short-term stability of 37.20 µg/ml Tenofovir 97 
4.33 Short-term stability of 83.70 µg/ml Tenofovir 97 
4.34 Short-term stability of 31.20 µg/ml Zidovudine 98 
4.35 Short-term stability of 72.80 µg/ml Zidovudine 98 
7.1 Calibration graph of Abacavir used in precision and accuracy 
testing, Day 1 
120 
7.2 Calibration graph of Abacavir used in precision and accuracy 
testing, Day 2 
121 
7.3 Calibration graph of Abacavir used in precision and accuracy 
testing, Day 3 
122 
7.4 Calibration graph of Efavirenz used in precision and accuracy 
testing, Day 1 
123 
7.5 Calibration graph of Efavirenz used in precision and accuracy 
testing, Day 2 
124 
7.6 Calibration graph of Efavirenz used in precision and accuracy 
testing, Day 3 
125 
7.7 Calibration graph of Lamivudine used in precision and accuracy 
testing, Day 1 
 
 
126 
© Central University of Technology, Free State
  xviii 
7.8 Calibration graph of Lamivudine used in precision and accuracy 
testing, Day 2 
127 
7.9 Calibration graph of Lamivudine used in precision and accuracy 
testing, Day 3 
128 
7.10 Calibration graph of Lopinavir used in precision and accuracy 
testing, Day 1 
129 
7.11 Calibration graph of Lopinavir used in precision and accuracy 
testing, Day 2 
130 
7.12 Calibration graph of Lopinavir used in precision and accuracy 
testing, Day 3 
131 
7.13 Calibration graph of Nevirapine used in precision and accuracy 
testing, Day 1 
132 
7.14 Calibration graph of Nevirapine used in precision and accuracy 
testing, Day 2 
133 
7.15 Calibration graph of Nevirapine used in precision and accuracy 
testing, Day 3 
134 
7.16 Calibration graph of Stavudine used in precision and accuracy 
testing, Day 1 
135 
7.17 Calibration graph of Stavudine used in precision and accuracy 
testing, Day 2 
136 
7.18 Calibration graph of Stavudine used in precision and accuracy 
testing, Day 3 
137 
7.19 Calibration graph of Tenofovir used in precision and accuracy 
testing, Day 1 
138 
7.20 Calibration graph of Tenofovir used in precision and accuracy 
testing, Day 2 
139 
7.21 Calibration graph of Tenofovir used in precision and accuracy 
testing, Day 3 
140 
7.22 Calibration graph of Zidovudine used in precision and accuracy 
testing, Day 1 
141 
7.23 Calibration graph of Zidovudine used in precision and accuracy 
testing, Day 2 
 
 
142 
© Central University of Technology, Free State
  xix 
7.24 Calibration graph of Zidovudine used in precision and accuracy 
testing, Day 3 
143 
 
  
© Central University of Technology, Free State
  xx 
LIST OF TABLES 
TABLE NAME PAGE 
1 Standardised national ART regimens for adults and adolescents 7 
2 Classes of ARVs 8 
3.1 Concentrations of ARVs used to construct calibration curve 48 
3.2 Concentrations of ARVs used for short term stability 53 
4.1 HPLC calibations for Abacavir 68 
4.2 HPLC calibrations for Efavirenz 70 
4.3 HPLC calibrations for Lamivudine 72 
4.4 HPLC calibrations for Lopinavir 74 
4.5 HPLC calibrations for Nevirapine 76 
4.6 HPLC calibrations for Stavudine 78 
4.7 HPLC calibrations for Tenofovir 80 
4.8 HPLC calibrations for Zidovudine 82 
4.9 Summary of spiked concentrations obtained for Abacavir 84 
4.10 Summary of precision, accuracy and recovery for Abacavir 84 
4.11 Summary of spiked concentrations obtained for Efavirenz 85 
4.12 Summary of precision, accuracy and recovery for Efavirenz 85 
4.13 Summary of spiked concentrations obtained for Lamivudine 85 
4.14 Summary of the precision, accuracy and recovery for 
Lamivudine 
86 
4.15 Summary of spiked concentrations obtained for Lopinavir 86 
4.16 Summary of the precision, accuracy and recovery for Lopinavir 86 
4.17 Summary of spiked concentrations obtained for Nevirapine 87 
4.18 Summary of the precision, accuracy and recovery for Nevirapine 87 
4.19 Summary of spiked concentrations obtained for Stavudine 87 
4.20 Summary of the precision, accuracy and recovery for Stavudine 88 
4.21 Summary of spiked concentrations obtained for Tenofovir 88 
4.22 Summary of the precision, accuracy and recovery for Tenofovir 88 
4.23 Summary of spiked concentrations obtained for Zidovudine 88 
4.24 Summary of the precision, accuracy and recovery for Zidovudine 89 
4.25 ARV concentrations used in the determination of short-term 
stability 
90 
© Central University of Technology, Free State
  xxi 
4.26 Summary of the short-term stability determination of  
19.20 µg/ml Abacavir and 38.40 µg/ml Abacavir 
91 
4.27 Summary of the short-term stability determination of  
85.20 µg/ml Efavirenz and 170.40 µg/ml Efavirenz 
92 
4.28 Summary of the short-term stability determination of  
15.17 µg/ml Lamivudine and 30.33 µg/ml Lamivudine 
93 
4.29 Summary of the short-term stability determination of  
19.80 µg/ml Lopinavir and 44.55 µg/ml Lopinavir 
94 
4.30 Summary of the short-term stability determination of  
31.60 µg/ml Nevirapine and 63.20 µg/ml Nevirapine 
95 
4.31 Summary of the short-term stability determination of  
11.24 µg/ml Stavudine and 16.86 µg/ml Stavudine 
96 
4.32 Summary of the short-term stability determination of  
37.20 µg/ml Tenofovir and 83.70 µg/ml Tenofovir 
97 
4.33 Summary of the short-term stability determination of 
31.20 µg/ml Zidovudine and 72.80 µg/ml Zidovudine 
98 
4.34 Limit of detection 100 
4.35 Patient Results 102 
7.1 Precision and accuracy data for Abacavir, day 1 120 
7.2 Precision and accuracy data for Abacavir, day 2 121 
7.3 Precision and accuracy data for Abacavir, day 3 122 
7.4 Precision and accuracy data for Efavirenz, day 1 123 
7.5 Precision and accuracy data for Efavirenz, day 2 124 
7.6 Precision and accuracy data for Efavirenz, day 3 125 
7.7 Precision and accuracy data for Lamivudine, day 1 126 
7.8 Precision and accuracy data for Lamivudine, day 2 127 
7.9 Precision and accuracy data for Lamivudine, day 3 128 
7.10 Precision and accuracy data for Lopinavir, day 1 129 
7.11 Precision and accuracy data for Lopinavir, day 2 130 
7.12 Precision and accuracy data for Lopinavir, day 3 131 
7.13 Precision and accuracy data for Nevirapine, day 1 132 
7.14 Precision and accuracy data for Nevirapine, day 2 133 
7.15 Precision and accuracy data for Nevirapine, day 3 134 
7.16 Precision and accuracy data for Stavudine, day 1 135 
© Central University of Technology, Free State
  xxii 
7.17 Precision and accuracy data for Stavudine, day 2 136 
7.18 Precision and accuracy data for Stavudine, day 3 137 
7.19 Precision and accuracy data for Tenofovir, day 1 138 
7.20 Precision and accuracy data for Tenofovir, day 2 139 
7.21 Precision and accuracy data for Tenofovir, day 3 140 
7.22 Precision and accuracy data for Zidovudine, day 1 141 
7.23 Precision and accuracy data for Zidovudine, day 2 142 
7.24 Precision and accuracy data for Zidovudine, day 3 143 
 
  
© Central University of Technology, Free State
  xxiii 
LIST OF APPENDIXES 
APPENDIX NAME PAGE 
7.1 Precision and Accuracy testing of HPLC method for Abacavir,  
Day 1 
120 
7.2 Precision and Accuracy testing of HPLC method for Abacavir,  
Day 2  
121 
7.3 Precision and Accuracy testing of HPLC method for Abacavir,  
Day 3  
122 
7.4 Precision and Accuracy testing of HPLC method for Efavirenz,  
Day 1 
123 
7.5 Precision and Accuracy testing of HPLC method for Efavirenz,  
Day 2  
124 
7.6 Precision and Accuracy testing of HPLC method for Efavirenz  
Day 3 
125 
7.7 Precision and Accuracy testing of HPLC method for 
Lamivudine, Day 1 
126 
7.8 Precision and Accuracy testing of HPLC method for 
Lamivudine, Day 2 
127 
7.9 Precision and Accuracy testing of HPLC method  for 
Lamivudine, Day 3 
128 
7.10 Precision and Accuracy testing of HPLC method for Lopinavir,  
Day 1 
129 
7.11 Precision and Accuracy testing of HPLC method for Lopinavir,  
Day 2  
130 
7.12 Precision and Accuracy testing of HPLC method for Lopinavr,  
Day 3 
131 
7.13 Precision and Accuracy testing of HPLC method for 
Nevirapine, Day 1 
132 
7.14 Precision and Accuracy testing of HPLC method for 
Nevirapine, Day 2 
133 
7.15 Precision and Accuracy testing of HPLC method for 
Nevirapine, Day 3 
 
134 
© Central University of Technology, Free State
  xxiv 
7.16 Precision and Accuracy testing of HPLC method for 
Stavudine, Day 1 
135 
7.17 Precision and Accuracy testing of HPLC method for 
Stavudine, Day 2 
136 
7.18 Precision and Accuracy testing of HPLC method for 
Stavudine, Day 3 
137 
7.19 Precision and Accuracy testing of HPLC method for Tenofovir,  
Day 1 
138 
7.20 Precision and Accuracy testing of HPLC method for Tenofovir,  
Day 2 
139 
7.21 Precision and Accuracy testing of HPLC method for Tenofovir,  
Day 3 
140 
7.22 Precision and Accuracy testing of HPLC method for 
Zidovudine, Day 1 
141 
7.23 Precision and Accuracy testing of HPLC method for 
Zidovudine, Day 2 
142 
7.24 Precision and Accuracy testing of HPLC method for 
Zidovudine, Day 3 
143 
7.25 UV spectrum of Abacavir 144 
7.26 UV spectrum of Efavirenz 144 
7.27 UV spectrum of Lamivudine 145 
7.28 UV spectrum of Lopinavir 145 
7.29 UV spectrum of Nevirapine 146 
7.30 UV spectrum of Stavudine 146 
7.31 UV spectrum of Tenofovir 147 
7.32 UV spectrum of Zidovudine 147 
7.33 Example of consent form 148 
7.34 Example of information document 149 
 
 
© Central University of Technology, Free State
  1 
1.  BACKGROUND 
1.1 INTRODUCTION 
Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) have 
become a leading cause of death in South Africa.  South Africa has one of the most explosive 
HIV epidemics in the world with about 2500 new infections every day; it is estimated that 
10.2% of the South African population is infected with the virus (Infographic, 2014).  Fifteen 
percent of all the estimated HIV infections in the world occur in South Africa (5.51 million), the 
highest infection rate in the world, while South Africa constitutes only 0.68% of the world 
population (Statistics South Africa 2014). 
Since AIDS was first recognized in 1981, development of drugs for the treatment and 
prophylaxis of HIV have been researched extensively, but no successful cure for the 
pandemic has been discovered yet.  Many antiretroviral drugs (ARVs) have been developed 
since, increasing the quality of life and the life expectancy of infected patients (Rang, Dale & 
Ritter 1999). 
After a patient is diagnosed with HIV, treatment commences with a combination of three or 
more antiretroviral agents before immunodeficiency becomes evident, and the aim of 
treatment is to reduce the plasma viral concentration as much as possible, and for as long as 
possible (Denelsbeck, 2006).  The ARVs are well absorbed after oral administration, with 
relatively good bioavailability.  The ARVs are metabolized by the liver and excreted in the 
urine (Rang et al. 1999). 
Of importance with the use of ARVs is therapeutic drug monitoring (TDM) related.  Poor 
compliance and pharmacokinetic problems also warrants the monitoring of these drugs in 
patients using ARV treatment (Slish, 2008).  Unfortunately all of these drugs pose the threat 
of toxicity, and where the use of ARVs become ever increasing in the population, so does the 
tendency in using these ARVs in overdose (Holtt & Ju, 2006).  Diagnosis and treatment of 
patients with a suspected overdose are cumbersome and extremely costly.   
Because of new drugs that become available and an increase in requests for a method to 
identify ARVs, it was necessary to develop and evaluate this method.  Although the purpose 
of this method is only the identification of ARVs in urine, it is also important as part of method 
validation and good laboratory practice (GLP) to analyse samples from patients using 
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antiretroviral drugs to see if the method that was developed complies with the analytical 
criteria required.  
1.2 RATIONALE 
South Africa has the highest HIV infection rate in the world.  Extensive rollout of ARV 
treatment has been mobilized to treat the growing HIV positive population of South Africa.  
The current HPLC method developed by the Department of Pharmacology/Toxicology, 
University of the Free State in Bloemfontein, South Africa, can identify the presence of 
lamivudine, abacavir, zidovudine, nevirapine and efavirenz in urine.  Because of new drugs 
that become available and requests for TDM it is necessary to extend the application of the 
method.  It is also important as part of method validation and GLP to analyse samples from 
patients using ARVs to see if the method that was developed complies with the analytical 
criteria required (Micromedex, 2013).   
1.3 AIM 
The aim of the study is to detect the presence of antiretroviral drugs in urine using high 
performance liquid chromatography. 
1.4 OBJECTIVES 
Further method development and investigation was necessary to identify and include 
stavudine, didanosine, lopinavir, ritonavir and tenofovir in the spectrum of antiretroviral drugs 
detectable by the method used by Pharmacology which only included the identification of 
lamivudine, abacavir, zidovudine, nevirapine and efavirenz in urine.  
1.4.1 Modification of a qualitative HPLC method for the identification of antiretroviral drugs 
 in urine by means of diode array detection 
1.4.2 Expanding the spectrum of antiretroviral drugs detectable by the current method 
1.4.3 Record peak retention time and spectra in a computerized library 
1.4.4 Identify ARV in patient urine samples 
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2  LITERATURE REVIEW 
2.1 INTRODUCTION 
Antiretroviral drugs are medications used in the treatment of retroviral infections, primarily 
HIV.  ARVs are classified by the phase of retrovirus lifecycle that the drug inhibits.  
Nucleoside and nucleotide reverse transcriptase inhibitors (nRTI) inhibit reverse transcription 
by being incorporated into the newly synthesized viral DNA and preventing its elongation.  
Non-nucleoside reverse transcriptase inhibitors (NNRTI) inhibit reverse transcriptase directly 
by binding the enzyme and disrupting its function.  Protease Inhibitors (PIs) inhibit the activity 
of protease, an enzyme used by HIV to cleave proteins for final assembly of new virions.  
Integrase inhibitors inhibit the enzyme integrase which is responsible for the integration of 
viral DNA into the DNA of the infected cell.  Fusion inhibitors (or entry inhibitors) disrupts 
binding, fusion and entry of HIV to the host cell by blocking of targets on the cell.  Maturation 
inhibitors block the conversion of the viral polyprotein into the mature capsid protein, thereby 
releasing defective and non-infectious virions.  Broad spectrum inhibitors are natural 
antivirals such as extracts from certain mushrooms that contain multiple pharmacologically 
active compounds which attack the virus at different stages in its lifecycle (Rang et al. 1999).  
2.2 HIV AND AIDS IN SOUTH AFRICA 
According to the World health organization (WHO), there are approximately 35 million people 
living with HIV/AIDS worldwide of which 3.2 million are children.  Sub-Saharan Africa 
accounts for almost 70% of the global total of new HIV infections with 24.7 million [23.5 
million – 26.1 million] people living with HIV in sub-Saharan Africa.  Women account for 58% 
of the total number of people living with HIV in sub-Saharan Africa.  An estimated 2.1 million 
new infections occur annually of which 240 000 are children.  Most of these children live in 
sub Saharan Africa and were infected by their HIV-positive mothers during pregnancy, 
childbirth or breastfeeding (UNAIDS 2013).   
South Africa has the highest infection rate globally with 5.51 million people of the global 35 
million people infected.  This is an alarming 15% of all HIV infections worldwide occurring in 
South Africa.  Nigeria rates second with 3.3 million people infected and India third with 2.4 
million people living with HIV/AIDS.  HIV prevalence continues to vary by gender and race.  In 
South Africa, females aged 30–34 years (36%) and males aged 35–39 years (28.8%) have 
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been found to have the highest HIV prevalence, which is probably a function of both 
treatment and new infections in this group.  Among adults aged 15–49 years, the number of 
new infections was 1.7 times higher in females than in males.  The incidence rates among 
young females remain concerning.  The HIV-incidence rate among female youth aged 15–24 
was over four times higher than the incidence rate found in males in this age group (2.5% vs 
0.6%).  Almost a quarter (24.1%) of all new HIV infections occurred in young females aged 
15–24 years.  Black Africans, especially females, continue to be disproportionately affected 
by HIV and AIDS, followed by Coloureds.  The highest levels of HIV prevalence are observed 
among female black African adults aged 20–34 years.  The probable reasons for the high 
prevalence of HIV in this group, above and beyond the implementation of ART, are both 
biological susceptibility and the socio-economic conditions in which these women live which 
may give rise to risky sexual behaviour.  The high prevalence observed among black Africans 
made it necessary to interrogate the results further.  It was found that the high HIV 
prevalence in the black African population is associated with low prevalence of marriage, low 
socio-economic status, and other behavioural and social factors that affect this group 
(Shisana et al. 2014; Statistics South Africa 2014). 
The prevalence for Indians, Asians and whites is less than 1%.  However, the figures for 
whites are considered unreliable because of the low response rate.  In attempting to clarify 
the possible reasons for differential racial HIV prevalence, the findings suggest that black 
Africans (39.1%) were less likely than all other races (>85%) to live in urban formal areas.  
Urban informal areas are generally under-resourced and lack some of the basic necessities 
such as formal housing, water, sanitation, and access to preventive health services.  The 
other distinguishing factor among races is marital status.  Black Africans are less likely to 
report being married than whites and Indians or Asians.  HIV prevalence was found to be 
higher in the unmarried, co-habiting population than in the married population (UNAIDS 2013, 
Shisana et al. 2014). 
HIV prevalence is estimated to be 28 times higher among people who inject drugs, 12 times 
higher among sex workers, 19 times higher among gay men and other men who have sex 
with men and up to 49 times higher among transgender women than among the rest of the 
adult population.  In sub-Saharan Africa, adolescent girls and young women account for one 
in four new HIV infections (UNAIDS 2013).   
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2.3 HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED 
IMMUNODEFICIENCY SYNDROME 
Kaposi's sarcoma (KS) was a rare form of relatively benign cancer that tended to occur in 
older people.  But by March 1981 at least eight cases of a more aggressive form of KS had 
occurred amongst young gay men in New York (Hymes et al. 1981).  The United States’ 
Centre for disease control (CDC) published a morbidity and mortality weekly report (MMWR) 
on the 5th of June 1981 describing peculiar cases of a lung infection Pneumocystis carinii 
pneumonia in five young, previously healthy, gay men in Los Angeles.  All the men suffered 
from other unusual infections as well, indicating that their immune systems did not function 
properly.  By the time the report was published, two of the men already passed away.  This 
edition of the MMWR marked the first official reporting of what will become known as the 
AIDS epidemic.  Within days of this report, the CDC was flooded with reports of similar cases 
across America, and within six months 270 cases have been reported of which 121 have died 
(MMWR, 1981).  In June of 1982 report of a group of cases amongst gay men in Southern 
California suggested that the disease might be caused by a virus that was sexually 
transmitted.  By the beginning of July 1982 a total of 452 cases, from 23 states, had been 
reported to the CDC (CDC, 1982).  Later that month the first reports appeared that the 
disease was occurring in Haitians, as well as hemophiliacs, heterosexual males and females, 
and similar cases was reported abroad in the United Kingdom and Africa (MMWR, 1982).  
The acronym AIDS was suggested at a meeting in Washington, D.C., and extensive research 
programs were launched to investigate the causative agent.   
A transmissible retrovirus that was isolated by three different laboratories and named human 
T cell lymphotropic virus type III (HTLV–III), lymphadenopathy associated virus (LAV) and 
acquired immunodeficiency virus associated retrovirus (ARV) has been renamed the human 
immunodeficiency virus (HIV) (Victor & Daniels, 1987).  Two closely related viruses, HIV-1 
and HIV-2 have been identified as causing acquired immunodeficiency syndrome (AIDS).  
HIV-1 causes most cases of AIDS in the Western Hemisphere, Europe, and Central, South, 
and East Africa: HIV-2, which appears less virulent than HIV-1, is the principle agent of AIDS 
in West Africa (Harvey & Mycek, 2000). 
Retroviruses contain the reverse transcriptase enzyme that converts viral ribonucleic acid 
(RNA) into a proviral deoxyribonucleic acid (DNA) copy that becomes integrated into the host 
cell DNA, where they duplicate with normal cellular genes during each cell division.  Multiple 
copies of the infectious virus may be produced, causing other cells to be infected.  The virus 
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destroys helper T cells, thus depressing cell mediated immunity.  Although B cells and T cells 
initially mount a vigorous response to viral exposure, in time a profound deficit of antibodies 
develops and the cytotoxic cells become nonresponsive to viral cues, resulting in the 
increased susceptibility of patients to opportunistic infections, malignancies, neurological 
dysfunction and a variety of other syndromes (Berkow, Fletcher & Beers, 1992). 
The virus multiplies steadily in the lymph nodes throughout most of the chronic asymptomatic 
period.  Symptomatic AIDS gradually appears a few months to ten years later when the 
lymph nodes are destroyed and can no longer contain the virus.  The infectious specificity of 
HIV reflects the fact that the cluster of differentiation 4 (CD4) proteins, through which immune 
cells exchange information, provide the avenue for HIV’s attack.  A particular harpoon-like 
HIV coat glycoprotein (gp120) fits into the CD4 receptor (Marieb, 1997).  HIV also needs a 
co-receptor that changes with the stage of infection.  The protein chemokine receptor gene 5 
(CC-CKR- 5) is the CD4’s partner during the early stage, whereas the fusin receptor aids HIV 
entry during later stages of infection.  Once inside, the virus uses the enzyme reverse 
transcriptase to produce DNA from the information encoded in its viral RNA.  This DNA copy 
or provirus then inserts itself in the host cell to produce new copies of viral RNA and proteins 
so that the virus can multiply and infect other cells (Marieb, 1997; Bradshaw, 2008). 
Unfortunately, no cure has been discovered for HIV and AIDS yet.  The introduction of 
antiretroviral (ARV) drugs changed the prospects of an HIV/AIDS patient dramatically.  The 
aim of current treatment regimens is to reduce the plasma viral concentration as much as 
possible, and for as long as possible.  Although the ARVs cannot cure HIV/AIDS, they can 
increase the life expectancy and support the general health of an HIV positive patient.  The 
national antiretroviral treatment (ART) programme in South Africa was launched in April 
2004.  Patients were considered eligible for ART if they had a stage IV illness (excluding 
extra pulmonary tuberculosis) or a CD4 count less than 200 cells/µl.  The adult regimens 
consisted of two nucleotide reverse transcriptase inhibitors (NRTIs) and one non-nucleotide 
reverse transcriptase inhibitor (NNRTI).  Initially, the NRTI backbone consisted of zidovudine 
and lamivudine, but was later changed to stavudine and lamivudine.  Paediatric regimens 
varied, with NNRTIs and protease inhibitors being variously used with the NRTI backbone. 
Six-monthly CD4 counts and viral-load testing were provided in the programme, together with 
safety monitoring according to the specific regimens.  Today a standardised national line of 
ART regimens are in place specifically designed for South Africa’s unique challenges facing 
the pandemic (Table 1) 
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Table 1: Standardised national ART regimens for adults and adolescents 
Population 1st line Comments 
All new patients needing treatment, 
including pregnant women 
TDF + FTC (or 3TC) + EFV 
FDC preferred 
Replace EFV with NVP in patients with 
significant psychiatric co-morbidity or 
intolerance to EFV and where the 
neuropsychiatric 
toxicity of EFV may impair daily 
functioning, e.g. shift workers. 
Contraindications to EFV TDF + FTC (or 3TC) + NVP Use NVP based regimen: In patients 
with significant psychiatric co morbidity 
or intolerance to EFV and where the 
neuropsychiatric toxicity of EFV may 
impair daily functioning, e.g. shift 
workers. 
Contraindication to TDF AZT+ 3TC + EFV (or NVP) Renal disease or the use of other 
nephrotoxic drugs e.g. aminoglycosides 
Contraindication to TDF and AZT d4T + 3TC+ EFV (or NVP) Renal disease and anaemia or the use 
of other nephrotoxic drugs, 
aminoglycosides 
Contraindication to TDF, AZT 
and d4T 
ABC + 3TC + EFV (or NVP) Renal disease, anaemia, peripheral 
neuropathy, the use of other nephrotoxic 
drugs 
Currently on d4T-based regimen TDF + FTC (or 3TC) + EFV 
FDC preferred 
Mandatory if patients experience toxicity 
and patients who are at high risk of 
toxicity 
(high BMI or pregnant). Switch to TDF if 
virally suppressed and the patient has 
normal creatinine clearance, even if well 
tolerated 
Who 2nd line Action 
Management of virological failure  If plasma HIV RNA >1000 copies, 
Check for adherence, compliance, 
tolerability and drug-drug interaction and 
assess psychological issues. 
Repeat VL test 2 months later 
Failing on a TDF-based 1st line 
regimen 
AZT+3TC+ LPV/r Patients with anaemia and renal failure 
switch to ABC 
Failing on a d4T-based 1st line 
regimen 
TDF+3TC (or FTC) and 
LPV/r 
 
Dyslipidaemia or diarrhoea associated 
with LPV/r 
Switch LPV/r to ATV/r  
Who 3rd line Action 
Failing any 2nd line regimen Specialist referral  
Should be expert and genotype 
resistance testing based decision and 
supervised care 
Patients failing on second line therapy 
will be managed by an expert panel. The 
drugs for third line will be managed 
centrally. More discussion is required to 
deal with the 
modalities 
Most likely regimen would be 
Raltegravir/Darunavir//Etravirine 
adjusted according to genotype 
interpretation. Should be by expert and 
take into account prior exposure and 
predictable mutations 
 
(The national department of health antiretroviral treatment guidelines, 2015) 
List of abbreviations used in table 1 
3TC, lamivudine   FDC fixed-dose combination 
ABC abacavir    FTC emtricitabine 
ATV/r atazanavir/ritonavir   LPV/r lopinavir/ritonavir 
AZT zidovudine   NVP Nevirapine 
d4T stavudine    TDF Tenofovir 
EFV efavirenz 
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2.4 ANTIRETROVIRAL DRUGS 
There are currently six classes (table 2) of ARV drugs available, each classified according to 
their mechanism of action: nucleoside reverse transcriptase inhibitors (NRTIs), 
nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase 
inhibitors (IIs), fusion inhibitors (FIs) and chemokine receptor antagonists (CRAs).  Each 
class of ARV drug targets a different step in the life cycle of the virus (figure 1) during 
infection of a CD4+ T lymphocyte or other target cells (Arts & Hazuda, 2012; Rathbun, 2013). 
Table 2: Classes of ARVs 
NRTIs NNRTIs PIs IIs FIs CRAs 
abacavir 
didanosine 
lamivudine 
tenofovir 
zidovudine 
emtricitabine 
stavudine 
efavirenz 
nevirapine 
delavirdine 
rilpivirine 
etravirine  
atazanavir 
darunavir 
fosamprenavir 
indinavir 
nelfinavir 
saquinavir 
tipranavir 
lopinavir/ritonavir 
raltegravir 
elvitegravir 
 
enfuvirtide maraviroc 
 
List of abbreviations used in table 2 
3TC lamivudine FPV fosamprenavir 
ABC abacavir FTC emtricitabine 
ATV atazanavir IDV indinavir 
AZT zidovudine LPV/r lopinavir/ritonavir 
d4T stavudine MVC maraviroc 
ddl didanosine NVF nelfinavir 
DLV delavirdine NVP nevirapine 
DRV darunavir RAL raltegravir 
EFV efavirenz RPV rilpivirine 
ENF enfuvirtide SQV saquinavir 
ETR etravirine TDF tenofovir 
EVG elvitegravir TPV tipranavir 
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Figure 1: Site of action of ARVs in the HIV life cycle 
(AIDS approach patients, 2010) 
2.4.1 NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS) 
Nucleoside reverse transcriptase inhibitors (NRTIs) were the first antiretroviral drugs 
available for HIV management.  The NRTIs remain part of the current standard care although 
they are less potent than nonnucleoside reverse transcriptase inhibitors (NNRTIs) and 
protease inhibitors (PIs).  They show activity against both HIV-1 and HIV-2.  The NRTIs 
include abacavir, didanosine, lamivudine, tenofovir and zidovudine described in the study 
(Arts & Hazuda, 2012; Rathbun, 2013).   
2.4.1.1 Mechanism of action 
NRTIs disrupt HIV replication through competitive inhibition of HIV reverse transcriptase and 
DNA chain termination.  The HIV-specific DNA polymerase, reverse transcriptase, allows the 
HIV RNA to be transcribed into single strand and double-strand proviral DNA and 
incorporation into the host-cell genome.  NRTIs are structurally similar to DNA nucleoside 
bases and become incorporated into the proviral DNA chain, resulting in termination of the 
proviral DNA chain formation (Arts & Hazuda, 2012; Rathbun, 2013).   
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2.4.1.2 Pharmacokinetics 
NRTIs must undergo phosphorylation by intracellular kinase in order to exert their activity.  
Oral bioavailability ranges from 25%-93% with tenofovir and didanosine at the lowest end of 
the spectrum of bioavailability.  Most of the NRTIs’ absorption is not affected by food, except 
didanosine which must be taken on an empty stomach to achieve optimal absorption.  Most 
NRTIs are eliminated by the kidneys and require dose adjustments in patients with renal 
insufficiency.  Drug interactions are minimal, mainly because of the fact that NRTIs are not 
metabolized by the cytochrome P450 system.  In the case of didanosine, some significant 
drug interactions have been noted.  When didanosine is taken in combination with tenofovir, 
lower doses of didanosine are given to avoid serious adverse effects (Arts & Hazuda, 2012; 
Rathbun, 2013).   
2.4.1.3 Adverse events 
Mitochondrial toxicities such as lactic acidosis, pancreatitis, peripheral neuropathy, 
lipoatrophy and neuropathy can occur.  This is due to NRTI binding to mitochondrial DNA 
polymerase-y enzyme which impairs cellular respiration.  Hypersensitivity reactions may 
occur with abacavir, and bone marrow suppression, myopathy and headaches with 
zidovudine.  Increased risk for adverse cardiovascular events has been associated with 
abacavir and didanosine.  Bone turnover increases with bone loss from the spine and hip, 
with an average 6% loss in bone mass density within a year of commencing treatment 
(McNicholl, 2012; Rathbun, 2013).   
2.4.2 NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) 
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) have been used in the treatment of 
HIV since 1996 with the introduction of nevirapine onto the market.  NNRTIs form part of the 
initial regimens and they exhibit potent activity against HIV-1.  First generation NNRTIs 
include efavirenz, nevirapine and delavirdine.  Second generation NNRTIs currently include 
rilpivirine and etravirine (Arts & Hazuda, 2012; Rathbun, 2013).   
2.4.2.1 Mechanism of action 
NNRTIs bind the p66 subunit of HIV reverse transcriptase.  They induce the formation of a 
hydrophobic pocket proximal to the active site which changes the spatial conformation of the 
substrate-binding site and reduces polymerase activity.  All NNRTIs show activity against 
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HIV-1 isolates, and in vitro studies have shown that etravirine are also active against HIV-2 
(Arts & Hazuda, 2012; Rathbun, 2013).   
2.4.2.2 Pharmacokinetics 
NNRTIs are metabolized by utilizing the cytochrome P450 system and exert either induction 
or inhibition effects on the isoenzymes CYP3A4 or CYP2C9.  This results in a significant 
potential for drug-drug interactions.  Etravirine is a substrate of 3A4, 2C9 and 2C19.  
Nevirapine is metabolized by 3A4 and 2B6 to some degree.  Delavirdine primarily uses the 
3A4 isoenzyme for metabolism (Arts & Hazuda, 2012; Rathbun, 2013).   
2.4.2.3 Adverse events 
NNRTIs are associated with severe allergic reactions of the skin and may cause Stevens-
Johnson syndrome.  Elevation in liver function tests, hepatitis, nausea and diarrhoea is also 
common in patients.  All NNRTIs may have significant interactions with other drugs.  Dosage 
adjustment of interacting agents may be required to eliminate severe adverse reactions.  
Delavirdine and efavirenz may increase transaminase levels, while nevirapine can cause 
severe toxicity, including liver necrosis in patients with CD4 counts above 250 cells/µL.  CNS 
effects such as insomnia, vivid dreaming, hallucinations and confusion may be caused by 
efavirenz.  Side effects can be minimized by avoiding food at the time of administration and 
by taking the agent at bedtime (McNicholl, 2012; Rathbun, 2013).   
2.4.3 PROTEASE INHIBITORS 
HIV protease inhibitors (PIs) forms an integral part of treatment of HIV infection and was first 
introduced in 1995.  The group consists of 8 compounds: atazanavir, darunavir, 
fosamprenavir, indinavir, nelfinavir, saquinavir, tipranavir and lopinavir/ritonavir.  
Lopinavir/ritonavir was investigated in this study.  All the protease inhibitors exhibit the same 
mode of action, although some differences in pharmacokinetics, efficacy and side effects 
exist (Arts & Hazuda, 2012; Rathbun, 2013).   
2.4.3.1 Mechanism of action 
HIV protease inhibitors (PIs) are competitive inhibitors that bind to HIV protease and prevent 
cleavage of polypeptides.  The aspartic acid protein, HIV protease, is a 99-amino-acid protein 
responsible for maturation of virus particles in the later viral life cycle.  HIV protease cleaves 
individual proteins from the gag and gag-pol precursors into functional subunits of viral capsid 
formation during or after viral budding from infected cells.  While HIV can still replicate in the 
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presence of protease inhibitors, the resulting virions are immature and unable to infect new 
cells (Rathbun, 2013).   
2.4.3.2 Pharmacokinetics 
Great variability exists in the pharmacokinetics of patients on PIs.  First-pass metabolism by 
cytochrome P450 (CYP) 3A4 and 3A5 is significant and intestinal efflux by p-glycoprotein 
occurs.  Great potential exists for drug-drug interaction due to the reliance on metabolism via 
CYP3A4, a pathway relied on by many medications for clearance.  Protease inhibitors are 
mainly protein bound (97-99%) to albumin and alpha 1 acid glycoprotein with the exception of 
indinavir.  A low dose of ritonavir is frequently co administered to block hepatic 3A and 
intestinal metabolism.  This co administration improves pharmacokinetic variability and 
consistency in serum concentrations (Rathbun, 2013).   
2.4.3.3 Adverse events 
Metabolic complications such as insulin resistance, lipodystrophy and dyslipidaemia are most 
commonly experienced by patients on PIs.  Dyslipidaemia occurs in 70% of patients and 
requires lipid lowering therapy.  Genetics and lifestyle are important contributing factors to the 
severity of lipid abnormalities.  Modest effects on glucose metabolism have been observed 
with fosamprenavir, tipranavir, nelfinavir and lopinavir/ritonavir, while indinavir shows the 
greatest potential for glucose metabolism abnormalities.  Fat redistribution is observed in 40-
50% of patients on combinations of PIs and NRTIs.  Cardiac abnormalities may develop in 
5% of patients taking atazanavir, ritonavir, lopinavir/ritonavir and nelfinavir.  Intracranial 
bleeding and gastrointestinal side effects can also occur (Rathbun, 2013).  
2.4.4 INTEGRASE INHIBITORS 
HIV’s RNA is converted into DNA by the reverse transcriptase enzyme.  After this process 
has taken place, the HIV DNA must then be incorporated into the DNA of a CD4 cell.  This is 
known as integration.  Integrase was the most recent HIV-1 enzyme successfully targeted for 
potential drug development with the FDA approval of raltegravir in 2007 and other integrase 
inhibitors including elvitegravir.  Integrase catalyses 3’ end processing and viral DNA and 
strand transfer.  Integration inhibitors block this process (Arts & Hazuda, 2012; Hicks, 2013).   
2.4.4.1 Mechanism of action 
HIV integrase is responsible for proviral DNA attachment and transportation to host-cell 
chromosomes.  It allows the transcription of viral proteins and subsequent assembly of virus 
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particles involving two catalytic reactions: 3’-processing in the host-cell cytoplasm to prepare 
proviral strands for attachment and strand transfer where proviral DNA is covalently linked to 
cellular DNA.  The integrase inhibitors inhibit the strand transfer reaction by binding metallic 
ions in the active site (Arts & Hazuda, 2012; Hicks, 2013).   
2.4.4.2 Pharmacokinetics 
Raltegravir is rapidly absorbed and may be taken with or without food.  The terminal half-life 
is 10-12 hours and is administered twice a day.  Raltegravir is 83% bound to plasma proteins 
and is a substrate for P-glycoprotein.  Its pharmacokinetics demonstrates a sex-related 
variation due to the fact that the half-life is slightly longer in women than in men.  Antacids 
may decrease absorption, but no interaction with proton pump inhibitors and H2 antagonists 
are expected.  Uridine diphosphate glucuronyl transferse 1A1 (UGT1A1) is responsible for its 
metabolism and dosage adjustment is not required in patients with renal insufficiency or 
hepatic impairment.  Low-dose ritonavir is co administered with elvitegravir to reduce its first-
pass metabolism.  This results in a 20-fold increase in systemic exposure and a half-life of 
10-13 hours.  Elvitegravir is metabolized via CYP3A4 and UGT1A1/ UDP 
glucuronosyltransferase 1 family, polypeptide A3 (UGT1A3).  Less than 7% is eliminated via 
the kidneys and dosage adjustment is unlikely in patients with renal insufficiency.  The co 
administration of ritonavir is likely to cause drug-drug interactions (Arts & Hazuda, 2012; 
Hicks, 2013). 
2.4.4.3 Adverse events 
Cases of myopathy, rhabdomyolysis and elevated creatinine kinase levels have been 
reported.  More common adverse effects include headaches and gastrointestinal effects such 
as nausea and diarrhoea.  Alanine aminotransferase and aspartate aminotransferase, serum 
cholesterol, triglycerides, amylase and lipase may increase.  A relative risk of malignancy of 
1.2 cases per 100 patient-years has been reported with the use of raltegravir in phase II and 
phase III clinical studies and requires continued surveillance (Arts & Hazuda, 2012; Hicks, 
2013).   
2.4.5 FUSION INHIBITORS 
Fusion inhibitors (FIs) were the first class of antiretroviral drugs to target the replication cycle 
of HIV with the approval of enfuvirtide in 2003.  The development of enfuvirtide emerged from 
a serendipitous observation made during epitope-mapping experiments in the race to find an 
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HIV vaccine.  Synthetic peptides derived from the HIV envelope glycoprotein 41 (gp41) 
produced an antiviral effect when incubated with HIV virus and human T cells.  Subsequent 
insight and comprehension of the fusion process, and how envelope glycoproteins interact, 
led to an appreciation of how these peptides inhibit the fusion of HIV with the human cell 
membrane, and interrupt the HIV life cycle.  Fusion inhibitors have a unique mechanism of 
action that provides additional treatment options for patients who are highly treatment 
resistant (Boyd & Pett, 2008; Rathbun, 2013).   
2.4.5.1 Mechanism of action 
Fusion inhibitor act extracellularly to prevent the fusion of HIV to CD4 cells or other target 
cells by blocking the second step in the fusion pathway by binding to the HR1 region of gp41.  
This mechanism prevents conformational change of gp41 required to complete the final step 
in the fusion process by preventing HR1 and HR2 to fold properly (Rathbun, 2013).   
2.4.5.2 Pharmacokinetics 
Enfuvirtide cannot be administered orally as it is a large peptide which is broken down in the 
digestive tract before absorption.  It requires a twice-daily subcutaneous injection.  As a 
peptide it is catabolised and does not rely on hepatic metabolism.  It does not show any 
influence on the metabolism of other drugs utilizing the cytochrome P450 which limits the 
potential for meaningful drug-drug interactions (Boyd & Pett, 2008; Rathbun, 2013).   
2.4.5.3 Adverse events 
Enfuvirtide requires extensive patient counselling on management of possible side effects, 
adherence and injection technique.  Injection site reactions are common, especially 
erythema, cysts and nodules may occur.  Hypersensitivity reactions include rash, fever, chills, 
nausea and vomiting.  Neutropenia may encourage an increased frequency of pneumonia 
(Boyd & Pett, 2008; McNicholl, 2012).   
2.4.6 CHEMOKINE RECEPTOR ANTAGONISTS (CRAS) 
Maraviroc was introduced to the market in 2007.  It was the first drug in a novel class of 
ARVs known as the chemokine receptor 5 (CCR5) antagonists.  Chemokine receptor 
antagonists inhibit the entry of HIV into the host cell.  Two chemokine receptors, CXCR4 and 
CCR5, are necessary for the virus to enter the cell, so by inhibiting these chemokine 
receptors the disease can be suppressed (Arts & Hazuda, 2012; Rathbun, 2013).   
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2.4.6.1 Mechanism of action  
HIV binds to CD4 cells and ultimately fuses with the host cell.  The gp120 HIV surface protein 
binds to the CD4 receptor which induces a structural change that reveals the third variable 
loop (V3 loop) of the protein.  The V3 loop binds with either CCR5 or CXCR4, allowing 
glycoprotein 41 (gp41) to insert itself into the host cell leading to cell membrane fusion.  
Maraviroc is a small molecule that reversibly and selectively binds the CCR5 coreceptor, 
blocking interaction of the V3 loop, inhibiting fusion of the cellular membranes (Rathbun, 
2013).   
2.4.6.2 Pharmacokinetics 
Maraviroc is extensively metabolized by CYP3A4, with renal clearance accounting for 
approximately 23% of total clearance.  It is also a substrate for the efflux pump p-
glycoprotein.  The half-life of maraviroc is approximately 15-30 hours.  It is approximately 
75% protein bound, mainly to albumin and alpha1 acid glycoprotein.  Maraviroc does not 
inhibit any of the major CYP450 enzymes at clinically significant doses and it has not shown 
any clinically relevant effects on plasma concentrations of other agents; therefore no dose 
adjustments of co-administered drugs are required.  Maraviroc exposure is altered by agents 
that modulate the activity of CYP3A4 and, in some circumstances; maraviroc dose 
adjustment is required (Abel, Back & Vourvahis, 2009; Rathbun, 2013).   
2.4.6.3 Adverse events 
Maraviroc may cause gastrointestinal disturbances including diarrhoea and nausea.  An 
increased incidence of upper respiratory tract infections and persistent cough has been 
reported.  Some patients may experience elevations in liver function tests, hepatitis, joint and 
muscle pain, fatigue, dizziness and headaches.  Caution is advised in patients with hepatic 
impairment.  Postural hypotension may occur in patients receiving in excess of 600mg/day 
(McNicholl, 2012; Rathbun, 2013).   
Abacavir, didanosine efavirenz, lamivudine, lopinavir/ritonavir, nevirapine, stavudine, 
tenofovir and zidovudine are the most popular ARVs considered in current HIV/AIDS 
treatment regimens (Shisana et al. 2014). 
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2.4.7 ABACAVIR 
2.4.7.1 Therapeutic use 
Abacavir (Trizivir®) is a drug indicated for the treatment of HIV infections in adults and 
children older than 12 years (Mallal et al. 2008; Micromedex, 2009).   
2.4.7.2 Contra-indications 
Abacavir is contra-indicated in patients with hepatic impairment, neutropenia and patients 
with low haemoglobin (Hb).  Abacavir is not recommended in breastfeeding mothers, and 
safety during pregnancy is not established (Micromedex, 2009). 
2.4.7.3 Mechanism of action 
Abacavir is a carbocyclic nucleoside with reverse transcriptase inhibitory properties.  
Abacavir is an “indirect” prodrug of carbovir.  Carbovir triphosphate metabolite is active 
intracellularly, although the initial activation step is the phosphorylation to abacavir 
monophosphate (Mallal et al. 2008; Micromedex, 2009). 
2.4.7.4 Absorption, Distribution, Metabolism and Excretion 
Abacavir has a high bioavailability of 83% and its first-pass metabolism is calculated to be 
approximately 17%.  Abacavir may be taken with or without food, and no effect on 
bioavailability was noted.  Fifty percent of Abacavir binds to plasma proteins and protein 
binding is independent of the concentration.  Abacavir levels in cerebrospinal fluid were 18-
33% of the concentrations reached in the plasma.  Abacavir is extensively metabolized by the 
liver.  The primary routes of metabolism are alcohol dehydrogenase and glucoronyl 
transferase.  Excretion of abacavir is mainly via the kidneys.  Only 1% of the unchanged 
compound can be retrieved from urine.  
Recovery for abacavir’s metabolites from the urine range from 36% for the 5-glucuronide 
metabolite; 30% as the carboxylic acid metabolite and approximately 15% of unidentified 
metabolites.  Sixteen percent of abacavir is excreted in the faeces (Micromedex, 2009).  
2.4.7.5 Common side effects 
Side effects experienced with abacavir treatment include blood discrasias, myelosuppression, 
pancreatitis, muscle disorders, CNS effects, cough, skin rash, nail and skin pigmentation, 
urticaria, pruritus, sweat, fever, lethargy, fatigue, malaise, urinary frequency, chest pain and 
gynecomastia in male patients (Mallal et al. 2008; Micromedex, 2009). 
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2.4.7.6 Toxicological adverse effects 
Toxicological effects of abacavir include nausea, vomiting, fatigue, headache, diarrhoea, and 
loss of appetite.  Fatal lactic acidosis and severe hepatomegaly with steatosis have been 
reported.  Fatal hypersensitivity reactions have also been reported and symptoms may 
include skin rash, fever, fatigue, nausea, vomiting, diarrhoea, abdominal pain, pharyngitis, 
dyspnoea, or cough (Micromedex, 2009). 
2.4.7.7 Pharmacokinetic drug interactions of Abacavir 
The AUC of abacavir is increased by ethanol, methadone clearance increases and 
trimethoprim increases lamivudine plasma levels.  Renal excretion of zidovudine is reduced 
by probenecid, rifampicin decreases AUC of zidovudine and inhibition of microsomal 
metabolism may alter zidovudine metabolism.  Nephrotoxic and myelosuppressant drugs 
may increase the risk of zidovudine adverse reactions (Berkow et al. 1992). 
2.4.8 DIDANOSINE 
2.4.8.1 Therapeutic use 
Didanosine (Videx®) is a nucleoside reverse transcriptase inhibitor used in combination with 
other antiretroviral agents for the palliative treatment of advanced HIV in adults and children 
with progressive immunodeficiency (Brinkman et al. 1998; Micromedex, 2010). 
2.4.8.2 Contra-indications 
Didanosine safety in pregnancy and lactation has not been established.  Didanosine is 
contra–indicated in children and in patients with impaired renal and hepatic function.  
Concomitant treatment with allopurinol and ribavirin is not advised. 
2.4.8.3 Mechanism of action 
Didanosine is a purine nucleoside analogue.  The deamination product of dideoxyadenosine 
inhibits HIV replication in both T cells and monocytes.  Didanosine is converted intracellularly 
to the mono-, di- and triphosphates of dideoxyadenosine.  These triphosphates inhibit HIV 
reverse transcriptase thereby blocking viral DNA synthesis and suppression of HIV replication 
(Brinkman et al. 1998; Micromedex, 2010). 
2.4.8.4 Absorption, Distribution, Metabolism, and Excretion 
Didanosine bioavailability ranges from 38% to 43% when taken with an antacid orally.  The 
fraction of didanosine absorbed after oral administration is dependent upon the dosage and 
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the buffering capacity of the antacid administered concomitantly.  Absorption of didanosine is 
greatly decreased when taken with a meal and it is therefore advised to take didanosine at 
least 30 minutes before, or 2 hours after a meal.  Less than 5% of didanosine is bound to 
plasma proteins.  The cerebrospinal fluid (CSF) to plasma concentration ratio is 21%.  
Didanosine is metabolized via the same pathways responsible for the elimination of 
endogenous purines.  Eighteen percent of didanosine is excreted via the kidneys 
(Micromedex, 2010). 
2.4.8.5 Common side effects 
Side effects commonly experienced by patients include cardiovascular effects such as 
dysrhythmia, heart failure, myocardial infarction, palpitations and thrombophlebitis.  Rash, 
alopecia, Steven-Johnson syndrome, myalgia and rhabdomyolysis can also occur.  Fat 
maldistribution, diabetes mellitus, hypoglycaemia, electrolyte disturbances, abdominal pain, 
diarrhoea, nausea, vomiting, pancreatitis and xerostomia are common side effects associated 
with didanosine.  Bilateral gynecomastia is seen in males on didanosine.  Didanosine may 
cause headaches, peripheral neuropathy, insomnia and asthenia, and is known to induce 
seizures in patients with electrolyte disturbances.  Haematological adverse effects include 
anaemia, leukopenia, thrombocytopenia and myelosuppression (Brinkman et al. 1998; 
Micromedex, 2010). 
2.4.8.6 Toxicological adverse effects 
Overdose may lead to fatal lactic acidosis, fatal pancreatitis and extensive hepatocellular 
necrosis with collapse-fibrosis and Steven-Johnson syndrome.  Heart failure and myocardial 
infarction can also occur in overdose (Brinkman et al. 1998; Micromedex, 2010). 
2.4.8.7 Pharmacokinetic drug interactions of Didanosine 
Concomitant treatment with allopurinol increases didanosine AUC 4-fold and should not be 
used together.  The bioavailability of didanosine is enhanced when taken with oral antacids.  
All didanosine formulations contain an antacid already, and by concomitant use of antacids 
such as aluminium carbonate and aluminium hydroxide will increase the risk of adverse 
effects from the antacids.  Didanosine reduces the effect of indinavir, itraconazole, 
amprenavir, cinoxacin, enoxacin, gatifloxacin delavirdine and atevirdine.  Atazanavir 
decreases the solubility of the didanosine formulation.  Didanosine reduces the bioavailability 
of ciprofloxacin.  Ganciclovir and hydroxyurea increases the risk of didanosine toxicity and 
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fatal pancreatitis and hepatotoxicity may develop.  Concomitant treatment with zalcitabine 
causes peripheral neuropathy (Micromedex, 2010). 
2.4.9 EFAVIRENZ 
2.4.9.1 Therapeutic use 
Efavirenz (Stocrin®) is a non-nucleoside reverse transcriptase inhibitor used in combination 
with other ARVs, indicated for HIV-1 infection in adults, adolescents and children 
(Denelsbeck, 2006; Micromedex, 2009). 
2.4.9.2 Contra-Indications 
Efavirenz is contra-indicated in pregnancy because of its teratogenic effect on the foetus.  
Safety in lactation and children under three years of age, or a bodyweight below 13 kg, is not 
established.  It is not recommended to use efavirenz with terfenadine, astemizole, cisapride, 
midazolam, triazolam, ergot derivatives or St John’s Wort (Micromedex, 2009). 
2.4.9.3 Mechanism of action 
The action of efavirenz is through non-competitive inhibition of HIV-1 reverse transcriptase.  
Efavirenz has no inhibitory effect on human immunodeficiency virus type-2 (HIV-2) reverse 
transcriptase or human cellular DNA polymerases alpha, beta, gamma, or delta (Micromedex, 
2009). 
2.4.9.4 Absorption, Distribution, Metabolism and Excretion 
Animal studies show a bioavailability of approximately 42%.  Oral absorption of efavirenz can 
be increased by 17-22% when taken with a fatty meal.  Efavirenz is highly protein bound, 
99.5% to 99.75%, to plasma protein, primarily albumin.  Cerebrospinal fluid values ranged 
from 0.26% to 1.19% of the corresponding plasma concentration in HIV-1 patients treated for 
at least one month with doses of 200mg to 600mg daily of efavirenz.  The volume of 
distribution for intravenous administration has been reported to be 2 to 4 litres per kilogram 
(L/kg).  Efavirenz is metabolized by the liver via the cytochrome P450 system, and efavirenz 
is also known to induce the cytochrome P450 system, thereby inducing its own metabolism.  
Approximately 14-34% of efavirenz is excreted in the urine, mainly as metabolites.  
Approximately 16-61% of the efavirenz mother compound is excreted in the faeces 
(Micromedex, 2009, Patel et al. 2014). 
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2.4.9.5 Common side effects 
Side effects commonly experienced are central nervous system (CNS) effects such as 
psychosis, severe acute depression and suicide, Steven Johnson syndrome, abnormal co-
ordination, hot flushes, flu–like symptoms, syncope, malaise, peripheral neuropathy, speech-, 
visual-, and taste disorders, paraesthesia, hepatitis and GI disturbances (Denelsbeck, 2006; 
Micromedex, 2009). 
2.4.9.6 Toxicological adverse effects 
Toxicological adverse effects include significant CNS effects such as psychiatric effects, rash 
(some with blistering, desquamation, and mucosal involvement), fever, and liver function test 
abnormalities occur (Micromedex, 2009). 
2.4.9.7 Pharmacokinetic drug interactions of Efavirenz 
Drug interactions associated with efavirenz treatment include CNS effects which are 
increased with alcohol and psychoactive drug use.  Plasma concentration of compounds that 
use the CYP3A4 substrate for metabolism is decreased.  The area under the curve (AUC) of 
plasma concentration/time is a common measure of the extent of bioavailability for a drug 
given by a particular route and is expressed as a percentage of the AUC when the drug is 
administered intravenously (100% absorption).  The AUC and maximum concentration of the 
drug reached in the plasma (Cmax) of indinavir, saquinavir and clarithromycin decrease.  
Methadone plasma levels also decrease in patients, resulting in withdrawal symptoms in HIV 
infected intravenous (IV) drug users (Patel et al. 2014).  It is not recommended to use 
efavirenz with terfenadine, astemizole, cisapride, midazolam, triazolam, Ergot derivatives or 
St John’s Wort (Micromedex, 2009). 
2.4.10 LAMIVUDINE 
2.4.10.1 Therapeutic use 
Lamivudine (Combivir®) is a drug used in combination with other antiretroviral agents for the 
treatment of HIV in adults and children with progressive immunodeficiency (Parkin et al. 
2000; Micromedex, 2009). 
2.4.10.2 Contra-indications 
Lamivudine is contra-indicated in patients with neutropenia, and low haemoglobin levels.  
Lamivudine safety in pregnancy and lactation has not been established. 
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2.4.10.3 Mechanism of action 
Lamivudine is a synthetic nucleoside used for the treatment of HIV and AIDS.  The 
mechanism of antiviral activity is related to the intracellular conversion to the 5’-triphosphate 
derivative, which inhibits HIV reverse transcriptase.  This metabolite also serves as a chain 
terminator (Micromedex, 2009). 
2.4.10.4 Absorption, Distribution, Metabolism, and Excretion 
Lamivudine has an excellent bioavailability ranging from 82% to 87%, and bioavailability is 
not affected by the intake of food.  Less than 36% of lamivudine is bound to plasma proteins.  
Lamivudine concentration in cerebrospinal fluid is approximately 54% of the concentration 
found in the plasma.  CSF levels increase proportionally to the dosage of lamivudine.  
Lamivudine has free passage over the placenta.  Metabolism of lamivudine is the minor route 
of elimination.  Approximately 4.2% of lamivudine is converted to its trans-sulfoxide 
metabolite.  Lamivudine is mainly excreted by the kidneys and 70% of the mother compound 
can be recovered in the urine (Micromedex, 2009). 
2.4.10.5 Common side effects 
Side effects commonly experienced by patients include pancreatitis, lactic acidosis, 
hepatomegaly, malaise, headache, musculoskeletal pain, peripheral neuropathy, blood 
discrasias and paraesthesia.  CNS effects such as convulsions and cerebral events, sweat, 
chest pain, chills, urticaria, pruritus, and flu like symptoms may occur (Parkin et al. 2000; 
Micromedex, 2009). 
2.4.10.6 Toxicological adverse effects 
Based on toxicities seen with chronic (therapeutic) administration, acute overdoses may be 
expected to result in bone marrow suppression, peripheral neuropathies, and gastrointestinal 
effects (Micromedex, 2009). 
2.4.10.7 Pharmacokinetic drug interactions of Lamivudine 
Lamivudine treatment can interfere with the metabolism of other drugs taken by the patient.  
Trimethoprim increases plasma levels, and an increased incidence of neutropenia with 
paracetamol use is observed.  Inhibition of hepatic microsomal metabolism causes an 
increased risk for toxicity of nephrotoxic and myelosuppressant drugs.  Probenecid increases 
lamivudine half-life and the AUC of zidovudine (Micromedex, 2009). 
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2.4.11 LOPINAVIR/RITONAVIR 
2.4.11.1 Therapeutic use 
Lopinavir/Ritonavir (Kaletra®, Aluvia®) are drugs used in combination with other dual-NRTI 
component antiretroviral agents for the treatment of HIV in adults and children with 
progressive immunodeficiency (Micromedex, 2010). 
2.4.11.2 Contra-indications 
Lopinavir/Ritonavir safety in pregnancy and lactation has not been established.  Concomitant 
use of lopinavir/ritonavir together with drugs highly dependent on CYP3A for clearance is not 
advised.  Lopinavir/ritonavir should be used with caution in patients at risk for cardiac 
conduction abnormalities (Delfraissy et al. 2008). 
2.4.11.3 Mechanism of action 
Lopinavir is a protease inhibitor of the human immunodeficiency virus.  It prevents the 
cleavage of the Gag-Pol polyprotein, thereby reducing the probability of viral particles 
reaching a mature, infectious state.  Ritonavir is administered solely to increase lopinavir 
levels by inhibiting the CYP3A mediated metabolism of lopinavir. 
2.4.11.4 Absorption, Distribution, Metabolism, and Excretion 
Lopinavir has a low bioavailability due to its rapid metabolism after oral administration.  The 
AUC of lopinavir increases significantly when given with ritonavir due to its inhibition of 
lopinavir’s CYP3A mediated metabolism.  The AUC and Cmax of lopinavir increases when 
taken with a fatty meal.  Lopinavir is highly protein bound.  Approximately 98% to 99% of the 
drug is bound primarily to alpha-1-acid glycoprotein and albumin.  Lopinavir is extensively 
metabolized in the liver via cytochrome P450 CYP3A.  Thirteen metabolites of lopinavir have 
been identified.  The major metabolites are 4-oxo-lopinavir and 4-hydroxy-lopinavir.  Less 
than 3% of lopinavir is excreted unchanged in the urine and approximately 20% in faeces 
(Micromedex, 2010). 
2.4.11.5 Common side effects 
Side effects commonly experienced by patients include cardiovascular abnormalities such as 
PR interval prolongation, prolonged QT interval and Torsades de pointes.  Diabetes mellitus, 
dyslipidaemia, fat maldistribution, impaired glucose tolerance, nausea, diarrhoea, vomiting, 
abdominal pain with flatulence, pancreatitis can also occur.  Patients with haemophilia type A 
and B often experience bleeding, spontaneous skin hematomas and hemarthrosis.  A 
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musculoskeletal abnormality such as osteonecrosis of the femoral head was also reported.  
Headaches, insomnia and asthenia are also common.  Lopinavir has a teratogenic and 
embryocidal effect in pregnancy and should be avoided unless the potential benefit justifies 
the potential risk to the foetus (Delfraissy et al. 2008; Micromedex, 2010). 
2.4.11.6 Toxicological adverse effects 
Based on toxicities seen with chronic (therapeutic) administration, acute overdoses may be 
expected to result in atrioventricular block and myocardial infarction, hyperglycaemia, 
pancreatitis and fatal hepatic dysfunction (Micromedex, 2010). 
2.4.11.7 Pharmacokinetic drug interactions of Lopinavir/Ritonavir  
Concomitant use of lopinavir with potent CYP3A inducers such as cisapride, ergotamine, St. 
John’s Wort, lovastatin, simvastatin and benzodiazepines will result in the increased 
metabolism of lopinavir and reduced plasma concentrations of the drug.  This will cause a 
loss of therapeutic efficacy and increase the possibility of resistance to lopinavir 
(Micromedex, 2010). 
2.4.12 NEVIRAPINE 
2.4.12.1 Therapeutic use 
Nevirapine (Viramune®) is a drug used in combination with other antiretroviral agents, and is 
indicated for HIV-1 infection and to reduce the risk of mother to child transmission 
(Denelsbeck, 2006; Micromedex, 2009). 
2.4.12.2 Contra-indications 
Nevirapine is contra-indicated in patients with severe hepatic impairment and in patients with 
end-stage renal failure when the patient is not being dialyzed.  Safety and efficacy in 
neonates with a bodyweight less than 2.5 kg is not established.  Nevirapine should not be 
used together with Ketoconazole, Rifampicin and St. John’s Wort (Micromedex, 2009). 
2.4.12.3 Mechanism of action 
Nevirapine is a nonnucleoside antiretroviral agent.  Nevirapine is a dipyrodiazepinone 
derivative which selectively inhibits reverse transcriptase activity and replication of HIV-1.  It 
has no activity against reverse transcriptase of other retroviruses such as HIV-2, and is 
inactive against human DNA polymerases.  Unlike nucleoside analogues, nevirapine does 
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not need intracellular phosphorylation for antiviral activity; it reacts directly with reverse 
transcriptase (Micromedex, 2009). 
2.4.12.4 Absorption, Distribution, Metabolism and Excretion 
Nevirapine has a good bioavailability of over 90% after oral ingestion.  The intake of food has 
no significant effect on nevirapine’s absorption, and can be taken with or without food.  
Nevirapine is approximately 60% bound to plasma proteins.  Nevirapine concentrations in 
cerebrospinal fluid were 45% of the concentration of the plasma, with the ratio approximately 
equivalent to the unbound fraction.  Nevirapine is extensively metabolized by the liver, and 
biotransformation of nevirapine occurs via auto induction of the cytochrome P450 CYP3A and 
CYP2B6 isoenzymes.  Nevirapine is known to induce these isoenzymes by as much as 20%.  
The excretion of nevirapine is 81.3% as metabolites, while the mother compound only 
comprises of 5% of the 81.3% that can be recovered from the urine.  Nevirapine is also 
excreted in the faeces and accounts for 10.1% of the total excretion (Micromedex, 2009).  
2.4.12.5 Common side effects 
Side effects found with nevirapine treatment include fatigue, headache, insomnia, 
lymphadenopathy, myalgia, arthralgia, angioedema, fever and blood discrasias (Holtt & Ju, 
2006; Micromedex, 2009). 
2.4.12.6 Toxicological adverse effects 
Overdose information regarding nevirapine is minimal.  Nevirapine appears to have minimal 
toxicity when taken in higher than normal doses.  Toxicological effects found with nevirapine 
overdose include severe and life threatening skin reactions such as Steven Johnson 
syndrome, toxic epidermal necrolysis, and severe hepatotoxicity (Micromedex, 2009). 
2.4.12.7 Pharmacokinetic drug interactions of Nevirapine 
Nevirapine can cause drug interactions with other medications used by the patient.  Low 
plasma concentrations of drugs metabolized by CYP3A4 or CYP2B, decreased enzymes and 
methadone levels, lower efavirenz levels, and increased levels with ketoconazole are found.  
The AUC and Cmax of nevirapine are reduced by Rifampicin (Berkow et al. 1992). 
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2.4.13 STAVUDINE 
2.4.13.1 Therapeutic use 
Stavudine (Stavir®, Zerit®) is a nucleoside reverse transcriptase inhibitor used in 
combination with other antiretroviral agents for the treatment of HIV in adults and children 
(Micromedex, 2010). 
2.4.13.2 Contra-indications 
Stavudine safety in pregnancy and lactation has not been established.  Stavudine is contra-
indicated in children under the age of 6 months, and concomitant use with didanosine and 
zidovudine should be avoided (Carr & Cooper 2000). 
2.4.13.3 Mechanism of action 
Stavudine is a synthetic thymidine nucleoside analogue.  Stavudine is phosphorylated by 
cellular enzymes to its monophosphate, diphosphate and triphosphate form of which the 
triphosphate form is responsible for its antiviral effects through selective inhibition of HIV 
reverse transcriptase.  
2.4.13.4 Absorption, Distribution, Metabolism, and Excretion 
Stavudine has good bioavailability of 77% to 86% after oral ingestion.  Stavudine may be 
taken with or without food.  Protein binding of the drug is negligible and mean CSF to plasma 
concentration ratio is 59%.  Metabolism of stavudine occurs in the liver although metabolism 
plays a minor role in the clearance of the drug.  Unchanged stavudine is the major circulating 
component in the plasma while metabolites such as oxidized stavudine, glucoronide 
conjugates and an N-acetylcysteine conjugate is the minor component in the plasma.  
Approximately 40% of the unchanged drug is excreted via the kidneys, and 3% is excreted in 
the faeces (Micromedex, 2010). 
2.4.13.5 Common side effects 
Side effects commonly experienced by patients include rash, diabetes mellitus, fat 
maldistribution, abdominal pain diarrhoea, nausea, vomiting and a loss of appetite.  Lactic 
acidosis, hepatomegaly, steatosis of the liver and liver failure may occur.  Muscle weakness 
and myalgia are common.  Haematological adverse effects include anaemia, leukopenia, 
macrocytosis, neutropenia and thrombocytopenia.  CNS effects such as Guillain-Barre 
syndrome, headaches, peripheral neuropathy and cramping has also been reported.  
Stavudine is ototoxic and may cause a bilateral neurosensorial hearing deficit.  Stavudine 
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may also cause nervousness and sleep disorders with mania and anxiety (Carr & Cooper 
2000; Micromedex, 2010). 
2.4.13.6 Toxicological adverse effects 
Acute overdoses may result in fatal lactic acidosis, bone marrow suppression, peripheral 
neuropathies, respiratory failure, liver failure, steatosis of the liver and manic episodes 
(Micromedex, 2010). 
2.4.13.7 Pharmacokinetic drug interactions of Stavudine 
Didanosine increases stavudine plasma concentrations and the combination may cause 
severe lactic acidosis and hepatotoxicity.  Doxorubicin hydrochloride, zidovudine, ribavirin 
and methadone decreases stavudine efficacy.  The hepatotoxic effects of stavudine are 
increased by hydroxyurea (Carr & Cooper 2000; Micromedex, 2010). 
2.4.14 TENOFOVIR 
2.4.14.1 Therapeutic use 
Tenofovir (Truvada®, Viread®) is a drug used in combination with other antiretroviral agents 
for the treatment of HIV in adults and children and for the treatment of chronic Type B 
Hepatitis in the HIV positive patient (Gallant & Deresinski, 2003; Micromedex, 2010). 
2.4.14.2 Contra-indications 
Tenofovir safety in pregnant and lactating woman, and children younger than 18 has not 
been established.  Tenofovir is contra-indicated in patients with renal failure, and should not 
be used in Hepatitis B virus co-infections unless an appropriate antiretroviral combination 
regimen is in place to avoid HIV-1 resistance. 
2.4.14.3 Mechanism of action 
Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate nucleotide.  It does not 
require intracellular phosphorylation and is rapidly converted to its corresponding active 
diphosphate form.  The active diphosphate form of tenofovir inhibits retroviral reverse 
transcriptase intracellularly (Micromedex, 2010). 
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2.4.14.4 Absorption, Distribution, Metabolism, and Excretion 
Tenofovir has an approximate bioavailability of 25% to 40% after oral administration.  
Tenofovir AUC and bioavailability increases when administered with food to HIV patients.  
Less than 7.2% of the drug is protein bound and is extensively distributed in lymphocytes 
where it is converted to its active diphosphate form.  Tenofovir undergoes minimal systemic 
metabolism.  Tenofovir disoproxil fumarate is rapidly hydrolysed to tenofovir by endogenous 
plasma esterases after oral absorption.  Tenofovir is excreted through both glomerular 
filtration and tubular secretion via the kidneys and approximately 70%-80% of the compound 
is excreted unchanged (Micromedex, 2010) 
2.4.14.5 Common side effects 
Side effects commonly experienced by patients include headaches, dizziness, depression, 
peripheral neuropathy, nausea, diarrhoea, vomiting, flatulence, neutropenia, pruritus, 
maculopapular rash, pustular rash and urticaria.  Common metabolic disturbances such as 
antiretroviral associated fat maldistribution and lipodystrophies including central obesity, 
dorsocervical fat enlargement, peripheral and facial wasting, breast enlargement, 
hypophosphatemia, renal failure, hepatotoxicity and lactic acidosis can also occur.  Disorders 
of the muscles and bones such as osteomalacia, osteopenia with associated increase in 
bone fragility, muscle weakness and rhabdomyolysis is a common phenomenon in patients 
on tenofovir treatment.  Tenofovir may cause Fanconi syndrome, allergic reactions and 
immune reconstitution syndrome where the patient may have an inflammatory response to 
indolent or residual opportunistic infections (Gallant & Deresinski, 2003; Micromedex, 2010). 
2.4.14.6 Toxicological adverse effects 
Severe and fatal lactic acidosis has been reported in acute and chronic overdoses of 
tenofovir.  Acute toxicological events such as severe allergic reactions, renal failure, 
hepatotoxicity and hepatic steatosis may occur in overdose (Micromedex, 2010). 
2.4.14.7 Pharmacokinetic drug interactions of Tenofovir 
Tenofovir treatment can interfere with the metabolism of other drugs taken by the patient.  
Tenofovir increases plasma levels of other drugs that are eliminated by active tubular 
secretion.  Tenofovir increases the Cmax and AUC of didanosine while a decrease in 
atazanavir AUC and Cmin may occur (Micromedex, 2010). 
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2.4.15 ZIDOVUDINE 
2.4.15.1 Therapeutic use 
Zidovudine (Retrovir®) is a drug used in combination with other ARVs, indicated for HIV in 
adults and children where the T helper cell count is below 500 per cubic millimetre (mm³) 
(Denelsbeck, 2006).  Zidovudine is indicated in pregnant, HIV positive women after 14 weeks 
of gestation and new born infants to reduce the risk of maternal-foetal transmission.  
Zidovudine is also indicated in advanced disease states of HIV e.g. AIDS and ARC, as well 
as post exposure prophylaxis (Delfraissy et al. 2008 Micromedex, 2009). 
2.4.15.2 Contra-indications 
Zidovudine is contra-indicated in patients with Neutropenia and low Hb levels less than 
7.5 gram per decilitre (g/dl).  The safety of zidovudine during the first trimester of pregnancy 
is not established, and data available for use in children under 3 months is insufficient to 
propose a specific dose recommendation (Micromedex, 2009). 
2.4.15.3 Mechanism of action 
Zidovudine is a synthetic Thymidine analogue with antiretroviral properties.  Zidovudine is a 
potent inhibitor of the in vitro replication and cytopathic effect of HIV.  Zidovudine interferes 
with retroviral DNA polymerase (reverse transcriptase) and inhibits viral replication.  
Zidovudine is intracellularly converted to zidovudine monophosphate.  It is further converted 
into a diphosphate and a triphosphate form.  Zidovudine triphosphate interferes with reverse 
transcriptase thus inhibiting viral replication.  The azido group substitution makes 
phosphadiester linkages impossible and terminates chain synthesis of DNA.  HIV is 
100 times more susceptible to inhibition by zidovudine than the DNA polymerase of human 
cells (Micromedex, 2009). 
2.4.15.4 Absorption, Distribution, Metabolism and Excretion 
Zidovudine has good bioavailability of 64%, and ingestion together with food does not affect 
the bioavailability, nor does gastric hypoacidity which occurs in 20% of patients with HIV.  
Less than 38% of zidovudine is plasma bound.  Cerebrospinal fluid concentrations are 50% 
to 70% of plasma levels.  Zidovudine crosses the placenta, and the foetal blood concentration 
is equivalent to concentrations in the maternal blood.  Zidovudine and its glucoronide 
metabolite are highly distributed into the semen with semen/serum ratio levels ranging from 
1.3 to 20.4, which are above the in vitro minimum inhibitory concentration (MIC) for HIV-1.  
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Zidovudine is extensively metabolized in the liver with significant first-pass metabolism and is 
mainly excreted via the kidneys, and urinary recovery of the drug is between fourteen to 
eighteen percent (14–18%).  The urinary recovery for the glucoronized metabolite is 74% 
(Delfraissy et al. 2008; Micromedex, 2009).  
2.4.15.5 Common side effects 
Side effects commonly experienced are central nervous system (CNS) effects such as 
psychosis, severe acute depression and suicide, Steven Johnson syndrome, abnormal co-
ordination, hot flushes, syncope, malaise, peripheral neuropathy, speech-, visual-, and taste 
disorders, paraesthesia, hepatitis and  gastrointestinal (GI) disturbances.  Side effects 
commonly experienced with zidovudine treatment include bone marrow depression, 
hepatomegaly, pancreatitis, lactic acidosis, convulsions, flu–like symptoms with cough, nail 
and skin pigmentations, chest pain, chills and gynecomastia in male patients ( Holtt & Ju, 
2006; Micromedex, 2009). 
2.4.15.6 Toxicological adverse effects 
Several cases of acute overdose with zidovudine have been reported in the literature with 
minimal toxicological effects.  Overdose effects may include bone marrow suppression, 
lethargy, fatigue, and possibly seizures (Delfraissy et al. 2008; Micromedex, 2009). 
2.4.15.7 Pharmacokinetic drug interactions of Zidovudine 
Zidovudine treatment poses several drug interactions with other medication.  Increased 
incidents of neutropenia occur with the use of paracetamol.  Inhibition of hepatic microsomal 
metabolism causes an increased toxic risk with potent nephrotoxic and myelosuppressant 
drugs (Micromedex, 2009). 
2.5 ANALYTICAL METHODS USED IN THE DETECTION OF 
METABOLITES IN URINE 
The identification of drug metabolites in biological matrixes such as urine, plasma, and bile, 
as well as in in vitro systems, is an important step in drug discovery and development.  Mass 
spectrometry, particularly when combined with high-performance liquid chromatography, can 
enable detailed structural information to be obtained on the metabolites of a drug as a result 
of metabolism.  The successful identification of drug metabolites by high performance liquid 
chromatography-mass spectrometry (HPLC-MS) based methods require careful optimization 
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of a number of factors.  First, the chromatographic separation should provide good resolution 
of the individual xenobiotic metabolites present in the sample.  It is also required to minimize 
the interference caused by the presence of endogenous metabolites, which may interfere 
with mass spectrometry (MS) detection.  Ideally, untreated samples should be profiled to 
reduce the likelihood of missing important metabolites due to losses during sample 
preparation, but, depending upon the matrix, some degree of sample extraction and 
concentration of the metabolites may be required using liquid–liquid or liquid–solid extraction.  
Second, the MS conditions must be carefully selected in order to maximize the potential of 
detecting the separated metabolites, which may have a very different character to the parent 
compound.  The use of radiolabeled drugs in metabolism experiments greatly aids in the 
detection and quantification of metabolites, directing the investigator towards peaks that need 
to be characterized by MS.  The presence of characteristic isotope patterns from either the 
incorporation of stable isotopes (e.g. 13C, 15N) or naturally occurring isotope patterns from 
substituents on the molecule (e.g. 35/37Cl, 79/81Br) can also provide a useful handle on the drug 
and its metabolites for the purposes of detection and spectrometric interpretation (Wilson, 
2010).   
The basic rule of thumb is that most metabolites are more hydrophilic when compared to the 
parent compound, and also more acidic.  The most used and versatile analytical methods for 
metabolite profiling are based on combining liquid chromatography with mass spectrometry 
(LC/MS), providing both qualitative and quantitative information simultaneously.  Use of mass 
spectrometry as a detection method provides also high detection specificity, as the mass 
selective detection decreases the need for complete chromatographic separation for 
compounds with different molecular weight. 
The most efficient approaches in metabolite identification are those using time-of-flight mass 
(TOF) spectrometry or Orbitrap mass spectrometry.  The high mass resolving power of these 
instruments provides high specificity of detection, whereas the high mass accuracy enables 
identification of biotransformations in the detected metabolites with very high certainty by 
elucidation of changes in molecular formula with respect to the parent compound 
(Admescope, 2014).   
Ter Heine et al. (2009) described liquid chromatography coupled to linear ion trap mass 
spectrometry and liquid chromatography coupled to triple quadrupole mass spectrometry to 
identify atazanavir metabolites.  Glucoronidase treatment and a liquid chromatography-
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tandem mass spectrometry (LC/MS/MS) method for the determination of nevirapine 
metabolites was proposed by Cammett et al. (2009).   
An LC/MS/MS method equipped with a triple-quadrupole mass spectrometer and an 
electrospray ion source, operated in positive-selective-reaction monitoring mode, was used 
by Chen et al. (2007).   
2.6 ANALYTICAL METHODS USED IN THE DETECTION OF ARV 
DRUGS IN URINE 
Several studies describe different methods for the detection of ARV drugs in biological 
matrixes.  A two-dimensional reversed-phase liquid chromatography – tandem mass 
spectrometric method to determine antiretroviral drugs abacavir, nevirapine and indinavir in 
rat serum and urine was proposed by Rao & Shinde (2009).  The analytes were extracted on-
line from rat serum and urine by a restricted access material (RAM) column and back-flushed 
into the reversed-phase C18 column for separation by LC.  Detection was carried out by 
electrospray tandem mass spectrometry (ESI-MS/MS). 
 
Morris & Selinger (1994) have described a high-pressure liquid chromatographic method for 
the determination of lamivudine in urine which allows direct injection of urine with column 
switching.  The method requires two columns, one for removal of unwanted urine 
constituents, and the other for elution of lamivudine.  Supriya, Ashish & Meena (2012) 
proposed a high performance liquid chromatography tandem mass spectrometric method for 
the estimation of emtricitabine in human urine by utilizing solid phase extraction.  The 
samples were chromatographed on Hypurity Advance, 50 x 2.1, 5μ column using a mobile 
phase consisting 5mM ammonium acetate: acetonitrile: methanol: (30:30:40 v/v).   
 
Elens et al. (2009) described an ultra-performance liquid chromatography (UPLC) method 
with a solid-phase extraction method used for plasma.  A linear gradient of 50 mmol/L 
ammonium acetate and 50 mmol/L formic acid in water versus acetonitrile was used to 
achieve chromatographic separations.  Direct injection of diluted urine (1:10/1:50) and 
analysis with a 150-mm column with UV detection was used by Agibothu et al. (2006).  The 
HPLC system used comprised of two pumps, a diode array detector, and a rheodyne manual 
injector attached with a 20 microliter sample loop for sample injection.   
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Remmel et al. (2000) proposed high performance liquid chromatography with a liquid-liquid 
extraction for sample preparation using methanol as a solvent.  Lemmer et al. (2005) 
described a gas chromatography-mass spectroscopy in selected ion monitoring mode 
(GC/MS-SIM) detection method together with solid-phase extraction for determination of 
antiretrovirals in human plasma. 
 
A reverse-phase high performance liquid chromatography method utilizing ultraviolet 
detection was proposed by de Oliveira et al. (2005) for the determination in didanosine 
tablets.  They proposed a pre-packed Lichrospher 100 Rp-8 column using 0.01 M sodium 
acetate solution: methanol (85:15 v/v).  Acetic acid was used as mobile phase at a flow rate 
of 1.5 ml/min and a 248 nm detection.  Fletcher et al. (2000) used a reverse-phase high 
pressure liquid chromatography method to quantify indinavir in plasma.  A 35:65 (v/v) solution 
of acetonitrile in a 50 mM phosphoric acid o-phosphoric acid buffer adjusted to a pH of 3.1 
was used.  A liquid-liquid extraction was used to separate compounds of interest from the 
plasma matrix.  A reverse-phase high performance liquid chromatography method utilizing a 
diode array detector and liquid-liquid extraction was used to develop the current HPLC 
method used by the Department of Pharmacology/Toxicology, University of the Free State in 
Bloemfontein, South Africa.  Various GC/MS and HPLC methods and conditions, as well as 
extraction methods have been investigated.  
2.6.1 CHROMATOGRAPHY 
Chromatography refers to a physical separation method used to separate components.  The 
components which need to be separated are distributed in two phases, a stationary phase 
and a mobile phase.  During the chromatographical process a continuing sorbsion and 
desorpsion of particles take place as the components move through the stationary bed.  
Separation is achieved because of the difference in distribution coefficients of each 
component (Dinunzio, Hutchison, & Yost 1985).  
2.6.2 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY  
High performance liquid chromatography refers to high speed, high resolution separation of 
substances.  Separation of substances is achieved by the extraction of the components from 
the urine and reconstituting the precipitate into a mobile phase compatible with the selected 
HPLC system.  The extraction is then injected into a liquid mobile phase which acts as a 
carrier for the different components.  The extraction is then carried through a 
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chromatographical column via the mobile phase.  The column consists of a cylindrical bed, 
tightly packed with small sorbsion particles with a diameter of 10µm or smaller (Dinunzio et 
al. 1985). 
The HPLC system is selected so that every component in the extraction has a unique and 
characteristic speed through which it will move through the column.  Sorbsion of the 
components causes its retention, and retention differences are a result of the chemical 
selectivity of the system.  Separation of the components takes place and the components 
form thin chromatographic bands which elutes at the end of the column.  The mobile phase 
flows through a detector which records the chromatographic bands and then sends a signal 
to a register which interprets the chromatographic bands as a series of peaks on a 
chromatogram (Dinunzio et al. 1985). 
2.6.3 REVERSED PHASE CHROMATOGRAPHY  
Reversed phase chromatography is the most popular form of HPLC because it can handle 
the greatest variety of sample types.  In reversed phase a non-polar stationary phase and 
polar mobile phase is used.  The introduction of alkyl chains bonded covalently to the silica 
support surface enables the polar compounds to elute first while the non-polar compounds 
are retained in the column.  The retention time of a compound can be increased by adding 
more water to the mobile phase.  This will increase the affinity of the hydrophobic compound 
for the hydrophobic stationary phase relative to the now more hydrophilic mobile phase.  
Retention times of compounds can be decreased by adding more organic solvent to the 
mobile phase mixture (Guzzetta, 2001). 
2.6.4 GRADIENT ELUTION 
Gradient elusion refers to a separation in which the mobile phase composition is changed 
during the separation process.  Gradient elusion decreases retention times of later-eluting 
components so that they elute faster, giving narrower and taller peaks for most compounds.  
This also improves the peak shape for tailed peaks.  A gradient elution method was used 
where the mobile phase composition was changed during the analysis time of 30 minutes.  At 
the beginning of the run Solvent B (organic solvent) is at 0% strength and Solvent A 
(aqueous solvent) at 100% (10% Acetonitrile (ACN) preservative added) strength resulting in 
the resolution of the early components.  As the separation progresses, the ratio of Solvent B 
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to Solvent A is gradually increased so that the subsequent components elute within a 
reasonable time (Du Plessis, 1994). 
2.7 COLUMN THEORY 
Chromatography separates a sample into its constituent parts because of the difference in 
the relative affinities of different molecules for the mobile phase and the stationary phase 
used in the separation.  A successful chromatographical separation requires a delicate 
balance between resolution, sample capacity and analysis time as described in 2.5.1 to 2.5.5 
below: 
2.7.1 RESOLUTION (R)  
Resolution reveres to the physical separation between two components (Figure 1).  For 
optimal quantitative and qualitative analysis, the resolution value must be equal to or greater 
than 1.25 (Dinunzio et al. 1985).  Resolution can be quantified by the following formula: 
    R = tR2 – tR1  
            __W2 + W1__ 
            2 
     =      ___2Δt___ 
      W2+W1 
R = resolution 
tR2 and tR1 = retention times of components 
W2 and W1 = peak width at the base of the peak 
Δt = difference in time 
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     tR2 
 
 Δt 
 
 
 
 
tm  
 tR1 
 
 
 
Time                                  WB1 WB2 
tR1 = retention time of component 1 
tR2 = retention time of component 2 
WB1 = peak width at base of peak 1 
WB2 = peak width at base of peak 2 
Δt = difference in time 
Figure 2: Resolution of the physical separation between two components 
For optimal quantitative and qualitative analysis: R ≥ 1.25 (Dinunzio et al. 1985). 
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2.7.2 COLUMN EFFICIENCY 
To obtain optimal separations of compounds, sharp, symmetrical chromatographic peaks 
must be obtained and peak broadening must be limited.  The efficiency of a column is 
expressed by the quantity of theoretical plates (N). 
Column efficiency increases as the quantity of theoretical plates increases (Dinunzio et al. 
1985).  The value of N is independent from the retention time and can be calculated by the 
following formula: 
     N  =   [tR/α]2 
N = quantity of theoretical plates 
tR = retention time 
α = column selectivity 
 
Column length is a variable factor.  Because of this it is necessary to standardize the formula 
for efficiency which is independent from the column length.  The highest equivalent of 
theoretical plates (HETP) is used to compare columns with different lengths: 
        HETP = L  
       N 
HETP = highest equivalent of theoretical plates 
L = length of the column 
N = quantity of theoretical plates 
 
2.7.3 COLUMN SELECTIVITY (Α) 
Column selectivity describes the relative position of two adjacent peaks. 
       α    = tR2-tm 
      tR1-tm 
        = tR2’ 
      tR1’ 
 
α = column selectivity 
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tR1 = retention time of peak 1 
tR2 = retention time of peak 2 
tm = retention time of solvent front 
 
When α = 1, the two peaks have the same retention time and therefore no resolution.  Better 
resolution can be achieved by changing α by changing either the mobile phase or the 
stationary phase (Dinunzio et al. 1985). 
2.7.4 FLOW RATE (U) 
Component molecules move through the column via a mobile phase.  The flow rate of the 
mobile phase influences the chromatographic process.  Flow rate can be determined with the 
following formula: 
    u   = L (tm) 
u = flow rate  
L = column length in mm 
tm = retention time of solvent front 
 
An optimal flow rate exists where the column is most effective in the separation of 
components.  If the flow rate is to slow, component molecules will diffuse in the mobile phase 
which will result in broad peaks.  If the flow rate is too fast, component molecules will elute 
with the solvent front and no separation will be achieved.  Most HPLC determinations use a 
flow rate of 0.5 – 2.0 ml/min. (Guzzetta, 2001). 
2.7.5 CAPACITY (K’) 
Resolution is a function of the relationship of the volumes of the mobile phase and the 
stationary phase in the column.  This relationship is known as the capacity factor.  The 
capacity factor indicates how long each compound is retained by the stationary phase, and 
the time the component spends in the mobile phase.  This relationship can be expressed by 
the following formula: 
    k’  =          tR 
      tm 
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tR = retention time 
k’ = capacity 
tm = retention time of solvent front 
Small values for k’ indicates that the component is minimally retained in the column and 
results in low resolution of the component.  An ideal value for k’ would be between 2 and 7 
(Dinunzio et al. 1985). 
The relationship of abovementioned characteristics can be expressed in the following 
formula: 
   R =  ¼ √N     (α – 1/ α)     (k’/ k’ + 1) 
     a         b                c 
 
a = column efficiency  
b = column selectivity 
c = capacity 
▪ Resolution can be optimized by either changing a, b or c. 
To obtain optimal separations of compounds, sharp, symmetrical chromatographic peaks 
must be obtained and peak broadening must be limited.  This can be achieved by 
manipulating the different factors in the column theory: 
 For optimal quantitative and qualitative analysis, resolution (R) must be equal to, or 
higher than 1.25 
 Column efficiency can be optimized by the addition of stationary phase.  If this is not 
possible, another column can be attached which in turn will increase the quantity of 
the theoretical plates 
 Increase resolution by changing column selectivity (α) 
 Changing column selectivity (α) by changing either the mobile phase or the stationary 
phase in order achieve good separation of peaks 
 By manipulation of the flow rate (u) 
 Capacity (k’) can be optimized by manipulating the flow rate (u), or by changing the 
mobile  phase or stationary phase to obtain a value between 2 and 7 
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 By changing the gradient elution 
The selectivity of the HPLC system can be increased by manipulation of the different factors 
involved.  Highly selective HPLC systems will ensure good quality separations of substances 
and easy identification and quantification of these substances (Snyder, 1997). 
2.8 DIODE ARRAY DETECTION  
Chemical compounds have characteristic spectra which can assist in their identification.  The 
diode array detector offers detection over a wide range of ultraviolet (UV) wavelength.  The 
most popular wavelengths range from 210 nanometre (nm) to 330nm.  Ultraviolet light from a 
deuterium lamp passes through a flow cell after which it is dispersed into its component 
wavelengths by a fixed grating.  The intensity at each wavelength is simultaneously 
measured by an array of several hundred photodiodes.  The output from each diode is 
processed, stored and displayed continuously as the run progresses.  The results can then 
be used to construct absorption spectra that can be compared with standard spectra for 
identification purposes (Scott, 2010). 
A special feature of some variable wavelength UV detectors is the ability to perform 
spectroscopic scanning and precise absorbance readings at a variety of wavelengths while 
the peak is passing though the flow cell.  Diode array adds a new dimension of analytical 
capability to liquid chromatography because it permits qualitative information to be obtained 
beyond simple identification by retention time.  Highly selective HPLC systems with diode 
array detection will ensure easy identification and quantification of these substances. 
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3 MATERIALS AND METHODS 
3.1 INTRODUCTION 
The development of a qualitative HPLC method for the identification of ARVs in urine will be 
presented in this chapter.  The identification, standardization and validation of this method 
included the recording of retention time and spectra of the known antiretroviral pure 
compounds, setting up of a calibration curve at different concentrations of each compound, 
accuracy, precision, recovery of the different antiretroviral compounds and the identification 
of ARV metabolites in a urine sample. 
3.2 STUDY LOCATION 
The study was conducted at the Department of Pharmacology/Toxicology of the University of 
the Free State in Bloemfontein, South Africa. 
3.3 STUDY DESIGN 
It is an experimental, explorative descriptive study  
3.4 STUDY LAYOUT 
The first step in the development of an HPLC method was to identify a suitable solvent in 
which the pure compounds to be investigated can dissolve in.  A solvent (Solvent C, a 
mixture of Tetraethylammonium phosphate buffer, Acetonitrile and H3PO4) was selected and 
Solvent C was used to prepare stock solutions and to reconstitute residues of urine samples 
after extraction method was completed.  A stock solution of each ARV, lamivudine, abacavir, 
zidovudine, nevirapine, efavirenz and the new additions, stavudine, didanosine, lopinavir, 
ritonavir and tenofovir was prepared by dissolving the pure compound in solvent C.  Initial 
trial runs were performed to assess the required concentration for each stock solution.  Each 
individual ARV stock solution was injected into the HPLC.  After the analysis was completed, 
retention times (Figure 4.11) and UV spectra (Appendix 7.25 to 7.32) of each ARV was 
recorded and stored in a computerised library.  Normal urine samples were spiked with the 
stock solutions and the pure compounds was extracted with the extraction procedure 
described in 3.10.  The precipitate was then reconstituted in Solvent C and injected into the 
HPLC to analyse the retention times and UV spectra after the extraction procedure was 
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performed on the samples.  The recovery of each compound was calculated to establish the 
efficacy of the extraction procedure.  Participants on ARV treatment donated urine samples 
for analysis of the method.  The patient urine samples were subjected to the same extraction 
procedure described in 3.10, injected into the HPLC and investigated.  Peaks and UV spectra 
detected in patient samples were compared to the stored database of ARVs in the 
computerised library.  Successful identifications of the ARVs could be made in the donor 
patient urine.   
 
 Stock solutions of ARV pure compounds  
↓ 
Injected into HPLC 
↓ 
Retention times and UV spectra recorded 
↓ 
Normal urine samples spiked with ARV stock solution 
↓ 
Antiretroviral drugs extracted with extraction procedure 
↓ 
Reconstitution in Solvent C (2.6)  
↓ 
Injected into HPLC 
↓ 
Retention times and UV spectra recorded 
↓ 
Calculation of recovery 
↓ 
Participants’ urine extracted 
↓ 
Injected into HPLC 
↓ 
Peak retention times and UV spectra recorded and compared to library for identification  
↓ 
↓ 
Identification of Antiretroviral drugs present in patients’ urine 
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3.5 ETHICAL ASPECTS 
Ethical approval was granted by the ethics committee, UFS. ETOVS no: 2010/100.  
Permission for the study was granted by Internal Medicine at Pelonomi Hospital in 
Bloemfontein, South Africa and the department of Pharmacology/Toxicology at the University 
of the Free State in Bloemfontein, South Africa.   
3.6 STUDY POPULATION 
The study population was HIV positive patients on ARV treatment.  Subjects were recruited 
from internal medicine at Pelonomi hospital, Bloemfontein.  The subjects were identified with 
a PM number supplied by Pelonomi hospital.  Thirty seven individuals were identified by 
clinicians from Internal medicine according to the ARV regimen of each patient in order to 
cover the spectrum of the antiretroviral drugs applicable to the study.  The clinicians 
introduced the subjects to the study by supplying them with an information document and 
explained the procedures and confidentiality of their participation.  They assisted the subjects 
with completion of the informed consent forms.  Urine samples were collected during four 
consecutive routine follow-up visits to the HIV clinic of Internal medicine.  The study was 
explorative in nature and did not require a large sample population.   
The donor of the urine samples that was spiked with pure ARV compounds was a healthy 
individual that has never taken antiretroviral drugs.  Some commonly used acidic drugs such 
as paracetamol, salicylic acid and the non-steroidal anti-inflammatory drugs (NSAIDs) can be 
detected by HPLC.  Therefore the donor was free from any medication for at least 24 hours 
prior to donation.  The donor also received an information document and was required to 
complete informed consent forms. 
3.6.1 INCLUSION CRITERIA 
 HIV positive male and female patients 
 Patients above the age of 18 years 
 Subjects must be on the following ARV treatment applicable to the study: Abacavir, 
Didanosine, Efavirenz, Lamivudine, Lopinavir/Ritonavir, Nevirapine, Stavudine, 
Tenofovir and Zidovudine. 
 Subjects must be on ARV treatment for at least 6 weeks in order to participate in the 
study  
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 Subjects who have given informed consent to participate in the study 
 
3.6.2 EXCLUSION CRITERIA 
 HIV negative patients 
 Patients not on ARV treatment 
 Patients younger than 18 years 
 Pregnant women 
3.6.3 FINANCIAL IMPLICATION FOR THE PATIENTS 
Participants did not receive any payment for their participation in the study, nor was any 
payment received from the patients.  Sample containers were supplied by the researcher at 
no cost to the patients. 
3.6.4 PATIENT SAFETY 
One urine sample was collected over 4 consecutive routine weekly follow-up visits to the HIV 
clinic.  Urine samples contained at least 20 ml of urine.  Samples were collected according to 
prescribed sterile sample collection techniques to insure patient safety. 
3.6.5 WITHDRAWAL CRITERIA 
Participants could withdraw from the study at any time, irrespective of the reason, without any 
penalty or effect on the current or future care and treatment.  No patients withdrew from the 
study and all participating patients adhered to their scheduled follow-up visits for a full 
medical check-up and sample collection.   
3.7 STORAGE AND DISPOSAL OF HUMAN TISSUE 
Urine samples were refrigerated until processed within 48 hours after donation.  Urine 
samples were then frozen at a temperature of -20˚C until the study has been completed.  
Samples were stored in a confidential manner.  No patient details were on the sample 
containers.  Samples were identified by a PM number supplied by Internal medicine at 
Pelonomi Hospital.  Biological samples were discarded in biological waste containers 
supplied by the Department of Pharmacology for safe removal after the study was completed.  
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Specimens were not used for any other tests than that mentioned to the patient and 
approved by the ethics committee. 
3.8 APPARATUS 
3.8.1 APPARATUS 
A precision balance from Mettler Toledo Instruments (Switzerland) was used to weigh the 
pure compounds of the individual stock solutions and the constituents of the mobile phases.  
The precision balance was calibrated daily and has a minimum weight capacity of 0.01g.  
Pipettes from Finnipipettes® and their consumables were used for the accurate pipetting of 
blood and urine samples, chemicals and solutions.  Pipettes were calibrated annually by AEC 
Amersham as determined by the manufacturer.  For the spiking of the stock solutions, 10µL 
and 100µL syringes from Hamilton (Switzerland) were used.  A horizontal shaker from 
Gesellschaft Labortechnik (Germany) was used for the mixing of the extraction samples.  
Samples were centrifuged with a Labofuge 400 from Haraeus Instruments (Germany).  All 
centrifuges were calibrated annually during the yearly service specified by the manufacturer.  
The organic layer of the extraction was evaporated to dryness by using an evaporator with a 
nitrogen gas supply manufactured by the Electronics division of the University of the Free 
State in Bloemfontein, South Africa (Du Plessis, 1994). 
HP 1090 Liquid Chromatograph by Hewlett Packard equipped with Chemetrix System 
Software and a solvent delivery system and auto sampler was used.  A synergi 4U Fusion – 
RP 80 Column with a size of 150 x 4.6 mm and a UV/VIS Diode array detector by Agilent 
Technologies was used. 
3.8.2 CHEMICALS AND REAGENTS 
3.8.2.1 Antiretroviral pure compounds 
Pure compounds of zidovudine (reference number 1736), abacavir (reference number 2067) 
and lamivudine (reference number 535) were donated by GlaxoSmithKline.  Nevirapine pure 
compound (reference number B1P1-0053) was obtained from Boehringer & Ingelheim, and 
efavirenz pure compound (reference number 050301) was obtained from Xiamen Mchem.  
Pure compounds of clomipramine (internal standard), didanosine, stavudine, tenofovir and 
lopinavir were obtained from the Pharmacology reference stock library. 
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3.8.2.2 Chemicals 
HPLC grade acetonitrile, isopropyl alcohol, and dichloromethane were purchased from 
Burdick & Jackson (USA).  Potassium bicarbonate (K2CO3), sodium hydroxy carbonate 
(NaHCO3), phosphoric acid (H3PO4) and Tetraethylammonium phosphate formula was 
purchased from Merck (SA). 
3.8.2.3 Solvents 
A gradient mobile phase was used in the HPLC analysis which consisted of two solvents, 
solvent A and solvent B.  The mobile phase solvents acts as carriers of the compounds of 
interest from the extraction through the HPLC column and are loaded on to the HPLC before 
the run commences.  This process will be clarified in section 3.11 Chromatographic systems 
and conditions discussed in this chapter.   
  
(Chromatography, 2008) 
Figure 3: The HPLC system 
Three different solvents were used in the study: 
1.  Solvent A: Tetraethylammonium phosphate (TEAP) buffer + Acetonitrile (9:1).  Solvent A 
was used as a mobile phase in the gradient elution and loaded on to the HPLC 
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2.  Solvent B: Acetonitrile + H3PO4.  Solvent B was used as a mobile phase in the gradient 
elution and loaded on to the HPLC 
3.  Solvent C was prepared by adding 150ml of Solvent A to 30ml of Solvent B (5:1).  Solvent 
C was used to reconstitute the evaporated extraction for injection into the HPLC.  
3.9 PREPARATION OF MOBILE PHASES 
A gradient mobile phase was used in the HPLC analysis which consisted of two solvents, 
solvent A and solvent B.  The mobile phase solvents acts as carriers of the compounds 
through the HPLC column.   
Solvent A (Aqueous solvent) 
Solvent A comprised of 450ml tetraethylammonium phosphate (TEAP) buffer and 50ml of 
acetonitrile (ACN).  It was prepared by adding 15.54g tetraethylammonium hydroxide to 
400ml of deionised water, adding 50ml of ACN, and reconstituting it to 500 ml by using 
deionised water. 
Solvent B (Organic solvent) 
Solvent B was prepared by adding 100µl H3PO4 to 950ml of ACN and reconstituting it to 1L 
with ACN. 
3.9.1 PREPARATIONS OF OTHER SOLVENTS 
K2CO3 / NaHCO3 Buffer 
The K2CO3 / NaHCO3 Buffer (pH 9.6) was prepared by adding 20g K2CO3 and 20g NaHCO3 to 
160ml deionised water.  The pH was gradually lowered to 9.6 by adding 20% NaHCO3. 
Dichloromethane isopropanol  
Dichloromethane isopropanol (CH2Cl2 / CH3CH (OH) CH3) in a 9:1 ratio was prepared by 
adding 100ml of isopropanol to 900ml dichloromethane.  Dichloromethane isopropanol was 
used to extract the compounds of interest from urine.  The compounds migrate from the urine 
matrix into the Dichloromethane isopropanol during mixing and centrifugation.  This is 
referred to as the organic layer. 
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3.9.2 PREPARATION OF STANDARD SOLUTIONS 
The current HPLC method developed by the Department of Pharmacology/Toxicology, 
University of the Free State in Bloemfontein, South Africa, can identify the presence of 
lamivudine, abacavir, zidovudine, nevirapine and efavirenz in urine.  Further method 
development and investigation was necessary to identify and include stavudine, didanosine, 
lopinavir, ritonavir and tenofovir in the spectrum of antiretroviral drugs detectable by the 
current method.  In the current method being used, stock solutions of ARVs were made up 
with methanol (Potgieter et al. 2009).  Unfortunately not all ARVs, particularly those added in 
this study, dissolved in methanol.  Other solvents such as ethanol, acetonitrile, 
tetraethylammonium phosphate (TEAP) buffer, dichloromethane, isopropanol, dimethyl 
sulfoxide (DMSO) and combinations of these solvents were explored to find a common 
solvent in which all ARVs for this study could dissolve.  A mixture of solvent A and solvent B 
(5:1) proved to be the best combination in which all the ARVs could dissolve.  This mixture 
was named solvent C.  The standard solutions were prepared weekly and refrigerated.  
Calibration curves were compared from day to day and indicated that stock solutions 
remained stable over 3 consecutive days it was required for. 
Solvent C 
Solvent C was prepared by adding 150ml of Solvent A to 30ml of Solvent B.  
Solvent C was used to prepare stock solutions and to reconstitute residues of urine samples 
after extraction method was completed.  A stock solution of each ARV was prepared by 
dissolving the pure compound in solvent C.  Initial trial runs were performed to assess the 
required concentration for each stock solution.   
The following concentrations of stock solutions were decided on: 
Abacavir: 400.00 µg/ml 
Efavirenz: 1443.75 µg/ml 
Lamivudine: 253.00 µg/ml 
Lopinavir: 643.50 µg/ml 
Nevirapine: 790.00 µg/ml 
Stavudine: 562.00 µg/ml 
Tenofovir: 1162.50 µg/ml 
Zidovudine: 832.00 µg/ml 
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Different volumes of the stock solutions were spiked to urine to obtain the different 
concentrations required for the construction of each ARV’s calibration curve (Vibhuti et al. 
2009). 
The following concentrations were used (Table 3): 
Table 3.1: Concentrations of ARVs used to construct calibration curve 
Name Concentration Volume spiked Stock Concentration 
 
(µg/ml urine) (µl) (µg/ml) 
Abacavir 1 6.40 16.00 400.00 
Abacavir 2 18.00 45.00 400.00 
Abacavir 3 32.00 80.00 400.00 
Abacavir 4 48.00 120.00 400.00 
Efavirenz 1 49.70 35.00 1443.75 
Efavirenz 2 71.00 50.00 1443.75 
Efavirenz 3 142.00 100.00 1443.75 
Efavirenz 4 231.00 160.00 1443.75 
Lamivudine 1 5.06 20.00 253.00 
Lamivudine 2 10.11 40.00 253.00 
Lamivudine 3 20.22 80.00 253.00 
Lamivudine 4 25.30 100.00 253.00 
Lopinavir 1 19.80 40.00 643.50 
Lopinavir 2 34.65 70.00 643.50 
Lopinavir 3 49.50 100.00 643.50 
Lopinavir 4 64.35 130.00 643.50 
Nevirapine 1 19.75 25.00 790.00 
Nevirapine 2 39.50 50.00 790.00 
Nevirapine 3 59.25 75.00 790.00 
Nevirapine 4 79.00 100.00 790.00 
Stavudine 1 14.05 25.00 562.00 
Stavudine 2 28.40 50.00 562.00 
Stavudine 3 42.15 75.00 562.00 
Stavudine 4 56.20 100.00 562.00 
Tenofovir 1 69.75 60.00 1162.50 
Tenofovir 2 93.00 80.00 1162.50 
Tenofovir 3 186.00 160.00 1162.50 
Tenofovir 4 232.50 200.00 1162.50 
Zidovudine 1 10.40 12.50 832.00 
Zidovudine 2 20.80 25.00 832.00 
Zidovudine 3 41.60 50.00 832.00 
Zidovudine 4 83.20 100.00 832.00 
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3.10 EXTRACTION PROCEDURE FOR SAMPLES AND STANDARDS 
The current HPLC method developed by the Department of Pharmacology/Toxicology, 
University of the Free State in Bloemfontein, South Africa, used 200µl methanol to 
reconstitute the evaporated residue after extraction was performed.  As previously discussed, 
methanol was not a common solvent for all the ARVs.  Solvent C proved to be the most 
appropriate solvent to use in reconstitution of the residues.  Solvent C was also found to be 
more compatible with the mobile phases used in the gradient elusion.   
The extraction procedure was applied to urine standards spiked with ARV stock solutions, as 
well as patient urine samples.   
The following procedure was used for the extraction of the ARVs from urine.  To 1ml of urine 
(from patients and urine standards spiked with stock solution), the internal standard (100 µl 
clomipramine), 500µl buffer and 5ml of dichloromethane isopropanol (9:1) was added.  The 
tubes were vortexed and shaken horizontally on a horizontal shaker for 5 minutes.  The tubes 
were then centrifuged at 2500 revolutions per minute (rpm) for 5 minutes. 
The organic phase containing the compounds of interest was situated beneath the water 
phase after centrifugation.  The water phase was removed and the organic layer was 
transferred to an ampoule and evaporated to dryness at 50˚C under a stream of nitrogen.  
The residue was reconstituted in 200µl of Solvent C, vortexed and transferred to a glass vial 
for injection into the HPLC. 
3.11 CHROMATOGRAPHIC SYSTEM AND CONDITIONS 
The HPLC method developed by the Department of Pharmacology/Toxicology, University of 
the Free State in Bloemfontein, South Africa, used a gradient elution method where the 
eluent composition was changed during the analysis time of 25 minutes.  At the beginning of 
the run Solvent B was at 10% strength and Solvent A at 90% strength resulting in the 
resolution of the early components.  As the separation progressed, Solvent B’s strength was 
increased and Solvent A’s strength was decreased gradually over 30 minutes so that the 
subsequent components elute within a reasonable time.  Chromatography was performed at 
ambient temperature using a flow rate of 0.8ml/min. for the first two minutes, after which the 
flow rate was raised to 2ml/min for the remaining 23 minutes of the run.   
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Various gradient elusion methods with different mobile phase composition strengths were 
explored.  Constant flow rates as well as varying flow rates were investigated to find the most 
suitable chromatographic conditions to separate and elute all components within a 
reasonable time.   
A gradient elution method was used where the mobile phase composition was changed 
during the analysis time of 30 minutes.  At the beginning of the run Solvent B was at 0% 
strength and Solvent A at 100% strength resulting in the resolution of the early components.  
As the separation progressed, Solvent B’s strength was gradually increased to 10% over the 
first 9 minutes and Solvent A’s strength was decreased gradually over the first 9 minutes to 
90%.  Solvent B was gradually increased to 50% from the 9th minute to the 20th minute after 
which the Solvent A to B ratio remained 1:1 for the last 10 minutes so that the subsequent 
components elute within a reasonable time. 
Separation was performed on a HP 1090 liquid chromatograph system with an auto sampler 
and an Agilent 1100 diode array detector.  Data was collected by using Chem Station 
Software. 
Detection was recorded at 210nm.  Chromatographic separations were performed with a 
Synergi 4U Fusion – RP 80 Column with a size of 150mm x 4.6mm, coupled to a 
Phenomenex C18 precolumn (4mm x 3mm).  Chromatography was performed at ambient 
temperature (±21ºC) using an initial flow rate of 0.8 ml/min which was increased to 2 ml/min 
after 9 minutes for optimal elution of each compound.  A post run of 5 minutes was added to 
ensure adequate equilibrium of the column before the next run. 
3.12 VALIDATION METHODOLOGY 
3.12.1 CALIBRATION CURVE 
Calibration of each individual ARV was achieved by constructing a 4 point calibration curve 
for each ARV compound (Kaiser, 2000).  General guidelines suggest the use of 5 and more 
calibration points for the construction of a calibration curve to adequately define the 
relationship between concentration and response.  A 5 point calibration was attempted, but 
outliers and certain points of influence were noted, particularly in the higher concentration 
ranges.  All patient samples produced results within the first four calibration points.  Taking 
this into account and adhering to guidelines stated by Kaiser, it was decided to discard 
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outliers in the higher concentration ranges.  The inconsistency noted in the higher 
concentration ranges may be due to on board instability which may be caused by time lapsed 
in between injections, and precipitation of compounds.  Since the main objective was not to 
develop a quantitative method, further investigation is required.  Each ARV concentration was 
repeated 5 times and all samples were prepared as described in the extraction procedure 
(3.10).  During the course of the study it was decided to spike calibration samples with more 
than one ARV stock solution at a time because of time and cost limitations.  The different 
concentrations to combine in the calibrations were carefully considered to ensure that the 
quality of the calibrations will not be compromised.  With limited funding available, this 
ensured extensive savings on time expenditure, the use of chemicals and pure compounds.  
The bulk calibration with compounds grouped together cut down on pure compound usage 
which ensured the completion of the study.  The concentrations used to construct the 
calibration curve can be viewed in table 3.   
The peak area-ratio of each drug concentration to the internal standard was plotted on a 
linear regression curve for the investigation of linearity and reproducibility, and for the 
determination and identification of patient samples.  Data acquired from the Chem Station 
program was used to calculate the ratios by using the following formula: (Area of ARV/Area of 
internal standard).  The ratio results were plotted against its respective spiked concentrations 
to obtain a calibration curve.  The procedure was repeated on three different days to 
determine accuracy and reproducibility. 
Mean values of the calculated ratios of the calibrations for the different concentrations were 
used to construct a calibration curve by plotting the mean ratios against the respective spiked 
concentrations. 
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3.12.2 ACCURACY 
Two different concentrations, one high, and one low concentration internal quality control 
samples were extracted and injected in duplicate.  The sample preparation procedure was 
followed as described in 3.10 and applied to the internal quality controls as well as the patient 
samples.  This procedure was repeated over three consecutive days. 
Values of the internal quality controls were read from the calibration curve.  The internal 
quality controls’ values were known and were compared to the values obtained from the 
calibration curve.  Results obtained over a period of three consecutive days were used to 
calculate the coefficient of variation by using the following formula: 
  (standard deviation/mean) x 100. 
3.12.3 RECOVERY 
Recovery describes the extraction efficiency of a methodology within the limits of variability.  
The following procedure was used to determine the recovery of this method.  Three different 
concentrations for each ARV were spiked into 1ml of urine.  The samples were prepared 
according to the sample preparation procedure described in 3.10.  The same three different 
concentrations for each ARV were spiked directly into an ampoule and the internal standard 
(Clomipramine) was added.  These reference samples were evaporated to dryness by using 
a steady stream of nitrogen gas at a temperature of 50˚C.  The precipitate was reconstituted 
with 200µl of Solvent C, vortexed and injected.  The areas obtained from the samples 
extracted were compared to the reference samples to determine each ARV drug’s recovery.  
Using the ratio obtained for the directly spiked samples as the 100% reference point and 
comparing the ratio obtained for the samples spiked in urine, the percentage of recovery was 
determined.  The following formula was used to determine the recovery: 
  (Area of extracted compound/Area of unextracted compound) x 100. 
3.12.4 SHORT TERM STABILITY 
Short term stability of abacavir, efavirenz, lamivudine, lopinavir, nevirapine, stavudine, 
tenofovir and zidovudine was determined after storage at different temperature conditions to 
evaluate the stability of these compounds in urine.  Stability was investigated using low and 
high quality control (QC) samples for each ARV.  The calibration curves were demonstrated 
to be linear.  Calibration curves were constructed everyday over three consecutive days and 
short term stability samples analysed.  Each sample was prepared in duplicate by following 
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the extraction procedure described in 3.10 and stored at different temperatures.  Fresh urine 
samples were spiked with stock solutions of each ARV on day one.  The first duplicate 
samples spiked with a low QC and high QC respectively was stored at room temperature; 
second samples were stored at 2-8˚C for 24 hours and 48 hours respectively and the third 
samples were stored at -20˚C for 24 hours and 48 hours respectively.  This procedure was 
applied to each individual ARV.  Duplicate samples were run on day one at room 
temperature.  Results were obtained by calculating the ratios by using the following formula: 
(Area of ARV/Area of internal standard), and comparing it to the calibration curve.  Duplicate 
samples stored at 2-8˚C and at -20˚C for 24 hours, and 48 hours respectively, were allowed 
to thaw and reach room temperature before extraction procedure was applied.  Freshly 
prepared samples was extracted together with 24 hour and 48 hour samples and injected for 
comparison purposes.  Stability was tested over a period of 48 hours because emergency 
overdose samples rarely take longer than 24 hours to reach the Pharmacology laboratory.  
Variations in ARV concentrations were observed over a period of 48 hours.  The short-term 
stability studies are shown in Tables 4.26 to 4.33, and results have been plotted in graphs 
and shown in Figures 4.20 to 4.35.  
The following concentrations were used:  
Table 3.2: Concentrations of ARVs used for short term stability 
ARV CONCENTRATIONS (µg/ml)  
Abacavir 19.20 38.40 
Efavirenz 85.20 170.40 
Lamivudine 15.17 30.33 
Lopinavir 19.80 44.55 
Nevirapine 31.60 63.20 
Stavudine 11.24 16.86 
Tenofovir 37.20 83.70 
Zidovudine 31.20 72.80 
 
3.12.5 INTERFERENCE 
Interference was investigated for all the ARV drugs in the study.  Interference among the 
individual ARVs was investigated, as well as interference from other drugs such as common 
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drugs used for the treatment of Tuberculosis (TB) which is often found in HIV positive 
patients.  During initial method development it was noted that peaks from lamivudine and 
abacavir overlapped.  Peaks from lopinavir and efavirenz also interfered with each other due 
to their similar retention times.  Interference can be eliminated by changing the 
chromatographical conditions such as the gradient elusion ratio of the mobile phases or the 
flow rate in the column until optimal separations of the drugs can be achieved.  Good 
separation with high quality peaks was achieved by reducing the initial flow rate and by 
modification of the extraction procedure.  Current HIV/TB co-infection rates exceed 70% with 
TB being the most prevalent opportunistic infection in HIV positive patients in South Africa.  
Due to this fact it was necessary to investigate interference from the most common TB drugs 
as well since patients on ARVs are likely to have TB drugs on board.  Trimethoprim and 
isoniazide, two commonly used drugs for the treatment of TB was detected with the method.  
Not all TB drugs could be detected by the method.  Pure compound stock solutions of 
100µg/ml trimethoprim and isoniazide was injected to determine their retention times and 
spectra and the data was stored in a computerised library.  Effective differentiation and 
identification of the substances was achieved and no interference with the ARVs was 
observed.   
3.12.6 LIMIT OF DETECTION (LOD) 
A limit of detection was established for each ARV drug investigated in the study.  There are 
several terms that have been used to define LOD.  In general, the LOD is taken as the lowest 
concentration of an analyte in a sample that can be detected, but not necessarily quantified, 
under the stated conditions of the analysis (Shrivastava & Gupta  2011). 
The International Conference on Harmonisation (ICH) guidelines for detection limit 
parameters of analytical method validation was used.  By using the signal-to-noise method, 
the peak-to-peak noise around the analyte retention time is measured, and subsequently, the 
concentration of the analyte that would give a signal equal to certain value of noise to signal 
ratio is estimated.  The noise magnitude can be measured either by auto integrator of the 
instrument, or manually on the chromatogram printout.  A signal-to-noise ratio (S/N) of three 
is generally accepted for estimating LOD.  This method is commonly applied to analytical 
methods that exhibit baseline noise (Shrivastava & Gupta  2011).   
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3.13 STATISTICAL ANALYSIS 
All statistical analysis was revised by a qualified biostatistician.  Data was captured by the 
researcher on a data sheet using Microsoft Excel.  Any further analysis was done by a 
biostatistician using SAS Version 90.1.3.  Descriptive statistics namely means and standard 
deviations or medians and percentiles were calculated for numerical data.  Frequencies and 
percentages were calculated for categorical data.  
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4 RESULTS  
4.1 RESULTS 
After the extraction procedure was followed as described in 3.10, the extraction was injected 
into the HPLC for analysis.  Each ARV was repeated 5 times to investigate reproducibility of 
the results.  The retention time and spectra for each ARV was recorded and stored.  Since it 
was established that there was no interference from the different ARV profiles, more than one 
ARV pure compound was spiked to urine samples at a time.  The specificity is indicated in 
the UV spectra in figure 7.25 to 7.32. The red line indicates the spectra of the pure 
compounds and the blue line indicates the spectra captured from the extractions.  The 
computer library matches the spectra of the extractions to the spectra of the pure compounds 
as a percentage match.  The spectra matched between 92 and 100%. 
The interference of other compounds is visible in all the chromatograms. The peaks would 
overlap if there was interference.  This was eliminated by changing the flow rate and gradient 
elution resulting in chromatograms that shows no overlapping of peaks, and therefore can be 
concluded that no interference was experienced after method development was concluded.  
The chromatograms have been selected to demonstrate the relevant peaks as clearly as 
possible.   
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4.1.1 CHROMATOGRAPHIC PERFORMANCE 
A blank urine sample was run to determine any chromatographic interference.  Figure 4.1 
shows the chromatogram of a blank urine sample that was subjected to the extraction 
procedure described in 3.10.  Each ARV was repeated 5 times and all samples were 
prepared as described in the extraction procedure (3.10).  No interference from the blank 
urine sample, or any other components used in the extraction procedure was detected. 
Figure 4.1: Chromatogram of blank urine sample 
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A sample of the internal standard (clomipramine) was run to determine its retention time and 
spectrum.  The internal standard was repeated 5 times and was prepared as described in the 
extraction procedure (3.10).  Figure 4.2 illustrates the high resolution quality peak of the 
internal standard Clomipramine and its retention time of approximately 16.8 minutes, after it 
has been subjected to the extraction procedure and injected into the HPLC. 
Figure 4.2: Chromatogram of internal standard Clomipramine 
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A urine sample was spiked with both abacavir (16 µg/ml) and the internal standard 
clomipramine (71.4 µg/ml).  Figure 4.3 indicates the high resolution quality peaks and 
retention times of abacavir and clomipramine after the sample was subjected to the extraction 
procedure described in 3.10 and injected into the HPLC.  The chromatogram confirms that no 
interference exists between the two substances 
 
Figure 4.3: Chromatogram of Abacavir and Clomipramine  
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A urine sample was spiked with both efavirenz (142 µg/ml) and the internal standard 
clomipramine (71.4 µg/ml).  According to figure 4.4, the high resolution quality peaks and 
retention times of efavirenz and clomipramine are indicated after the sample was subjected to 
the extraction procedure described in 3.10 and injected into the HPLC.  The chromatogram 
confirms that no interference exists between the two substances. 
Figure 4.4: Chromatogram of Efavirenz and Clomipramine 
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A urine sample was spiked with both lamivudine (20.22 µg/ml) and the internal standard 
clomipramine (71.4 µg/ml).  Figure 4.5 demonstrates the high resolution quality peaks and 
retention times of Lamivudine and Clomipramine after the sample was subjected to the 
extraction procedure described in 3.10 and injected into the HPLC.  The chromatogram 
confirms that no interference exists between the two substances, nor any additional ARV 
spiked for the purposes of bulk calibration. 
Figure 4.5: Chromatogram of Lamivudine and Internal standard (Clomipramine) 
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A urine sample was spiked with both lopinavir (49.5 µg/ml) and the internal standard 
clomipramine (71.4 µg/ml).  Figure 4.6 shows the high resolution quality peaks and retention 
times of lopinavir and clomipramine after the sample was subjected to the extraction 
procedure described in 3.10 and injected into the HPLC.  The chromatogram confirms that no 
interference exists between the two substances.  
 
Figure 4.6: Chromatogram of Lopinavir and Clomipramine 
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A urine sample was spiked with both nevirapine (79.0 µg/ml) and the internal standard 
clomipramine (71.4 µg/ml).  Figure 4.7 illustrates the high resolution quality peaks and 
retention times of nevirapine and clomipramine after the sample was subjected to the 
extraction procedure described in 3.10 and injected into the HPLC.  The chromatogram 
confirms that no interference exists between the two substances. 
Figure 4.7: Chromatogram of Nevirapine and Clomipramine 
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A urine sample was spiked with both stavudine (28.1 µg/ml) and the internal standard 
clomipramine (71.4 µg/ml).  Figure 4.8 illustrates the high resolution quality peaks and 
retention times of stavudine and clomipramine after the sample was subjected to the 
extraction procedure described in 3.10 and injected into the HPLC.  The chromatogram 
confirms that no interference exists between the two substances. 
Figure 4.8: Chromatogram of Stavudine and Clomipramine 
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A urine sample was spiked with both tenofovir (28.1 µg/ml) and the internal standard 
clomipramine (71.4 µg/ml).  Figure 4.9 illustrates the high resolution quality peaks and 
retention times of tenofovir and clomipramine after the sample was subjected to the 
extraction procedure described in 3.10 and injected into the HPLC.  The chromatogram 
confirms that no interference exists between the two substances, and no interference was 
observed with other ARVs spiked for the purposes of bulk calibration. 
Figure 4.9: Chromatogram of Tenofovir and Clomipramine 
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A urine sample was spiked with both zidovudine (20.8 µg/ml) and the internal standard 
clomipramine (71.4 µg/ml).  Figure 4.10 shows the high resolution quality peaks and retention 
times of zidovudine and clomipramine after the sample was subjected to the extraction 
procedure described in 3.10 and injected into the HPLC.  The chromatogram confirms that no 
interference exists between the two substances.  
Figure 4.10: Chromatogram of Zidovudine and Clomipramine 
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A urine sample was spiked with abacavir, efavirenz, lamivudine, lopinavir, nevirapine, 
stavudine, tenofovir, zidovudine and the internal standard (clomipramine).  Figure 4.11 
summarizes the high resolution quality peaks and retention times after the sample was 
subjected to the extraction procedure described in 3.10 and injected into the HPLC.  Optimal 
separation of each substance was achieved and the chromatogram confirms that no 
interference exists between any of the substances. 
Figure 4.11: Chromatogram of Abacavir, Efavirenz, Lamivudine, Lopinavir, Nevirapine, 
Stavudine, Tenofovir, Zidovudine and Clomipramine (Extracted) 
4.1.2 CALIBRATION CURVE 
Calibration of each individual ARV was achieved by constructing a calibration curve for each 
ARV compound.  Each ARV concentration was repeated five times and over three 
consecutive days.  All samples were prepared daily as described in the extraction procedure.  
The peak area-ratio of each drug concentration to the internal standard was plotted on a 
linear regression curve for the investigation of linearity and reproducibility.  The data for the 
calibration curves is shown in Tables 4.1 to 4.8.  The average curve for each ARV is 
demonstrated in Figures 4.12 to 4.19. 
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4.1.2.1 HPLC calibrations for Abacavir 
Tables 4.1 represent the HPLC calibrations for abacavir, and are summarized in figure 4.12: 
r = 0.9989 
r² = 0.9979 
P < 0.0001 
Table 4.1 HPLC calibrations for Abacavir 
Concentration (µg/ml) Calibration day 1 
Ratio 
Calibration day 2 
Ratio 
Calibration day 3 
Ratio 
6.40 0.100 0.103 0.100 
6.40 0.101 0.104 0.100 
6.40 0.100 0.096 0.100 
6.40 0.100 0.098 0.100 
6.40 0.100 0.100 0.100 
Mean 0.100 0.100 0.100 
18.00 0.304 0.269 0.266 
18.00 0.294 0.276 0.302 
18.00 0.272 0.294 0.274 
18.00 0.271 0.271 0.293 
18.00 0.277 0.305 0.269 
Mean 0.273 0.283 0.281 
32.00 0.538 0.599 0.544 
32.00 0.528 0.556 0.542 
32.00 0.551 0.539 0.542 
32.00 0.534 0.537 0.604 
32.00 0.594 0.542 0.557 
Mean 0.549 0.555 0.558 
48.00 0.806 0.793 0.815 
48.00 0.784 0.842 0.792 
48.00 0.833 0.792 0.820 
48.00 0.811 0.820 0.797 
48.00 0.796 0.812 0.846 
Mean 0.806 0.811 0.814 
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Figure 4.12: Average calibration curve of Abacavir for the daily calibrations 
ug/ml
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4.1.2.2 HPLC calibrations for Efavirenz 
Tables 4.2 represent the HPLC calibrations for efavirenz, and are summarized in figure 4.13: 
r = 0.9959 
r² = 0.9919 
P < 0.0001 
Table 4.2 HPLC calibrations for Efavirenz  
Concentration (µg/ml) Calibration day 1 
Ratio 
Calibration day 2 
Ratio 
Calibration day 3 
Ratio 
49.70 0.232 0.230 0.211 
49.70 0.229 0.202 0.228 
49.70 0.209 0.223 0.223 
49.70 0.205 0.197 0.202 
49.70 0.199 0.210 0.197 
Mean 0.215 0.212 0.212 
71.00 0.288 0.273 0.240 
71.00 0.302 0.286 0.261 
71.00 0.287 0.263 0.224 
71.00 0.263 0.302 0.312 
71.00 0.274 0.288 0.236 
Mean 0.283 0.282 0.255 
142.00 0.519 0.531 0.528 
142.00 0.536 0.543 0.537 
142.00 0.555 0.540 0.543 
142.00 0.533 0.531 0.528 
142.00 0.541 0.527 0.522 
Mean 0.537 0.534 0.532 
213.00 0.687 0.683 0.676 
213.00 0.753 0.703 0.776 
213.00 0.770 0.785 0.739 
213.00 0.758 0.733 0.662 
213.00 0.744 0.702 0.659 
Mean 0.742 0.721 0.702 
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Figure 4.13: Average calibration curve of Efavirenz for the daily calibrations 
ug/ml
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4.1.2.3 HPLC calibrations for Lamivudine 
Tables 4.3 represent the HPLC calibrations for lamivudine, and are summarized in figure 
4.14: 
r = 0.9993 
r² = 0.9985 
P <0.0001 
Table 4.3 HPLC calibrations for Lamivudine 
Concentration (µg/ml) Calibration day 1 
Ratio 
Calibration day 2 
Ratio                    
Calibration day 3 
Ratio 
5.06 0.100 0.097 0.098 
5.06 0.123 0.123 0.100 
5.06 0.105 0.103 0.125 
5.06 0.106 0.103 0.098 
5.06 0.099 0.099 0.136 
Mean 0.107 0.105 0.111 
10.11 0.202 0.201 0.210 
10.11 0.203 0.196 0.195 
10.11 0.203 0.201 0.196 
10.11 0.198 0.202 0.195 
10.11 0.212 0.211 0.190 
Mean 0.204 0.202 0.197 
20.22 0.440 0.412 0.413 
20.22 0.387 0.432 0.433 
20.22 0.395 0.390 0.389 
20.22 0.431 0.442 0.397 
20.22 0.414 0.398 0.442 
Mean 0.413 0.415 0.415 
25.30 0.499 0.496 0.496 
25.30 0.484 0.489 0.496 
25.30 0.490 0.480 0.543 
25.30 0.533 0.531 0.503 
25.30 0.497 0.496 0.511 
Mean 0.501 0.498 0.510 
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Figure 4.14: Average calibration curve of Lamivudine for the daily calibrations 
ug/ml
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4.1.2.4 HPLC calibrations for Lopinavir 
Tables 4.4 represent the HPLC calibrations for lopinavir, and are summarized in figure 4.15: 
r = 0.9992 
r² = 0.9983 
P <0.0001 
Table 4.4 HPLC calibrations for Lopinavir 
Concentration (µg/ml) Calibration day 1 
Ratio 
Calibration day 2 
Ratio                    
Calibration day 3 
Ratio 
19.80 0.046 0.052 0.058 
19.80 0.040 0.050 0.053 
19.80 0.053 0.054 0.050 
19.80 0.051 0.052 0.059 
19.80 0.053 0.050 0.051 
Mean 0.049 0.052 0.054 
34.65 0.110 0.109 0.105 
34.65 0.100 0.101 0.110 
34.65 0.104 0.103 0.107 
34.65 0.107 0.108 0.104 
34.65 0.105 0.108 0.100 
Mean 0.105 0.106 0.105 
49.50 0.151 0.147 0.153 
49.50 0.155 0.147 0.156 
49.50 0.158 0.152 0.154 
49.50 0.153 0.150 0.160 
49.50 0.150 0.154 0.152 
Mean 0.153 0.150 0.155 
64.35 0.211 0.201 0.198 
64.35 0.204 0.194 0.200 
64.35 0.202 0.199 0.207 
64.35 0.206 0.205 0.203 
64.35 0.201 0.204 0.203 
Mean 0.205 0.200 0.202 
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Figure 4.15: Average calibration curve of Lopinavir for the daily calibrations 
ug/ml
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4.1.2.5 HPLC calibrations for Nevirapine 
Tables 4.5 represent the HPLC calibrations for nevirapine, and are summarized in figure 
4.16: 
r = 0.9996 
r² = 0.9993 
P < 0.0001 
Table 4.5 HPLC calibrations for Nevirapine 
Concentration (µg/ml) Calibration day 1 
Ratio 
Calibration day 2 
Ratio 
Calibration day 3 
Ratio 
19.75 0.103 0.133 0.142 
19.75 0.132 0.118 0.124 
19.75 0.132 0.103 0.148 
19.75 0.118 0.122 0.114 
19.75 0.121 0.097 0.123 
Mean 0.121 0.115 0.130 
39.50 0.294 0.300 0.267 
39.50 0.258 0.261 0.261 
39.50 0.298 0.267 0.287 
39.50 0.286 0.294 0.297 
39.50 0.265 0.287 0.293 
Mean 0.280 0.282 0.281 
59.25 0.470 0.460 0.430 
59.25 0.438 0.433 0.435 
59.25 0.433 0.471 0.439 
59.25 0.428 0.430 0.458 
59.25 0.458 0.439 0.471 
Mean 0.445 0.447 0.447 
79.00 0.640 0.584 0.641 
79.00 0.660 0.662 0.601 
79.00 0.624 0.581 0.630 
79.00 0.580 0.626 0.598 
79.00 0.584 0.641 0.557 
Mean 0.618 0.619 0.605 
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Figure 4.16: Average calibration curve of Nevirapine for the daily calibrations 
ug/ml
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4.1.2.6 HPLC calibrations for Stavudine 
Tables 4.6 represent the HPLC calibrations for stavudine, and are summarized in figure 4.17: 
r = 0.9957 
r² = 0.9914 
P < 0.0001 
Table 4.6 HPLC calibrations for Stavudine 
Concentration (µg/ml) Calibration day 1 
Ratio 
Calibration day 2 
Ratio                    
Calibration day 3 
Ratio 
14.05 0.168 0.175 0.178 
14.05 0.169 0.172 0.171 
14.05 0.179 0.161 0.161 
14.05 0.176 0.180 0.175 
14.05 0.161 0.184 0.173 
Mean 0.171 0.174 0.172 
28.40 0.389 0.377 0.415 
28.40 0.415 0.416 0.407 
28.40 0.415 0.405 0.407 
28.40 0.404 0.406 0.378 
28.40 0.379 0.419 0.415 
Mean 0.400 0.405 0.404 
42.15 0.593 0.613 0.632 
42.15 0.650 0.613 0.560 
42.15 0.646 0.563 0.707 
42.15 0.622 0.610 0.667 
42.15 0.573 0.622 0.789 
Mean 0.617 0.605 0.671 
56.20 0.853 0.822 0.812 
56.20 0.811 0.778 0.782 
56.20 0.893 0.792 0.764 
56.20 0.894 0.820 0.817 
56.20 0.881 0.800 0.848 
Mean 0.866 0.802 0.805 
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Figure 4.17: Average calibration curve of Stavudine for the daily calibrations 
ug/ml
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4.1.2.7 HPLC calibrations for Tenofovir 
Tables 4.7 represent the HPLC calibrations for tenofovir, and are summarized in figure 4.18: 
r = 0.9962 
r² = 0.9924 
P < 0.0001 
Table 4.7 HPLC calibrations for Tenofovir 
Concentration (µg/ml) Calibration day 1 
Ratio 
Calibration day 2 
Ratio                    
Calibration day 3 
Ratio 
69.75 0.217 0.205 0.204 
69.75 0.181 0.180 0.181 
69.75 0.194 0.196 0.198 
69.75 0.196 0.193 0.195 
69.75 0.183 0.183 0.185 
Mean 0.194 0.191 0.193 
93.00 0.252 0.250 0.250 
93.00 0.213 0.211 0.211 
93.00 0.229 0.212 0.234 
93.00 0.234 0.234 0.233 
93.00 0.227 0.228 0.229 
Mean 0.231 0.227 0.231 
186.00 0.450 0.458 0.460 
186.00 0.520 0.525 0.525 
186.00 0.361 0.366 0.367 
186.00 0.469 0.471 0.469 
186.00 0.442 0.472 0.447 
Mean 0.448 0.458 0.454 
232.50 0.588 0.590 0.559 
232.50 0.613 0.601 0.640 
232.50 0.648 0.647 0.630 
232.50 0.562 0.629 0.586 
232.50 0.597 0.566 0.608 
Mean 0.602 0.607 0.605 
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Figure 4.18: Average calibration curve of Tenofovir for the daily calibrations 
ug/ml
230220210200190180170160150140130120110100908070
A
v
e
r
a
g
e
 
R
a
t
i
o
0.594
0.573
0.553
0.532
0.512
0.492
0.471
0.451
0.43
0.41
0.389
0.369
0.348
0.328
0.307
0.287
0.266
0.246
0.225
0.205
0.184
0.164
X axis = Concentration (µg/ml) 
Y axis = Ratio average 
r² = 0.9924 
 
© Central University of Technology, Free State
  82 
4.1.2.8 HPLC calibrations for Zidovudine 
Tables 4.8 represent the HPLC calibrations for zidovudine, and are summarized in figure 
4.19: 
r = 0.9990 
r² = 0.9981 
P < 0.001 
Table 4.8 HPLC calibrations for Zidovudine 
Concentration (µg/ml) Calibration day 1 
Ratio 
Calibration day 2 
Ratio                    
Calibration day 3 
Ratio 
10.40 0.081 0.082 0.090 
10.40 0.089 0.090 0.070 
10.40 0.070 0.072 0.080 
10.40 0.080 0.083 0.080 
10.40 0.090 0.090 0.090 
Mean 0.082 0.083 0.082 
20.80 0.230 0.224 0.224 
20.80 0.217 0.200 0.231 
20.80 0.211 0.218 0.199 
20.80 0.225 0.211 0.217 
20.80 0.200 0.230 0.224 
Mean 0.217 0.217 0.219 
41.60 0.412 0.423 0.407 
41.60 0.397 0.414 0.409 
41.60 0.413 0.406 0.402 
41.60 0.404 0.400 0.427 
41.60 0.421 0.406 0.413 
Mean 0.409 0.410 0.412 
83.20 0.816 0.801 0.822 
83.20 0.789 0.817 0.798 
83.20 0.806 0.798 0.836 
83.20 0.825 0.836 0.806 
83.20 0.803 0.822 0.820 
Mean 0.808 0.815 0.816 
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Figure 4.19: Average calibration curve of Zidovudine for the daily calibrations 
ug/ml
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4.2 PRECISION, ACCURACY AND RECOVERY 
Acceptable levels of accuracy require that the method consistently reproduce average 
concentration results that range between 80 percent and 120 percent of the actual 
concentration (Shabir, 2004).  The optimal is 100 percent, which means that the average 
concentration matches exactly with the actual concentration in the sample.  While this 
eventuality is rare, a deviation of less than 20 percent in either direction is still considered 
acceptable.  Recovery percentages close to 100 percent are desirable, which would clearly 
indicate that the extraction procedure is capable of removing the entire ARV fraction from the 
urine matrix.  In practice however, results as low as 50 percent are acceptable.  A summary 
of the precision (CV%), accuracy (%), recovery, average concentration, actual concentration 
and standard deviation is presented in the tables 4.9 to 4.24 below for the ARVs over a 
period of 3 days. 
4.2.1 ABACAVIR 
4.2.1.1 Values for spiked concentrations obtained 
Table 4.9 Summary of spiked concentrations obtained for Abacavir 
Stock 
solution 
Day 1 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 2 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 3 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Low 
(19.2 
µg/ml) 
0.308 18.73 0.278 16.98 0.308 18.73 
High 
(38.4 
µg/ml) 
0.583 34.59 0.564 33.49 0.591 35.05 
 
4.2.1.2 Precision, accuracy and recovery 
Table 4.10 Summary of the precision, accuracy and recovery for Abacavir  
Concentration 
µg/ml 
Day 1 Day 2 Day 3 Mean SD CV% 
Accuracy 
(%) 
Recovery 
(%) 
19.2 18.73 16.98 19.88 18.53 1.46 7.88 96.50 96.51 
38.4 34.59 33.49 35.05 34.38 0.80 2.33 89.53 89.53 
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4.2.2 EFAVIRENZ 
4.2.2.1 Values for spiked concentrations obtained 
Table 4.11 Summary of spiked concentrations obtained for Efavirenz 
Stock 
solution 
Day 1 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 2 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 3 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Low 
(85.20 µg/ml) 
0.300 76.29 0.286 71.88 0.293 74.09 
High 
(170.40 
µg/ml) 
0.674 193.90 0.667 191.70 0.676 194.53 
 
4.2.2.2 Precision, accuracy and recovery 
Table 4.12 Summary of the precision, accuracy and recovery for Efavirenz 
Concentration 
µg/ml 
Day 1 Day 2 Day 3 Mean SD CV% Accuracy 
(%) 
Recovery 
(%) 
85.20 76.29 71.88 74.09 74.09 2.21 2.98 86.96 86.96 
170.40 193.90 191.70 194.53 193.38 1.49 0.77 113.49 113.49 
 
4.2.3 LAMIVUDINE 
4.2.3.1 Values for spiked concentrations obtained 
Table 4.13 Summary of spiked concentrations obtained for Lamivudine 
Stock 
solution 
Day 1 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 2 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 3 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Low 
(15.17 
µg/ml) 
0.263 12.98 0.263 12.98 0.266 13.13 
High 
(30.33 
µg/ml) 
0.592 29.56 0.513 25.58 0.488 24.32 
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4.2.3.2 Precision, accuracy and recovery 
Table 4.14 Summary of the precision, accuracy and recovery for Lamivudine 
Concentration 
µg/ml 
Day 1 Day 2 Day 3 Mean SD CV% Accuracy 
(%) 
Recovery 
(%) 
15.17 12.91 12.91 13.13 12.98 0.09 0.69 85.56 85.89 
30.33 29.56 25.58 24.32 26.49 2.74 10.34 87.34 87.34 
 
4.2.4 LOPINAVIR 
4.2.4.1 Values for spiked concentrations obtained 
Table 4.15 Summary of spiked concentrations obtained for Lopinavir 
Stock 
solution 
Day 1 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 2 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 3 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Low  
(19.80 µg/ml) 
0.032 13.53 0.041 16.20 0.035 14.42 
High   
(44.55 µg/ml) 
0.128 42.08 0.118 39.10 0.114 37.91 
 
4.2.4.2 Precision, accuracy and recovery 
Table 4.16 Summary of the precision, accuracy and recovery for Lopinavir 
Concentration 
µg/ml 
Day 1 Day 2 Day 3 Mean SD CV% Accuracy 
(%) 
Recovery 
(%) 
19.80 13.53 16.20 14.42 14.72 1.36 9.24 74.34 74.34 
44.55 42.08 39.10 37.91 39.70 2.15 5.42 89.11 89.11 
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4.2.5 NEVIRAPINE 
4.2.5.1 Values for spiked concentrations obtained 
Table 4.17 Summary of spiked concentrations obtained for Nevirapine 
Stock 
solution 
Day 1 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 2 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 3 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Low  
(31.60 µg/ml) 
0.210 30.62 0.219 31.71 0.205 30.02 
High   
(63.20 µg/ml) 
0.489 64.20 0.509 66.60 0.504 66.00 
 
4.2.5.2 Precision and accuracy 
Table 4.18 Summary of the precision, accuracy and recovery for Nevirapine 
Concentration 
µg/ml 
Day 1 Day 2 Day 
3 
Mean SD CV% Accuracy 
(%) 
Recovery 
(%) 
31.60 30.62 31.71 30.02 30.78 0.86 2.79 97.41 97.40 
63.20 64.20 66.60 66.00 65.6 1.25 1.91 103.80 103.80 
 
4.2.6 STAVUDINE 
4.2.6.1 Values for spiked concentrations obtained 
Table 4.19 Summary of spiked concentrations obtained for Stavudine 
Stock 
solution 
Day 1 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 2 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 3 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Low  
(25.30 µg/ml) 
0.081 15.79 0.077 15.04 0.084 16.36 
High   
(39.35 µg/ml) 
0.161 30.91 0.171 32.80 0.165 31.67 
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4.2.6.2 Precision, accuracy and recovery 
Table 4.20 Summary of the precision, accuracy and recovery for Stavudine 
Concentration 
µg/ml 
Day 1 Day 2 Day 3 Mean SD CV% Accuracy 
(%) 
Recovery 
(%) 
11.24 7.81 7.55 8.00 7.79 0.23 2.95 69.31 69.30 
16.86 12.95 13.59 13.20 13.24 0.32 2.42 78.53 78.59 
 
4.2.7 TENOFOVIR 
4.2.7.1 Values for spiked concentrations obtained 
Table 4.21 Summary of spiked concentrations obtained for Tenofovir 
Stock 
solution 
Day 1 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 2 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 3 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Low  
(37.20 µg/ml) 
0.92 34.91 0.117 44.84 0.128 49.20 
High   
(83.70 µg/ml) 
0.198 77.00 0.223 86.92 0.213 82.95 
 
4.2.7.2 Precision, accuracy and recovery 
Table 4.22 Summary of the precision, accuracy and recovery for Tenofovir 
Concentration 
µg/ml 
Day 1 Day 2 Day 3 Mean SD CV% Accuracy 
(%) 
Recovery 
(%) 
37.20 34.9 44.84 49.20 42.98 7.32 17.03 115.54 115.54 
83.70 77.00 86.92 82.95 82.29 4.99 6.06 98.32 98.32 
 
4.2.8 ZIDOVUDINE 
4.2.8.1 Values for spiked concentrations obtained 
Table 4.23 Summary of spiked concentrations obtained for Zidovudine 
Stock 
solution 
Day 1 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 2 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Day 3 
Average 
Ratio 
Concentration 
from 
calibration 
curve 
Low  
(31.20 µg/ml) 
0.287 29.49 0.279 28.68 0.296 30.40 
High   
(72.80 µg/ml) 
0.644 65.67 0.643 65.57 0.662 67.49 
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4.2.8.2 Precision, accuracy and recovery 
Table 4.24 Summary of the precision, accuracy and recovery for Zidovudine 
Concentration 
µg/ml 
Day 1 Day 2 Day 3 Mean SD CV% Accuracy 
(%) 
Recovery 
(%) 
31.20 29.49 28.68 30.40 29.52 0.86 2.91 94.61 94.62 
72.80 65.67 65.57 67.49 66.24 1.08 1.63 90.98 90.99 
 
Accuracy of the method was found to be within required levels for abacavir, efavirenz, 
lamivudine, nevirapine, tenofovir, and zidovudine, showing that the results obtained by the 
method closely reflects the true value of the ARV.  For lopinavir and stavudine however, 
accuracy within the acceptable range could not be achieved and further investigation is 
needed.  The method however, will not be used for quantification of these drugs, but only for 
identification purposes in suspected overdose cases.  Quantification needs further 
investigation.  During the precision determination of the method, it was found that both 
concentration ranges of the ARVs yielded a coefficient of variation that did not exceed 10% in 
most cases.  In the case of lamivudine high control samples and tenofovir low control 
samples, a smaller degree of precision was found.  The recovery achieved by the analytical 
method was good for all the ARVs.  The recovery achieved was not optimal for stavudine and 
lopinavir, but values within these ranges are considered to be acceptable, provided that the 
method has been proved to be precise and accurate.  In the case of stavudine and lopinavir, 
precision was achieved, but accuracy and recovery was not optimal for the lower extracted 
concentrations.  Although accuracy is not achieved for all the ARVs, the method however, 
proves precision and reproducibility, and for the purposes and aim of the study which 
required a qualitative method development, the method is of great value considering the fact 
that all the ARVs evaluated by this method can be identified. 
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4.3 SHORT-TERM STABILITY 
Stability was determined for two different concentrations of each ARV.  The following 
concentrations were used as summarised in table 4.25:  
 
Table 4.25 ARV concentrations used in the determination of short-term 
stability 
ARV Low concentration (µg/ml) High concentration (µg/ml) 
Abacavir 19.20 38.40 
Efavirenz 85.20 170.40 
Lamivudine 15.17 30.33 
Lopinavir 19.80 44.55 
Nevirapine 31.60 63.20 
Stavudine 11.24 16.86 
Tenofovir 37.20 83.70 
Zidovudine 31.20 72.80 
 
Each sample was prepared in duplicate by following the procedure described in 3.10 and 
stored at different temperatures.  The first was stored at room temperature; second samples 
were stored at 2-8˚C for 24 hours and 48 hours respectively and the third samples were 
stored at -20˚C for 24 hours and 48 hours respectively.  Duplicate samples were run on day 
one at room temperature.  Duplicate samples stored at 2-8˚C and at -20˚C were run after 24 
hours, and after 48 hours.  Stability was tested over a period of 48 hours because emergency 
overdose samples rarely take longer than 24 hours to reach the Pharmacology laboratory.  
Variations in ARV concentrations were observed over a period of 48 hours.  The short-term 
stability studies are shown in Tables 4.58 to 4.73, and results have been plotted in graphs 
and shown in Figures 4.20 to 4.35. 
The short term stability determination for two different concentrations of abacavir, 19.2 µg/ml 
and 38.4 µg/ml are summarized in Tables 4.58 and 4.59, and demonstrated in figures 4.20 
and 4.21. 
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Table 4.26 Summary of the short-term stability determination of  
19.20 µg/ml Abacavir and 38.40 µg/ml Abacavir 
 
Concentration 
µg/ml 
Temperature stability 
0 hours 
stability 
24 hours 
stability 
48 hours 
mean SD CV% 
19.20 Ambient 
temp 
18.73 17.00 19.88 18.54 1.45 7.82 
19.20 2-8˚C  17.23 
 
17.63 17.43 0.28 1.61 
19.20 -20˚C  16.48 
 
16.54 16.51 0.04 0.24 
38.40 Ambient 
temp 
34.59 33.49 35.05 34.38 0.80 2.33 
38.40 2-8˚C  34.82 
 
34.53 34.68 0.21 0.61 
38.40 -20˚C  33.84 
 
34.53 34.19 0.49 1.43 
 
            
Figure 4.20: Short-term stability of   Figure 4.21: Short-term stability of 
19.20 µg/ml Abacavir       38.40 µg/ml Abacavir 
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The short term stability determination for two different concentrations of efavirenz, 85.2 µg/ml 
and 170.4 µg/ml are summarized in Tables 4.60 and 4.61, and demonstrated in figures 4.22 
and 4.23. 
Table 4.27 Summary of the short-term stability determination of  
85.20 µg/ml Efavirenz and 170.40 µg/ml Efavirenz 
 
Concentration 
µg/ml 
Temperature stability 
0 hours 
stability 
24 hours 
stability 
48 hours 
mean SD CV% 
85.20 Ambient 
temp 
76.29 71.88 74.09 74.09 2.21 2.98 
85.20 2-8˚C  75.34 
 
75.03 75.19 0.22 0.30 
85.20 -20˚C  75.03 
 
72.20 73.62 2.00 2.72 
170.40 Ambient 
temp 
193.90 191.70 194.53 193.38 1.49 0.77 
170.40 2-8˚C  179.44 
 
153.96 166.70 18.09 10.85 
170.40 -20˚C  179.44 
 
176.61 178.03 2.00 1.12 
 
     
Figure 4.22: Short-term stability of    Figure 4.23: Short-term stability of  
85.20 µg/ml Efavirenz    170.40 µg/ml Efavirenz 
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The short term stability determination for two different concentrations of lamivudine, 
15.17 µg/ml and 30.33 µg/ml are summarized in Tables 4.62 and 4.63, and demonstrated in 
figures 4.24 and 4.25. 
Table 4.28 Summary of the short-term stability determination of  
15.17 µg/ml Lamivudine and 30.33 µg/ml Lamivudine 
 
Concentration 
µg/ml 
Temperature stability 
0 hours 
stability 
24 hours 
stability 
48 hours 
mean SD CV% 
15.17 Ambient 
temp 
 12.98 13.13 13.0 0.09 0.70 
15.17 2-8˚C  13.13 
 
13.33 13.23 0.14 1.1 
15.17 -20˚C  13.64 
 
13.69 13.67 0.04 0.30 
30.33 Ambient 
temp 
29.56 25.58 
 
28.30 28.81 2.03 7.05 
30.33 2-8˚C  25.38 
 
25.58 25.48 0.14 0.55 
30.33 -20˚C  24.17 
 
24.92 24.55 0.53 2.16 
 
   
Figure 4.24: Short-term stability of   Figure 4.25: Short-term stability 
of15.17 µg/ml Lamivudine       30.33 µg/ml lamivudine 
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The short term stability determination for two different concentrations of lopinavir, 19.80 µg/ml 
and 44.55 µg/ml are summarized in Tables 4.64 and 4.65, and demonstrated in figures 4.26 
and 4.27. 
Table 4.29 Summary of the short-term stability determination of  
19.80 µg/ml Lopinavir and 44.55 µg/ml Lopinavir 
 
Concentration 
µg/ml 
Temperature stability 
0 hours 
stability 
24 hours 
stability 
48 hours 
mean SD CV% 
19.80 Ambient 
temp 
13.53 16.20 14.42 14.72 1.36 9.24 
19.80 2-8˚C  15.61 
 
15.31 15.46 0.21 1.36 
19.80 -20˚C  14.12 
 
14.12 14.12 0.00 0.00 
44.55 Ambient 
temp 
42.08 39.10 37.91 39.70 2.15 5.42 
44.55 2-8˚C  38.51 
 
37.91 38.21 0.40 1.05 
44.55 -20˚C  37.61 
 
37.32 37.47 0.21 0.56 
 
            
Figure 4.26: Short-term stability of    Figure 4.27: Short-term stability of 
19.80 µg/ml Lopinavir    44.55 µg/ml Lopinavir 
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The short term stability determination for two different concentrations of nevirapine, 
31.60 µg/ml and 63.20 µg/ml are summarized in Tables 4.66 and 4.67, and demonstrated in 
figures 4.28 and 4.29. 
Table 4.30 Summary of the short-term stability determination of  
31.60 µg/ml Nevirapine and 63.20 µg/ml Nevirapine 
 
Concentration 
µg/ml 
Temperature stability 
0 hours 
stability 
24 hours 
stability 
48 hours 
mean SD CV% 
31.60 Ambient 
temp 
30.62 31.71 30.02 30.78 0.86 2.79 
31.60 2-8˚C  32.55 
 
32.31 32.43 0.17 0.52 
31.60 -20˚C  32.67 
 
32.67 32.67 0 0 
63.20 Ambient 
temp 
64.20 66.60 66.00 65.6 1.25 1.91 
63.20 2-8˚C  63.96 
 
64.08 64.02 0.08 0.12 
63.20 -20˚C  63.23 
 
64.92 64.08 1.20 1.87 
 
            
Figure 4.28: Short-term stability of    Figure 4.29: Short-term stability of  
31.60 µg/ml Nevirapine    63.20 µg/ml Nevirapine 
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The short term stability determination for two different concentrations of stavudine, 
11.24 µg/ml and 16.86 µg/ml are summarized in Tables 4.68 and 4.69, and demonstrated in 
figures 4.30 and 4.31. 
Table 4.31 Summary of the short-term stability determination of  
11.24 µg/ml Stavudine and 16.86 µg/ml Stavudine 
 
Concentration 
µg/ml 
Temperature stability 
0 hours 
stability 
24 hours 
stability 
48 hours 
mean SD CV% 
11.24 Ambient 
temp 
7.81 7.55 8.00 7.79 0.225 2.89 
11.24 2-8˚C  7.43 
 
8.00 7.72 0.403 5.22 
11.24 -20˚C  8.33 
 
8.45 8.39 0.085 1.01 
16.86 Ambient 
temp 
12.88 12.75 12.95 12.86 0.101 0.79 
16.86 2-8˚C  13.59 
 
13.20 13.40 0.276 2.06 
16.86 -20˚C  13.33 
 
12.82 13.08 0.360 2.75 
 
          
Figure 4.30: Short-term stability of    Figure 4.31: Short-term stability of  
11.24 µg/ml Stavudine    16.86 µg/ml Stavudine 
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The short term stability determination for two different concentrations of tenofovir, 
37.20 µg/ml and 83.70 µg/ml are summarized in Tables 4.70 and 4.71, and demonstrated in 
figures 4.32 and 4.33. 
Table 4.32 Summary of the short-term stability determination of  
37.20 µg/ml Tenofovir and 83.70 µg/ml Tenofovir 
 
Concentration 
µg/ml 
Temperature stability 
0 hours 
stability 
24 hours 
stability 
48 hours 
mean SD CV% 
37.20 Ambient 
temp 
34.91 44.84 49.20 42.98 7.28 16.9 
37.20 2-8˚C  43.64 
 
44.44 44.04 0.57 1.29 
37.20 -20˚C  40.47 
 
39.67 40.07 0.57 1.42 
83.70 Ambient 
temp 
76.99 86.92 82.95 82.29 5.0 6.07 
83.70 2-8˚C  89.30 
 
88.11 88.71 0.84 0.95 
83.70 -20˚C  126.22 
 
127.81 127.02 1.12 0.88 
 
     
Figure 4.32: Short-term stability of    Figure 4.33: Short-term stability of  
37.20 µg/ml Tenofovir     83.70 µg/ml Tenofovir 
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The short term stability determination for two different concentrations of zidovudine, 
31.20 µg/ml and 72.80 µg/ml are summarized in Tables 4.72 and 4.73, and demonstrated in 
figures 4.34 and 4.35. 
Table 4.33 Summary of the short-term stability determination of 
31.20 µg/ml Zidovudine and 72.80 µg/ml Zidovudine 
 
Concentration 
µg/ml 
Temperature stability 
0 hours 
stability 
24 hours 
stability 
48 hours 
mean SD CV% 
31.20 Ambient 
temp 
29.69 28.68 30.40 29.59 0.86 2.91 
31.20 2-8˚C  28.38 
 
29.19 28.79 0.57 1.98 
31.20 -20˚C  27.57 
 
29.19 28.38 1.14 4.02 
72.80 Ambient 
temp 
65.67 65.57 67.49 66.24 1.08 1.63 
72.80 2-8˚C  64.76 
 
64.25 64.51 0.36 0.56 
72.80 -20˚C  62.53 
 
63.95 63.24 1.00 1.58 
 
           
Figure 4.34: Short-term stability of    Figure 4.35: Short-term stability of  
31.20 µg/ml Zidovudine    72.80 µg/ml Zidovudine 
The short term stability of a drug in urine can be influenced by many factors including 
physiochemical properties of the drug, tendency to conjugate/deconjugate, specimen 
collection procedure, degree of microorganism contamination, container selection and the 
use of preservatives or other additives.  In general, drug instability in any toxicological 
specimen is due to metabolic degradation, chemical transformation, or a combination of both.  
Most ARVs remained stable at room temperature and refrigeration over 48 hours.  Freezing 
of samples rendered variable results.  Long term stability of the ARVs was not determined.  It 
is therefore concluded that the samples should be refrigerated to limit bacterial degradation of 
the sample and be evaluated within 48 hours. 
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4.4 LIMIT OF DETECTION 
A limit of detection was established for each ARV drug investigated in the study.  The LOD is 
taken as the lowest concentration of an analyte in a sample that can be detected, but not 
necessarily quantified, under the stated conditions of the analysis. 
The International Conference on Harmonisation (ICH) guidelines for detection limit 
parameters was applied in the validation of the analytical method.  The signal to noise 
method was used whereby the peak-to-peak noise around the analyte retention time was 
measured, and subsequently, the concentration of the analyte that would give a signal equal 
to a specific value of noise to signal ratio was assessed.  A signal-to-noise ratio (S/N) of three 
is generally accepted for estimating LOD and was applied in the validation.  The limit of 
detection is represented in Table 4.74.  
Table 4.34 Limit of detection  
ARV drug Limit of detection 
(µg/ml) 
Abacavir 4.40 
Efavirenz 22.49 
Lamivudine 5.06 
Lopinavir 11.80 
Nevirapine 14.20 
Stavudine 11.13 
Tenofovir 58.75 
Zidovudine 7.84 
 
4.5 INTERFERENCE 
Interference was tested individually for each of the ARV drugs.  Interference among the 
different ARV drugs, as well as interference from other drugs was investigated.  Interference 
was eliminated by reducing or increasing the initial flow rate until all ARV compounds 
achieved excellent separation, or by modification of the extraction procedure.  Overlapping of 
peaks from lamivudine and abacavir was detected as they both had a similar retention times.  
Overlapping of peaks from lopinavir and efavirenz was also noted.  The overlapping was 
eliminated by reducing the initial flow rate to 0.8ml/min for the first two minutes, after which it 
was adjusted to 2ml/min for the rest of the run period.  A gradient elution method was also 
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implemented where the mobile phase composition was changed during the analysis time of 
30 minutes.  At the beginning of the run Solvent B (organic solvent) was at 0% strength and 
Solvent A (aqueous solvent) at 100% (10% ACN preservative added) strength resulting in the 
resolution of the early components.  As the separation progressed, Solvent B’s strength was 
gradually increased to 10% over the first 9 minutes and Solvent A’s strength was decreased 
gradually over the first 9 minutes to 80%.  Solvent B was gradually increased to 50% from the 
9th minute to the 20th minute after which the Solvent A to B ratio remained 1:1 for the 
remainder of the run so that the subsequent components elute within a reasonable time and 
overlapping of peaks were eliminated.  All compounds achieved excellent separation after 
flow rate adjustments.  No further interferences occurred.  Current HIV/Tuberculosis (TB) co-
infection rates exceed 70% with TB being the most common opportunistic infection in South 
Africa.  It was therefore necessary to investigate interference from TB drugs as well.  Not all 
TB drugs are detectable by the method.  Trimethoprim and isoniazide, two commonly used 
drugs for the treatment of TB was detected with the method.  Pure compound stock solutions 
of trimethoprim (100 µg/ml) and isoniazide (100 µg/ml) was injected to determine retention 
times and spectra.  Data was stored in a computerized library.  Samples were spiked with 
ARVs, trimethoprim and isoniazide, extracted and injected.  No overlapping of peaks were 
observed, and effective differentiation and identification among substances were achieved.  
Neither of these drugs interfered with any of the ARVs.   
4.6 PATIENT RESULTS 
Thirty seven participants were identified to take part in the study.  The participants were HIV 
positive patients being treated with ARVs by the Pelonomi Hospital HIV centre of excellence 
as part of the ARV rollout program in the Free State.   
Each participating patient received an ARV regimen as established according to the CD4 
count and viral load of each patient, and a detailed medical history of previous failed 
regimens, nephropathy and psychiatric conditions.  All identified participants were being 
treated by combination regimens of the required ARVs in the study.  Each participant’s 
regimen was known, and extracted sample results were compared to the known regimen of 
each patient as illustrated in Table 4.75.  Each participant’s HPLC results were compared 
over four consecutive follow up visits to the clinic.   
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Table 4.35 Patient Results 
Patient no 
Abacavir 
600 mg 
Efavirenz 
600 mg 
Lamivudine 
300 mg 
Lopinavir 
400 mg 
Nevirapine 
400 mg 
Stavudine 
80 mg 
Tenofovir 
300 mg 
Zidovudine 
600 mg 
  Rx ID Rx ID Rx ID Rx ID Rx ID Rx ID Rx ID Rx ID 
1             √ X             √ √ 
2 √ X         √ X             √ X 
3         √ X     √ X √ X         
4     √ X √ X             √ X     
5     √ √ √ √                 √ √ 
6     √ √ √ √         √ √         
7     √ √ √ √                 √ √ 
8         √ √ √ √                 
9     √ √ √ √                 √ √ 
10     √ √ √ √             √ X     
11     √ √ √ √             √ √     
12     √ √ √ √             √ √     
13             √ √             √ √ 
14     √ √ √ √                 √ √ 
15     √ X √ √             √ X     
16     √ √ √ √             √ √     
17     √ √ √ √             √ √     
18         √ √     √ √ √ √         
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Patient no 
Abacavir 
600 mg 
Efavirenz 
600 mg 
Lamivudine 
300 mg 
Lopinavir 
400 mg 
Nevirapine 
400 mg 
Stavudine 
80 mg 
Tenofovir 
300 mg 
Zidovudine 
600 mg 
  Rx ID Rx ID Rx ID Rx ID Rx ID Rx ID Rx ID Rx ID 
19         √ √     √ √ √ √         
20     √ X √ √             √ X     
21         √ √     √ √ √ √         
22         √ √ √ √             √ √ 
23     √ X √ √             √ X     
24 √ X         √ √             √ X 
25     √ X √ √             √ X     
26     √ √ √ √             √ √     
27         √ √     √ √         √ √ 
28     √ √ √ √         √ √         
29     √ X √ X             √ X     
30     √ √ √ √     
 
      √ √     
31 √ √     √ √            √ √     
32 √ X         √ √             √ X 
33         √ √ √ √             √ √ 
34         √ √     √ √ √ √         
35 √ √     √ √             √ √     
36             √ X             √ √ 
37 √ X         √ √             √ X 
% Compliance 33.33 68.42 90.00 70.00 83.33 85.71 53.33 64.29 
 
Rx  treatment 
ID identification 
√ on treatment 
√ identified in urine 
X not identified in urine 
 patient compliant 
 Patient non-compliant 
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4.7 DISCUSSION AND CONCLUSION 
The HPLC method developed by the Department of Pharmacology/Toxicology, University of 
the Free State in Bloemfontein, South Africa, could only identify the presence of lamivudine, 
abacavir, zidovudine, nevirapine and efavirenz in urine.  However further method 
development/modification and investigation was necessary to identify and include stavudine, 
didanosine, lopinavir, ritonavir and tenofovir in the spectrum of antiretroviral drugs detectable 
by the HPLC method.   
A fast and effective high performance liquid chromatography method using UV detection and 
a liquid-liquid extraction for the qualitative identification of lamivudine, abacavir, zidovudine, 
nevirapine, efavirenz, stavudine, lopinavir and tenofovir was modified for the toxicology 
laboratory of the University of the Free State.  Good separations of the ARVs with high quality 
peaks were obtained, and no interference occurred among the ARVs, the tuberculosis drugs 
investigated or from the blank urine samples used in the study.  The linear regression curves 
constructed proved linearity and reproducibility of results obtained by the method. 
Accuracy of the method was found to be within required levels of 80 to 120% for abacavir, 
efavirenz, lamivudine, nevirapine, tenofovir, and zidovudine, showing that the results 
obtained by the method closely reflects the true value of the ARV.  For lopinavir and 
stavudine however, accuracy within the acceptable range could not be achieved and further 
investigation is needed.  Accuracy of the method for lopinavir and stavudine can be improved 
by exploring potential systematic errors such as faults in the analytical procedure or the 
HPLC system that may have occurred during the course of the study.  The possibility exists 
that lopinavir and stavudine may not be as soluble in the selected solvents as the rest of the 
ARVs included in the study.   
In the method being used, stock solutions of ARVs were made up with methanol to the 
following concentrations: 
Lamivudine = 1017.00 µg/ml 
Abacavir = 1005.00 µg/ml 
Zidovudine = 1053 µg/ml 
Nevirapine = 1040.75 µg/ml 
Efavirenz = 1014.00 µg/ml 
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Unfortunately not all ARVs, particularly those included in this study, dissolved in methanol.  
Other solvents such as ethanol, acetonitrile, tetraethylammonium phosphate (TEAP) buffer, 
dichloromethane, isopropanol, dimethyl sulfoxide (DMSO) and combinations of these 
solvents were explored in this study to find a common solvent in which all ARVs for this study 
could dissolve.   
Most of the combinations used by other researchers were successful for the extraction of one 
or two different ARVs.  Elens et al. (2009) described an ultra-performance liquid 
chromatography (UPLC) method with a solid-phase extraction method used for plasma.  A 
linear gradient of 50 mmol/L ammonium acetate and 50 mmol/L formic acid in water versus 
acetonitrile was used to achieve chromatographic separations.  Oliveira et al. (2005) 
proposed 0.01M sodium acetate solution: methanol (85:15 v/v) and acetic acid as a mobile 
phase for the determination of didanosine.  Supriya, Ashish & Meena (2012) proposed a high 
performance liquid chromatography tandem mass spectrometric method for the estimation of 
emtricitabine in using a mobile phase consisting 5mM ammonium acetate: acetonitrile: 
methanol: (30:30:40 v/v).  These combinations were not optimal for the simultaneous 
extraction of 8 different ARVs.  A universal solvent (Solvent C) was prepared by adding 
150ml of Solvent A [Tetraethylammonium phosphate (TEAP) buffer + Acetonitrile (9:1)] to 
30ml of Solvent B (100µl H3PO4 added to 950ml of ACN and reconstituted it to 1L with ACN) 
in a ratio of 5:1 and used to dissolve pure compounds in.  Solvent C proved to be the 
combination of solvents in which all ARVs explored in this study could dissolve.  A gradient 
elution method consisting of an aqueous solvent (Solvent A) containing 450ml 
tetraethylammonium phosphate (TEAP) buffer and 50ml of acetonitrile (ACN), and an organic 
solvent (Solvent B) consisting of acetonitrile and H3PO4 proved to be the most effective 
method to elude all the ARVs in this study.   
Didanosine could not be detected by the method.  Attempts were made to dissolve pure 
compound of didanosine in water, ACN, TEAP buffer, DMSO, methanol, ethanol, 
dichloromethane, isopropanol and combinations of different strengths of before mentioned 
chemicals.  Didanosine was only partially dissolvable in DMSO.  It was therefore decided to 
exclude didanosine from the study to preserve the integrity of the method without 
compromising the quality of extraction of the other ARVs.  DMSO is also a highly toxic agent.  
Ritonavir is an ARV combined with lopinavir for the treatment of HIV and AIDS.  Ritonavir is 
administered solely to increase lopinavir levels by inhibiting the CYP3A mediated metabolism 
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of lopinavir.  It was therefore removed from the study as ritonavir is only produced 
concomitantly bound to lopinavir and potential risk of overdose is minimal. 
The method developed did unfortunately not achieve accuracy and precision for all the ARVs.  
This method however, will not be used for quantification of these drugs, but only for 
qualitative identification purposes.  Quantification was not achieved.  Although quantification 
did not form part of the envisaged outcomes, it could have been achieved if two or more 
calibration points were included.  Limited quantities of pure compounds were available during 
the course of the study.  Had larger quantities of pure compounds been available, more 
calibration points (six to eight points are generally recommended) could have been included 
during calibration, which would have rendered an increase in precision of the method.   
The recovery achieved by the analytical method was good for all the ARVs.  The recovery 
achieved was not optimal for stavudine and lopinavir, but values within these ranges are 
considered to be acceptable, provided that the method has been proved to be precise and 
accurate.  The recovery for lopinavir ranged between 74% to 89%, and for stavudine between 
69% and 78%.  In the case of stavudine and lopinavir, precision was achieved, but accuracy 
and recovery was not optimal for the lower extracted concentrations.  The lower level of 
recovery may be attributed to various factors such as the method not extracting the pure 
compound completely from the urine matrix, or it might be that the compounds are not 
completely soluble in the universal solvent selected in the study.  The recovery of stavudine 
and lopinavir may be increased if a more suitable solvent is used.  It must however be taken 
into consideration that a universal solvent must be found that will dissolve all the ARVs 
required in this study.  Many solvents have been investigated and considered for the 
purposes of this study.  The solvents selected proved to be the most appropriate for the 
combination of ARVs explored in this study, and one must consider the integrity of the 
method and the purpose of the method in its entirety.  This method can now be used in 
conjunction with other emergency toxicology screenings such as GC/MS and rapid 
identification tests of individual substances, such as paracetamol and salicylic acid, on 
analysers to identify potential ARVs taken in overdose.  The method developed can identify 
the ARVs included in the study, and may serve as a helpful tool in the race to make a 
diagnosis in an overdose patient.   
The stability of a drug in a biological matrix is dependent on the chemical properties of the 
drug, the sample storage conditions, the container used and the matrix itself.  The stability of 
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the drug should be evaluated under conditions that would likely be encountered during 
analysis and sample handling (Vibuthi et al 2009).  Stability was tested over a period of 48 
hours because emergency overdose samples rarely take longer than 24 hours to reach the 
Pharmacology laboratory.  ARV concentrations remained stable at room temperature and 
refrigeration over 48 hours.  Freezing of samples rendered variable results.  Long term 
stability of the ARVs was not determined.  It is therefore advisable to analyse the urine as 
soon as possible, and if samples cannot be analysed immediately, storage at room 
temperature or 2-8˚C (to limit bacterial degradation) is required. 
The method was successfully applied to participating patient samples.  Compliance and non-
compliance were identified in the participants.  Twenty three patients (62%) were compliant 
on their ARV regimens.  The HPLC extraction results of these patients proved similar over 4 
consecutive follow-up visits to the clinic.  Fourteen patients (38%) did not comply.  ARVs 
were detected in 10 of the non-compliant patients, but not all ARVs that should have been 
detected according to their treatment (Rx) regimens, were detected.  Patient compliance was 
good for efavirenz, lopinavir, nevirapine, stavudine and zidovudine, with lamivudine showing 
the highest patient compliance of all the ARVs in the study.  Four non-compliant patients’ 
urine samples were negative for any ARVs.  High resolution peaks and spectra were 
observed in compliant patients. 
Low patient compliance was identified for abacavir and tenofovir.  Low patient compliance 
may be attributed to demographics and psychosocial factors such as unemployment and 
alcohol use, medication-related issues and other patient-related matters.  Medication-related 
adverse effects, such as neuropathy, headache, nausea, loss of memory, diarrhoea, fatigue 
and a heavy pill burden are probably the main reason for poor adherence (McNicholl, 2012; 
Rathbun, 2013).  Poor adherence to treatment is an important concern relating to HIV 
management in our setting and needs to be addressed.  Therapy selection proved to be a 
valuable tool to increase patient adherence.  Patient specific factors should be considered 
when selecting a treatment regimen.  The factors to consider include potential for pregnancy, 
associated comorbidities, treatment convenience, potential drug-drug and food-drug 
interactions (Rathbun, 2013).  Ongoing efforts to educate and eradicate the stigma 
associated with HIV/AIDS will contribute in the reduction of new infections and encourage 
patients to adhere to their treatment regimens.  
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Another threat to the integrity of the treatment campaign against HIV and AIDS emerged.  
Some of the ARVs for example efavirenz are used as a recreational drug.  Efavirenz are 
crushed and the powder is snorted or mixed and inhaled together with other substances of 
abuse to increase the euphoric effect.  Due to this fact, lifesaving stock of the ARVs are 
stolen and sold as recreational drugs, or are being abused by patients on ARV treatment.  
This contributes to the enormous challenges faced by our department of health that are 
already strained by financial, demographical and logistical factors in the fight against HIV and 
AIDS (Gatch et al 2013). 
Another pitfall in the developed method is the practical application with regards to therapeutic 
drug monitoring of the ARVs.  Some of the ARVs were quantifiable by the method, but further 
method development and research is required to increase quantification across a broad 
spectrum of ARVs.  The method may aid therapeutic drug monitoring, but only due to 
possible identification of the drugs the patient are taking or not.  Once again quantification 
becomes necessary to establish the degree of compliance by the patient by investigating 
levels of the ARVs and whether or not they comply with established therapeutic ranges of the 
drugs.  Another potential pitfall with quantification is that the work load may simply be too big 
once levels can be determined.  Thousands of patients are on ARV treatment, keeping this in 
mind, therapeutic drug monitoring with this method may overload the Pharmacology 
laboratory since each sample requires extensive and time consuming extraction procedures 
and the sample load is limited to only one sample at a time on HPLC, and each sample will 
have a processing time of 30 minutes.  It is clearly evident that the application of the method 
is limited to toxicology only, and can only deliver a significant contribution in the identification 
of potential overdoses, or the elimination thereof.  Other methods must be considered for 
quantification and therapeutic drug monitoring purposes. 
The method developed needs further investigation, especially with regards to quantification of 
the ARVs, and to include new drugs being used in HIV and AIDS management.  New 
emerging regimes include emtricitabine, atazanavir, darunavir, fosamprenavir and raltegravir 
in fixed dose combinations.  The method developed is reliable, cost effective and relatively 
user friendly.  The method however can only detect a limited number of the ARVs available 
on the market.  With newer and more effective drugs being researched and marketed every 
day, the method is likely to become outdated.  It is therefore essential to expand the 
spectrum of ARVs detectable by the method continuously to ensure positive identification of 
newer drugs to assess patient compliance or that may potentially be used in overdose cases.  
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A higher survival rate can also be achieved due to the reduction in organ damage.  Further 
method development is therefore necessary to include other ARVs in the screen, to enhance 
the current accuracy of the method, to quantify the ARVs and to lower the limit of detection.  
Further investigations with regards to the interferences of other drugs are also recommended. 
ARV determination on blood was also explored by applying the same method developed for 
urine on blood samples.  The method proved not to be successful on blood samples and 
other extraction methods such as solid phase, derivatisation and LC/MS can be considered 
for future research on blood samples. 
After the method was developed, it was applied to patients with suspected overdoses where 
severe lactic acidosis could not be explained by other diagnostic methods such as GC/MS 
screening and rapid identification assays for individual substances.  These patients’ 
chromatograms showed broad and erratic peaks with large areas under the curve.  When 
compared to chromatograms of patients compliant on ARVs, the broad and erratic peaks with 
large AUCs indicate overload of the urine matrix which translates into higher than normal 
quantities of ARVs present.  The assumption can be made that an overdose is present.  
Suspected overdose patients’ results were compared to results of compliant patients.  The 
comparison clearly indicated whether or not an overdose was present.  These results were 
successfully applied as a diagnostic tool and aided in the management of the patients.  In 
most suspected overdose cases, activated charcoal would be administered, a specific 
antidote can be used or in extreme overdose cases dialysis would be required.  Continued 
laboratory investigation to monitor improvement in reduction or elimination of a substance 
taken in overdose will assist and guide clinicians in the treatment of such a patient.   
Further investigation is essential for the identification of suspected metabolites since all of the 
ARVs are metabolized in the body to produce a number of different metabolites.  Positive 
identification and perhaps quantification of the metabolites may aid in diagnosis by identifying 
a substance were the parent compound can no longer be detected in the urine, thereby 
indicate the extent of an overdose, time after ingestion, contribute to the management of an 
overdose patient, and hopefully a better outcome.  The most used and versatile analytical 
methods for metabolite profiling are based on combining liquid chromatography with mass 
spectrometry (LC/MS), providing both qualitative and quantitative information simultaneously.  
The most efficient approaches in metabolite identification are those using time-of-flight mass 
(TOF) spectrometry or Orbitrap mass spectrometry.  The high mass resolving power of these 
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instruments provides high specificity of detection, whereas the high mass accuracy enables 
identification of biotransformations in the detected metabolites with very high certainty by 
elucidation of changes in molecular formula with respect to the parent compound.  
Unfortunately LC/MS and TOF facilities were not available were the study was conducted, 
and other avenues explored for the purposes of metabolite identification had failed. 
 
The method can only identify a limited number of the ARVs currently being used in treatment 
regimens.  The method developed has been implemented successfully as part of a range of 
diagnostic tools being used to aid in the identification of unknown substances in patients with 
a suspected overdose.  Since HIV and AIDS became more prevalent in our community, more 
of these drugs are currently in circulation in the general population than before.  The increase 
of ARV availability increased the risk of potential overdose in suicide attempts.  The method 
developed will aid in the identification or elimination of unknown substances, if present in the 
urine of patients with a suspected overdose.  The method covers another category of drugs 
that could not be identified previously by the Pharmacology department and may contribute to 
patient outcomes after overdose.  The method can also be used as a platform for future 
method development in the field of ARV investigation with numerous potential add on and 
modification capabilities.  The method expands the spectrum of identifiable substances of 
toxicology screens used by the toxicology laboratory of the University of the Free State and 
can make a valuable contribution to service delivery in future. 
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6 APPENDIXES 
Appendix 7.1: Precision and accuracy testing of HPLC method for Abacavir,  
Day 1 
 
Table 7.1: PRECISION AND ACCURACY DATA FOR ABACAVIR, DAY 1 
µg/ml (Spiked) µg/ml (Extracted) 
19.20 18.92 
19.20 17.99 
19.20 19.28 
 Average= 18.73 
 
µg/ml (Spiked) µg/ml (Extracted) 
38.40 33.25 
38.40 33.41 
38.40 37.11 
 Average= 34.59 
 
 
Figure 7.1: Calibration graph of Abacavir used in precision and accuracy testing, Day 1 
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Appendix 7.2: Precision and accuracy testing of HPLC method for Abacavir,  
Day 2 
 
Table 7.2: PRECISION AND ACCURACY DATA FOR ABACAVIR, DAY 2 
µg/ml (Spiked) µg/ml (Extracted) 
19.20 18.12 
19.20 17.55 
19.20 15.27 
 Average= 16.98 
 
µg/ml (Spiked) µg/ml (Extracted) 
38.40 30.63 
38.40 31.58 
38.40 38.26 
 Average= 33.49 
 
 
Figure 7.2: Calibration graph of Abacavir used in precision and accuracy testing, Day 2 
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Appendix 7.3: Precision and accuracy testing of HPLC method for Abacavir,  
Day 3 
 
Table 7.3: PRECISION AND ACCURACY DATA FOR ABACAVIR, DAY 3 
µg/ml (Spiked) µg/ml (Extracted) 
19.20 21.15 
19.20 18.62 
19.20 19.87 
 Average= 19.88 
 
µg/ml (Spiked) µg/ml (Extracted) 
38.40 36.34 
38.40 33.79 
38.40 35.02 
 Average= 35.05 
 
Figure 7.3: Calibration graph of Abacavir used in precision and accuracy testing, Day 3 
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Appendix 7.4: Precision and accuracy testing of HPLC method for Efavirenz,  
Day 1 
 
Table 7.4: PRECISION AND ACCURACY DATA FOR EFAVIRENZ, DAY 1 
µg/ml (Spiked) µg/ml (Extracted) 
85.20 73.45 
85.20 81.78 
85.20 73.64 
 Average= 76.29 
 
µg/ml (Spiked) µg/ml (Extracted) 
170.40 196.25 
170.40 191.94 
170.40 193.51 
 Average= 193.90 
 
 
Figure 7.4: Calibration graph of Efavirenz used in precision and accuracy testing, Day 1 
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Appendix 7.5: Precision and accuracy testing of HPLC method for Efavirenz,  
Day 2 
 
Table 7.5: PRECISION AND ACCURACY DATA FOR EFAVIRENZ, DAY 2 
µg/ml (Spiked) µg/ml (Extracted) 
85.20 73.00 
85.20 68.24 
85.20 74.40 
 Average= 71.88 
 
µg/ml (Spiked) µg/ml (Extracted) 
170.40 189.58 
170.40 190.89 
170.40 194.63 
 Average= 191.70 
 
Figure 7.5: Calibration graph of Efavirenz used in precision and accuracy testing, Day 2 
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Appendix 7.6: Precision and accuracy testing of HPLC method for Efavirenz,  
Day 3 
 
Table 7.6: PRECISION AND ACCURACY DATA FOR EFAVIRENZ, DAY 3 
µg/ml (Spiked) µg/ml (Extracted) 
85.20 71.84 
85.20 71.93 
85.20 78.50 
 Average= 74.09 
 
µg/ml (Spiked) µg/ml (Extracted) 
170.40 195.36 
170.40 196.16 
170.40 192.07 
 Average= 194.53 
 
 
Figure 7.6: Calibration graph of Efavirenz used in precision and accuracy testing, Day 3 
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Appendix 7.7: Precision and accuracy testing of HPLC method for Lamivudine,  
Day 1 
 
Table 7.7: PRECISION AND ACCURACY DATA FOR LAMIVUDINE, DAY 1 
µg/ml (Spiked) µg/ml (Extracted) 
15.17 13.34 
15.17 11.88 
15.17 13.51 
 Average= 12.91 
 
µg/ml (Spiked) µg/ml (Extracted) 
30.33 28.31 
30.33 31.27 
30.33 29.10 
 Average= 29.56 
 
Figure 7.7: Calibration graph of Lamivudine used in precision and accuracy testing, Day 1 
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Appendix 7.8: Precision and accuracy testing of HPLC method for Lamivudine,  
Day 2 
 
Table 7.8: PRECISION AND ACCURACY DATA FOR LAMIVUDINE, DAY 2 
µg/ml (Spiked) µg/ml (Extracted) 
15.17 12.64 
15.17 12.04 
15.17 14.05 
 Average=12.91  
 
µg/ml (Spiked) µg/ml (Extracted) 
30.33 28.19 
30.33 26.03 
30.33 22.52 
 Average= 25.58 
 
Figure 7.8: Calibration graph of Lamivudine used in precision and accuracy testing, Day 2 
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Appendix 7.9: Precision and accuracy testing of HPLC method for Lamivudine,  
Day 3 
 
Table 7.9: PRECISION AND ACCURACY DATA FOR LAMIVUDINE, DAY 3 
µg/ml (Spiked) µg/ml (Extracted) 
15.17 15.01 
15.17 13.34 
15.17 11.04 
 Average= 13.13 
 
µg/ml (Spiked) µg/ml (Extracted) 
30.33 26.59 
30.33 22.96 
30.33 23.41 
 Average= 24.32 
 
Figure 7.9: Calibration graph of Lamivudine used in precision and accuracy testing, Day 3 
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Appendix 7.10: Precision and accuracy testing of HPLC method for Lopinavir,  
Day 1 
 
Table 7.10: PRECISION AND ACCURACY DATA FOR LOPINAVIR, DAY 1 
µg/ml (Spiked) µg/ml (Extracted) 
19.80 14.12 
19.80 12.87 
19.80 13.60 
 Average= 13.53 
 
µg/ml (Spiked) µg/ml (Extracted) 
44.55 43.52 
44.55 40.27 
44.55 42.45 
 Average= 42.08 
 
Figure 7.10: Calibration graph of Lopinavir used in precision and accuracy testing, Day 1 
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Appendix 7.11: Precision and accuracy testing of HPLC method for Lopinavir,  
Day 2 
 
Table 7.11: PRECISION AND ACCURACY DATA FOR LOPINAVIR, DAY 2 
µg/ml (Spiked) µg/ml (Extracted) 
19.80 15.30 
19.80 16.92 
19.80 16.83 
 Average= 16.20 
 
µg/ml (Spiked) µg/ml (Extracted) 
44.55 37.44 
44.55 38.90 
44.55 40.96 
 Average= 39.10 
 
Figure 7.11: Calibration graph of Lopinavir used in precision and accuracy testing, Day 2 
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Appendix 7.12: Precision and accuracy testing of HPLC method for Lopinavir,  
Day 3 
 
Table 7.12: PRECISION AND ACCURACY DATA FOR LOPINAVIR, DAY 3 
µg/ml (Spiked) µg/ml (Extracted) 
19.80 12.68 
19.80 15.48 
19.80 15.10 
 Average= 14.42 
 
µg/ml (Spiked) µg/ml (Extracted) 
44.55 37.68 
44.55 40.21 
44.55 35.84 
 Average= 37.91 
 
Figure 7.12: Calibration graph of Lopinavir used in precision and accuracy testing, Day 3 
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Appendix 7.13: Precision and accuracy testing of HPLC method for Nevirapine,  
Day 1 
 
Table 7.13: PRECISION AND ACCURACY DATA FOR NEVIRAPINE, DAY 1 
µg/ml (Spiked) µg/ml (Extracted) 
31.60 30.79 
31.60 29.87 
31.60 31.20 
 Average= 30.62 
 
µg/ml (Spiked) µg/ml (Extracted) 
63.20 65.32 
63.20 61.56 
63.20 65.72 
 Average= 64.20 
 
 
Figure 7.13: Calibration graph of Nevirapine used in precision and accuracy testing, Day 1 
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Appendix 7.14: Precision and accuracy testing of HPLC method for Nevirapine,  
Day 2 
 
Table 7.14: PRECISION AND ACCURACY DATA FOR NEVIRAPINE, DAY 2 
µg/ml (Spiked) µg/ml (Extracted) 
31.60 32.04 
31.60 30.84 
31.60 32.25 
 Average= 31.71 
  
µg/ml (Spiked) µg/ml (Extracted) 
63.20 64.30 
63.20 67.81 
63.20 67.69 
 Average= 66.60 
 
Figure 7.14: Calibration graph of Nevirapine used in precision and accuracy testing, Day 2 
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Appendix 7.15: Precision and accuracy testing of HPLC method for Nevirapine,  
Day 3 
 
Table 7.15: PRECISION AND ACCURACY DATA FOR NEVIRAPINE, DAY 3 
µg/ml (Spiked) µg/ml (Extracted) 
31.60 28.31 
31.60 32.55 
31.60 29.20 
 Average= 30.02 
 
µg/ml (Spiked) µg/ml (Extracted) 
63.20 63.40 
63.20 67.62 
63.20 66.98 
 Average= 66.00 
 
Figure 7.15: Calibration graph of Nevirapine used in precision and accuracy testing, Day 3 
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Appendix 7.16: Precision and accuracy testing of HPLC method for Stavudine,  
Day 1 
 
Table 7.16: PRECISION AND ACCURACY DATA FOR STAVUDINE, DAY 1 
µg/ml (Spiked) µg/ml (Extracted) 
11.24 7.94 
11.24 7.38 
11.24 8.11 
 Average= 7.81 
 
µg/ml (Spiked) µg/ml (Extracted) 
16.86 13.13 
16.86 13.64 
16.86 12.08 
 Average= 12.95 
 
Figure 7.16: Calibration graph of Stavudine used in precision and accuracy testing, Day 1 
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Appendix 7.17: Precision and accuracy testing of HPLC method for Stavudine,  
Day 2 
 
Table 7.17: PRECISION AND ACCURACY DATA FOR STAVUDINE, DAY 2 
µg/ml (Spiked) µg/ml (Extracted) 
11.24 7.62 
11.24 8.02 
11.24 7.01 
 Average= 7.55 
 
µg/ml (Spiked) µg/ml (Extracted) 
16.86 13.97 
16.86 12.53 
16.86 14.27 
 Average= 13.59 
 
Figure 7.17: Calibration graph of Stavudine used in precision and accuracy testing, Day 2 
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Appendix 7.18: Precision and accuracy testing of HPLC method for Stavudine,  
Day 3 
 
Table 7.18: PRECISION AND ACCURACY DATA FOR STAVUDINE, DAY 3 
µg/ml (Spiked) µg/ml (Extracted) 
11.24 9.23 
11.24 7.95 
11.24 6.82 
 Average=8.00  
 
µg/ml (Spiked) µg/ml (Extracted) 
16.86 13.82 
16.86 13.35 
16.86 12.43 
 Average= 13.20 
 
Figure 7.18: Calibration graph of Stavudine used in precision and accuracy testing, Day 3 
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Appendix 7.19: Precision and accuracy testing of HPLC method for Tenofovir,  
Day 1 
 
Table 7.19: PRECISION AND ACCURACY DATA FOR TENOFOVIR, DAY 1 
µg/ml (Spiked) µg/ml (Extracted) 
37.20 33.34 
37.20 37.15 
37.20 34.21 
 Average=34.90  
 
µg/ml (Spiked) µg/ml (Extracted) 
83.70 77.15 
83.70 75.81 
83.70 78.04 
 Average= 77.00 
 
Figure 7.19: Calibration graph of Tenofovir used in precision and accuracy testing, Day 1 
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Appendix 7.20: Precision and accuracy testing of HPLC method for Tenofovir,  
Day 2 
 
Table 7.20: PRECISION AND ACCURACY DATA FOR TENOFOVIR, DAY 2 
µg/ml (Spiked) µg/ml (Extracted) 
37.20 46.11 
37.20 45.91 
37.20 42.50 
 Average= 44.84 
 
µg/ml (Spiked) µg/ml (Extracted) 
83.70 84.32 
83.70 84.98 
83.70 91.46 
 Average= 86.92 
 
Figure 7.20: Calibration graph of Tenofovir used in precision and accuracy testing, Day 2 
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Appendix 7.21: Precision and accuracy testing of HPLC method for Tenofovir,  
Day 3 
 
Table 7.21: PRECISION AND ACCURACY DATA FOR TENOFOVIR, DAY 3 
µg/ml (Spiked) µg/ml (Extracted) 
37.20 50.29 
37.20 49.95 
37.20 47.36 
 Average= 49.20 
  
µg/ml (Spiked) µg/ml (Extracted) 
83.70 83.88 
83.70 82.78 
83.70 82.19 
 Average= 82.95 
 
Figure 7.21: Calibration graph of Tenofovir used in precision and accuracy testing, Day 3 
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Appendix 7.22: Precision and accuracy testing of HPLC method for Zidovudine,  
Day 1 
 
Table 7.22: PRECISION AND ACCURACY DATA FOR ZIDOVUDINE, DAY 1 
µg/ml (Spiked) µg/ml (Extracted) 
31.20 29.87 
31.20 29.10 
31.20 29.50 
 Average= 29.49 
 
µg/ml (Spiked) µg/ml (Extracted) 
72.80 62.97 
72.80 67.42 
72.80 66.62 
 Average=65.67  
 
Figure 7.22: Calibration graph of Zidovudine used in precision and accuracy testing, Day 1 
 
 
 
 
 
8075706560555045403530252015
0.819
0.778
0.737
0.696
0.655
0.614
0.573
0.532
0.492
0.451
0.41
0.369
0.328
0.287
0.246
0.205
0.164
0.123
0.082
© Central University of Technology, Free State
  142 
Appendix 7.23: Precision and accuracy testing of HPLC method for Zidovudine,  
Day 2 
 
Table 7.23: PRECISION AND ACCURACY DATA FOR ZIDOVUDINE, DAY 2 
µg/ml (Spiked) µg/ml (Extracted) 
31.20 29.10 
31.20 28.95 
31.20 27.99 
 Average= 28.68 
 
µg/ml (Spiked) µg/ml (Extracted) 
72.80 66.41 
72.80 64.18 
72.80 66.12 
 Average=65.57  
 
Figure 7.23: Calibration graph of Zidovudine used in precision and accuracy testing, Day 2 
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Appendix 7.24: Precision and accuracy testing of HPLC method for Zidovudine,  
Day 3 
 
Table 7.24: PRECISION AND ACCURACY DATA FOR ZIDOVUDINE, DAY 3 
µg/ml (Spiked) µg/ml (Extracted) 
31.20 30.72 
31.20 29.01 
31.20 31.47 
 Average= 30.40 
 
µg/ml (Spiked) µg/ml (Extracted) 
72.80 67.24 
72.80 66.21 
72.80 69.02 
 Average= 67.49 
 
Figure 7.24: Calibration graph of Zidovudine used in precision and accuracy testing, Day 3 
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Appendix 7.25: UV spectrum of Abacavir 
 
 
 
Appendix 7.26: UV spectrum of Efavirenz 
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Appendix 7.27: UV spectrum of Lamivudine 
 
 
 
 
 
 
Appendix 7.28: UV spectrum of Lopinavir 
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Appendix 7.29: UV spectrum of Nevirapine 
 
 
 
 
 
 
Appendix 7.30: UV spectrum of Stavudine 
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Appendix 7.31: UV spectrum of Tenofovir 
 
 
 
 
 
 
Appendix 7.32: UV spectrum of Zidovudine 
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Appendix 7.33: Example of consent form 
CONSENT TO PARTICIPATE IN RESEARCH 
You have been asked to participate in a research study regarding the development of an 
HPLC method for the detection of antiretroviral drugs and their metabolites in urine. 
 
You have been informed about the study by your attending clinician. 
 
You may contact Margerite Potgieter at 072 384 3123 any time if you have questions about 
the research or if you are injured as a result of the research. 
 
You may contact the Secretariat of the Ethics Committee of the Faculty of Health Sciences, 
UFS at telephone number (051) 4052812 if you have questions about your rights as a 
research subject. 
 
Your participation in this research is voluntary, and you will not be penalized or lose benefits 
if you refuse to participate or decide to terminate participation. If you agree to participate, you 
will be given a signed copy of this document as well as the participant information sheet, 
which is a written summary of the research. 
 
The research study, including the above information has been verbally described to me. I 
understand what my involvement in the study means and I voluntarily agree to participate. 
 
_____________________   __________________ 
Signature of Participant   Date 
 
_____________________   __________________ 
Signature of Witness    Date 
(Where applicable) 
 
_____________________   __________________ 
Signature of Translator   Date 
(Where applicable) 
© Central University of Technology, Free State
  149 
Appendix 7.34: Example of information document 
INFORMATION DOCUMENT 
Antiretroviral drug detection in urine using high 
performance liquid chromatography 
A research study is being undertaken by Margerite Potgieter in collaboration with the 
Departments of Pharmacology and Internal medicine, University of the Free State.  The study 
aims to develop a High Performance Liquid Chromatography (HPLC) method for the 
identification and determination of ARV drugs and their metabolites in urine. 
We are inviting you to participate in a research study by donating urine samples.  If you are 
HIV positive and undergoing ARV treatment, you qualify for the study.  A urine sample of at 
least 10ml will initially be collected, urine will be screened for any drugs and medication, and 
participants will be required to provide further urine samples for four consecutive weeks after 
initial donation.  Biological samples collected will be stored for the duration of the study.  Only 
twenty participants who adhere to the inclusion criteria will be selected. 
There are no risks associated with the donation of urine samples. While involved in the 
project and after the results are available, the subject will be given relevant information about 
the study.  Every effort will be made to keep personal information confidential, although 
absolute confidentiality cannot be guaranteed.  Personal information may be disclosed if 
required by law. 
Participation is voluntary, and refusal to participate will not involve a penalty or loss of 
benefits to which the subject is otherwise entitled; the subject may discontinue participation at 
any time without penalty.  If results are published, this may lead to individual/cohort 
identification.  
Contact details of researchers:   Dr J.B du Plessis 082 491 7588 
            Ms M. Potgieter 072 384 3123 
Contact details of REC Secretariat:  051 – 405 2812 
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